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Abstract
Educational interventions to improve quality of life in people
with chronic inflammatory skin diseases: systematic reviews
of clinical effectiveness and cost-effectiveness
Karen Pickett, Emma Loveman,* Neelam Kalita, Geoff K Frampton
and Jeremy Jones
Southampton Health Technology Assessments Centre (SHTAC), University of Southampton,
Southampton, UK
*Corresponding author Emma.Loveman@EffectiveEvidence.org
Background: Inflammatory skin diseases include a broad range of disorders. For some people, these
conditions lead to psychological comorbidities and reduced quality of life (QoL). Patient education
is recommended in the management of these conditions and may improve QoL.
Objectives: To assess the clinical effectiveness and cost-effectiveness of educational interventions to
improve health-related quality of life (HRQoL) in people with chronic inflammatory skin diseases.
Data sources: Twelve electronic bibliographic databases, including The Cochrane Library, MEDLINE and
EMBASE, were searched to July 2014. Bibliographies of retrieved papers were searched and an Advisory
Group contacted.
Review methods: Systematic reviews were conducted following standard methodologies. Clinical
effectiveness studies were included if they were undertaken in people with a chronic inflammatory skin
condition. Educational interventions that aimed to, or could, improve HRQoL were eligible. Studies were
required to measure HRQoL, and other outcomes such as disease severity were also included. Randomised
controlled trials (RCTs) or controlled clinical trials were eligible. For the review of cost-effectiveness, studies
were eligible if they were full economic evaluations, cost–consequence or cost analyses.
Results: Seven RCTs were included in the review of clinical effectiveness. Two RCTs focused on children
with eczema and their carers. Five RCTs were in adults. Of these, two were of people with psoriasis, one
was of people with acne and two were of people with a range of conditions. There were few similarities
in the interventions (e.g. the delivery mode, the topics covered, the duration of the education), which
precluded any quantitative synthesis. Follow-up ranged from 4 weeks to 12 months, samples sizes were
generally small and, overall, the study quality was poor. There appeared to be positive effects on HRQoL
in participants with psoriasis in one trial, but no difference between groups in another trial in which
participants had less severe psoriasis. Carers of children in one RCT of eczema showed improvement in
HRQoL; however, in a RCT evaluating a website intervention there were no demonstrable effects on
HRQoL. Neither the RCT in those adults with acne nor the RCT in those adults with mixed skin conditions
demonstrated an effect on HRQoL. One RCT reported subgroups with atopic dermatitis or psoriasis and
education was effective for psoriasis only. Other outcomes also showed mixed results. It is unclear how
clinically meaningful any of the observed improvements are. Three studies of cost-effectiveness were
included. The interventions, comparators and populations varied across the studies and, overall, the studies
provided limited information on cost-effectiveness. The studies did provide detailed information on
resources and costs that could be useful to inform a future cost-effectiveness evaluation in this area.
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Limitations: The application of the inclusion criterion around whether the interventions were aimed at
improving HRQoL or the inference that they could improve HRQoL was difficult as information was
rarely reported.
Conclusions: There is uncertainty regarding whether educational interventions addressing issues that could
improve HRQoL in people with chronic skin conditions are effective. Tentative conclusions about the best
approach to delivering these kinds of interventions are that face-to-face, group, sessions may be beneficial;
however, text messages may also be effective. Delivery over a period of time and by a multidisciplinary
team may also be associated with positive outcomes. There is uncertainty over whether or not educational
interventions are cost-effective.
Study registration: This study is registered as PROSPERO CRD42014007426.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
A number of different skin conditions, such as eczema and psoriasis, are experienced by large numbersof people. Symptoms include itching and dry skin and, for some, quality of life (QoL) is reduced.
Educational interventions may be able to improve the QoL of people with these conditions. We reviewed
available studies of educational interventions to improve QoL in people with these skin diseases. We
included only studies with the most rigorous study design. Seven studies were included, with few
similarities between them. Education appears to show some beneficial effect on QoL in psoriasis, although
findings were mixed. QoL appeared to be improved in the carers of children with eczema in one study,
but another study found no effect. There was no beneficial effect of education on QoL in a study of those
with acne, or in a study that had populations with different itchy conditions.
We also considered studies investigating cost-effectiveness. There were differences in the interventions and
comparators, and no studies reported QoL in a format that could be used in policy-making. It is uncertain
whether educational interventions are cost-effective in improving QoL in those with chronic skin diseases.
Results suggest that there is uncertainty over whether or not these interventions are effective in improving
QoL. The best approach to delivering these kinds of interventions may be face-to-face, group sessions;
however, in some contexts, text messages may also be effective. Our report makes recommendations for
future research.
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Scientific summary
Background
Inflammatory skin diseases include a broad range of disorders of the skin. The most commonly recorded
conditions are eczema, psoriasis and acne. People with chronic inflammatory skin diseases experience
symptoms including itching, dry skin and changes in skin appearance to varying degrees of severity and bodily
involvement. For some people, these conditions lead to high levels of psychological comorbidities and reduced
quality of life (QoL). Patient education – typically defined as providing patients with information about, and
training in, skills for managing their condition – is a recommended part of the management of chronic
inflammatory skin conditions and may improve QoL. As part of these interventions, patients are often provided
with information about their condition and the use of treatments. However, it has been suggested that the
inclusion of additional elements in these interventions that specifically address issues related to poor QoL may
enhance the impact of educational interventions on QoL. Although such interventions are available to some
people with these conditions, their clinical effectiveness and cost-effectiveness is unclear.
Objectives
To undertake systematic reviews of the clinical effectiveness and cost-effectiveness of educational
interventions for improving health-related quality of life (HRQoL) in people with chronic inflammatory skin
diseases and to make recommendations for future research.
Methods
Electronic bibliographic resources, including MEDLINE, EMBASE, The Cochrane Library, Cumulative Index to
Nursing and Allied Health Literature, and PsycINFO, were searched for published studies from inception to
July 2014 for English language articles. Bibliographies of included articles and systematic reviews were also
searched for additional studies. An Advisory Group was contacted to identify additional published and
unpublished evidence.
Study selection
Titles and abstracts were independently screened for eligibility by two reviewers. Inclusion criteria were
applied to full texts by one reviewer and checked by a second reviewer. Inclusion criteria were as follows:
l Population: adults, young people and children with a chronic inflammatory skin condition and/or
their carers.
l Intervention: educational interventions that either specifically aim to improve HRQoL or could
improve HRQoL.
l Comparators: any comparator was eligible.
l Outcomes: only studies that measured HRQoL as an outcome, using a validated measure, were
included. Data were also extracted on outcomes, including measures of disease severity, disease control
and scratching behaviour. Patient-assessed subjective outcome measures were included if assessed by
validated tools.
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l Studies were included in the systematic review of clinical effectiveness if they were randomised
controlled trials (RCTs). If no RCT evidence was available, prospective trials with one or more
concurrent control groups were eligible.
l Studies were included in the systematic review of cost-effectiveness if they were full economic
evaluations (cost-effectiveness, cost–utility or cost–benefit analyses), cost–consequence analyses or
cost analyses.
Full-text papers were included only if they reported results in sufficient detail. Abstracts or conference
presentations were eligible for inclusion only if sufficient details of methods and results were presented.
Data extraction and quality assessment
Data extraction and quality assessment were undertaken by one reviewer and checked by a second
reviewer. Differences in opinion were resolved by discussion at each stage.
Data synthesis
Data were synthesised through narrative reviews with tabulation of the results of included studies.
Results
Clinical effectiveness
From 2628 references, 63 were retrieved for consideration. Seven RCTs were included (one additional
study, a controlled clinical trial, met the inclusion criteria, but was not reviewed, in line with the review
protocol). Two RCTs assessed the effects of educational interventions for adults with psoriasis, one RCT
assessed an education intervention for women with acne and two RCTs assessed the effects of
educational interventions in children with eczema and/or their carers. Two further RCTs focused on adults
with mixed skin conditions, one on those a range of pruritic skin conditions and the second on those with
either psoriasis or eczema (and results for these subgroups were provided). There were few similarities
between studies in terms of the interventions. The delivery mode (e.g. group or individual; face to face,
online or via text messaging), the topics covered, the provider of the education, and the duration and
intensity of the education differed between studies. There were also few similarities in the choices of
outcome measures employed, although all studies reported HRQoL, most often with the Dermatology Life
Quality Index. Follow-up ranged from 4 weeks to 12 months. The quality of the included RCTs was
generally poor. Sample sizes were generally small; in one study, there was a large sample size, but results
were reported for a number of different, smaller, subgroups. Three studies were reported to be pilot
studies. Only two studies were based in the UK and the findings of the majority of the trials were
considered to be of limited generalisability to the UK.
Three RCTs found statistically significant improvements in HRQoL. In RCTs of participants with psoriasis,
the effect of the educational interventions on HRQoL appeared to be positive in two trials (one was a
subgroup) when this was measured at the end of the 3-month interventions, with positive effects on one
of two HRQoL measures used persisting 6 months after the intervention in the one RCT with a longer-term
follow-up. In a pilot RCT of participants with mild-to-moderate psoriasis there was no statistically
significant impact on HRQoL at 6 weeks’ follow-up. One RCT investigated the impact of an educational
intervention on children and their carers and adolescents with eczema in three age-related subgroups.
HRQoL appeared to be improved in the carers of children in two age groups (3 months to 7 years and
8–12 years). HRQoL was not measured in the adolescent group (participants or carers). Another RCT
evaluating an educational website for carers of children aged up to 5 years with eczema found no effects
on HRQoL. An additional RCT reported on a small subgroup of adults with eczema. In this trial, there were
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no significant differences between those in the educational intervention group and those in the usual care
control group. In one RCT of participants with acne the educational intervention did not demonstrate
positive effects on HRQoL. In an educational intervention aimed at people with chronic pruritic skin
diseases (including atopic dermatitis, psoriasis and chronic urticaria) the focus was to help participants cope
with the associated itch of the condition. No benefit in terms of HRQoL was demonstrated at the 9-month
follow-up period. Other outcomes reported in the included studies, such as disease severity outcomes,
showed mixed results.
Cost-effectiveness
Three studies were included in the systematic review. Two were cost-effectiveness studies and one was a
cost analysis. The nature of the interventions and comparators varied and the populations of interest across
the included studies were children and adolescents in two studies and in adults in one study. None of the
studies reported HRQoL in terms of quality-adjusted life-years (QALYs) gained. The two cost-effectiveness
studies were based in the Netherlands and the cost analysis study was conducted in the UK. In general,
the studies provided detailed information on the resources used and unit costs. Two of the three included
studies provided resource use data that could be used to inform a future de novo cost-effectiveness model.
The UK-based cost analysis was conducted from the NHS perspective; however, details of data inputs in
terms of QALYs and costs were not reported. It is therefore difficult to draw conclusions on the results of
the analysis.
Owing to the limitations in the included studies, it is uncertain whether educational interventions are
cost-effective in the treatment of chronic inflammatory skin diseases.
To inform future modelling in this area, these three included studies, and four additional studies that had
been retrieved for screening for inclusion into the systematic review of cost-effectiveness but not included,
were scrutinised in more detail to determine the resources and costs used. There was heterogeneity
between these studies; however, the range of relevant resources can be grouped under three broad
categories – interventional, service use, non-service use – and these are discussed. A second area of focus
from the overview of these seven studies to inform future modelling was in terms of the choice of
outcomes. Again, heterogeneity between the studies meant that making conclusions was difficult;
however, the report makes recommendations for the choice of outcome measure in any future studies that
include the use of preference-based generic measures of HRQoL or disease-specific measures of HRQoL
that can be mapped to generic measures.
Discussion
Commonalities between effective interventions were a long delivery period (ranging from 6 weeks to
3 months) and delivery by a multidisciplinary team; however, this was not tested in any way and it remains
uncertain from the current evidence base which elements of educational interventions may be associated
with improvements in HRQoL. Our review has identified a number of gaps in the clinical effectiveness and
cost-effectiveness evidence base. In particular, no studies focused on the less common skin conditions. In
addition, approximately one-third of the evidence that met our eligibility criteria did not provide adequate
information about the results and could not be included. Few of the studies that were included reported
adequate details of the intervention, such as the aim or the theoretical basis. This indicates the need for
better reporting in this research area.
Strengths of our research are that the systematic reviews were conducted in line with good practice
following a published protocol. A limitation to the review is that the application of the inclusion criterion
around whether the interventions were aimed at improving HRQoL, or the inference that they could
improve HRQoL, was rarely reported.
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xxi
Conclusions
Overall, there is uncertainty over whether or not educational interventions addressing issues that could
improve HRQoL in people with chronic inflammatory skin conditions are effective. Tentative conclusions
about the best approach to delivering these kinds of interventions are that face-to-face, group sessions
may be beneficial; however, evidence also suggests that text messages may be effective. There are some
indications that delivery over a period ranging from 6 weeks to 3 months and delivery by a multidisciplinary
team may also be associated with positive outcomes. Based on available evidence, there is uncertainty over
whether or not educational interventions are cost-effective in terms of improving HRQoL. Priorities for
research are high-quality, adequately powered RCTs that evaluate theory-based interventions and include
an adequate long-term follow-up in all chronic inflammatory skin conditions. Ideally, such RCTs should
include an economic evaluation and a process evaluation.
Funding
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Institute for Health Research.
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Chapter 1 Background
Description of the underlying health problem
Chronic inflammatory skin diseases are commonly encountered conditions in dermatology. They include
commonly reported conditions, such as eczema, psoriasis and acne, which are associated with skin
inflammation. This inflammation can range in severity from mild to severe and, in some patients, can have
associated health complications. The focus of this report is on chronic inflammatory skin diseases that
have lasted for at least 12 weeks and may have caused significant tissue destruction and, potentially,
impacted the individual significantly. Our initial scoping of this project identified a number of conditions
that come under the term chronic inflammatory skin diseases; however, only the most commonly studied
in educational intervention studies are discussed in the background of this report.
Classification of disease
Dermatologists in the UK use a disease classification based on aetiology and anatomical site which has
been developed by the British Association of Dermatologists.1 This is a very detailed and comprehensive
system used to obtain information about skin diseases and, as such, has not been described here.
Common types of chronic inflammatory skin conditions include eczema (a general term covering a range
of conditions, which may or may not be atopic), psoriasis and acne vulgaris (commonly known as acne).
There is also a wide range of other types of skin condition such as rosacea, lichen planus, hidradenitis
suppurativa, cutaneous lupus erythematosus, lichen sclerosus and seborroeic dermatitis. The working
definitions, causes and epidemiology for the three most common conditions are summarised below.
Eczema
Eczema (of which atopic dermatitis eczema is the most common type) is a common skin condition that
presents as red, dry, itchy skin, often on the elbow, knee or face, but sometimes all over the body.2,3 Often
associated with atopy (a predisposition to developing hypersensitivity reactions), the predominant symptom
is itching.4 In some people, the skin can weep or blister and become thickened. In the chronic form of the
condition there can also be altered skin pigmentation and exaggerated surface markings.2 Eczema can
start at any age, but is most common in children. It is considered to be caused by a combination of genetic
and environmental factors.2 Concurrent illness and psychological factors such as stress can also function as
a trigger.5 For the purpose of this report, we refer to the general term ‘eczema’ unless an individual study
specifies that the condition is atopic dermatitis or atopic eczema.
Psoriasis
Psoriasis is a skin disease that is typically characterised by pink or red lesions which are covered with
scales.6 These lesions are well delineated and can vary in extent and shape, and the severity of psoriasis
typically follows a relapsing and remitting course.6,7 The most common form, plaque psoriasis, occurs in
approximately 90% of people with the condition. Other types include guttate psoriasis and pustular
forms.7 The cause of psoriasis is thought to be a complex interplay between genetic and environmental
factors, with the immune system having an important role in the disease process.8
Acne vulgaris
Acne vulgaris (commonly known as acne) is a common inflammatory skin disease, which usually starts
during puberty. It is characterised by a combination of comedones (blackheads and whiteheads), papules,
pustules, nodules and scarring.9 Genetic and hormonal causes are some of the key factors that trigger
the condition.10
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Epidemiology
Scholfied and colleagues1 undertook a health-care needs assessment in 2009 and reported that 55% of
the overall population in the UK have had some form of skin disease, and that in previous studies 23–33%
of people have had a skin problem that could benefit from medical care (i.e. a moderate or severe
condition). This section presents a brief overview of the incidence and prevalence across the different
inflammatory skin conditions discussed above.
Eczema
A recent review noted that, although there are several studies considering the epidemiology of atopic
eczema in children, a wide range of prevalence estimates are available given differences in study
populations, the definitions used and the survey methods applied.5 It is generally estimated that atopic
eczema affects one in every five children in the UK at some stage3 and it is the most commonly diagnosed
dermatological disorder in children and adolescents.11 The prevalence of atopic eczema appears to be
increasing, although the reasons for this are unclear.2,5
A recent guideline5 reported an increasing trend in point prevalence of the skin disease in the 1990s and
early 2000s. Numerous studies, mostly of low-level evidence, were reviewed. In this overview, we have
focused on those from the UK where available. The point prevalence rates differed between the studies;
in five UK-based studies, the guideline reports that this ranged from 5.9% in 3- to 11-year olds to 14.2%
in 4-year olds. Trends in point prevalence for those who had ever had eczema increased.5
One-year period prevalence was reported in two studies; this was reported as 11.5% in 3- to 11-year
olds12 and 16.5% in 1- to 5-year olds.13 In a birth cohort study that followed children until the age of
10 years, it was reported that the period prevalence of atopic eczema was 9.6% at 1 year of age, which
increased up to 10.3% at 2 years of age; 11.9% at 4 years and 14.3% at 10 years.14 In one UK study,
period prevalence rates were also reported; these were highest, at 25.6%, for children aged 6–18 months,
followed by those aged 18–23 months at 23.2%, those aged between 0–6 months at 21%, and those
aged 30–42 months at 19.9%.5,15
The prevalence of atopic eczema varies across the world. A recent systematic review of incidence and
prevalence studies published between 1990 and 2010 included 69 studies. Evidence suggested that
the prevalence is increasing in many regions of the world, including the UK.16
In one UK study reviewed in the recent guideline, the incidence of atopic eczema in children aged up to
2.5 years born in 1991 and 1992 was found to be highest at 21% during the first 6 months of life,
declining to 11.2% by the age of 6–18 months, and to 3.8% by the age of 30 months.15 In another birth
cohort study set up in 1982–4 to monitor the natural history of allergic diseases for 23 years, eczema
usually remitted between 1 and 7 years of age; the prevalence of eczema was more likely to persist if a
child was atopic, especially in girls.4
Psoriasis
Psoriasis is estimated to affect around 1.3–2.2% of the population in the UK. It occurs equally in men
and women, at any age, although it is uncommon in children, and can persist for up to 50 years.6,7,17
Gelfand and colleagues18 estimated the overall prevalence of psoriasis in the UK from 1987 to 2002 to be
1.5%, with the prevalence increasing more rapidly in young female patients compared with their male
counterparts. As the population ages, the prevalence is similar between sexes. Furthermore, the prevalence
declines significantly in people aged 70 years and above, regardless of sex. In studies reviewed in a recent
systematic review,17 similar trends were noted. Another study by Seminara and colleagues19 showed an overall
prevalence of 1.9% based on the electronic records of The Health Improvement Network (THIN) database,
which contained medical records of around 4.6% of the UK’s total population. The database presented
prevalence data based on age groups and sex. Females had a slightly higher prevalence rate compared with
males (1.9% vs. 1.8%).19 Table 1 presents the UK-based prevalence rates reported by Gelfand and colleagues18
and Seminara and colleagues.19
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Recent estimates from a 2013 systematic review of global epidemiology of psoriasis17 found that the UK
had a prevalence of between 1% and 3% (three studies) in adults. The review authors state that these rates
were lower than estimates from other countries.17 No UK-specific studies were identified in children, but the
European prevalence rates were reported to be up to 0.71%.17 A recent Norwegian population-based
cohort study, following patients for 30 years, showed that the self-reported lifetime prevalence rose from
4.8% in 1979–80 to 11.4% in 2007–8.20
No studies on the UK incidence of psoriasis specifically in children or adults were identified in the 2013
systematic review.17 One UK study was identified that reported the combined incidence in all ages. The
reported incidence rate was 140/100,000 person years.21 A retrospective cohort study from the UK
conducted in 2008 has since reported results that indicate an incidence of psoriasis in adults of 28/100,000
person years.22
Acne
Epidemiological studies of acne show broad ranges of incidence and prevalence.23 Acne affects up to 80%
of people at some point in their lives, predominantly between the ages of 15 and 17 years.24 Chronic acne
can persist, however, into adulthood,24 and approximately 14% of people with acne are thought to consult
their general practitioner (GP) (3.5 million visits annually).9 A study suggests that this condition is prevalent
in up to 50% of 14- to 16-year-olds in a community sample, and up to 30% of these teenagers had acne of
sufficient severity to require medical treatment.25 The prevalence of moderate-to-severe acne is likely to
increase with age during puberty.23 The incidence of the condition is similar in both men and women,
with the numbers peaking in adults up to 25 years of age.25
Other conditions
Other chronic inflammatory skin conditions include rosacea, lichen planus, hidradenitis suppurativa,
cutaneous lupus erythematosus, lichen sclerosus and seborrhoeic dermatitis. Rosacea may affect up to 1 in
10 people; however, epidemiological data are scarce and controversial. The reported prevalence rates have
ranged from 0.09% to 22% in the UK.26 Lichen planus is reported to affect 1–2% of the population.
Although the condition can occur at any age, it typically arises in females of middle age. A study reported
that the condition primarily occurred in women aged over 45 years, with an annual incidence of 27/100,000
people in 2003. Hidradenitis suppurativa may have a prevalence of approximately 1% in the UK and is more
prevalent in females than males.27 Cutaneous lupus erythematosus is an uncommon autoimmune disorder,
which has a variety of types. Those most commonly affected are women aged 20 to 50 years, although
TABLE 1 Prevalence of psoriasis in the General Practice Research Database by age group and sex (1987 to 2002)
and in THIN database by age
GPRD by age group and sex (1987–2002)
Prevalence/10,000
Age group (years)
0–9 10–19 20–29 30–39 40–49 50–59 60–69 70–79 80–89 ≥ 90 Total
Male 48.6 118.6 149.1 186.6 219.1 232.3 226.3 168.4 89.6 46.4 152.7
Female 61.8 154.8 152.6 169.8 187.9 213.7 225.7 156.6 87.9 47.6 151.4
Total 55.0 137.4 151.0 178.0 203.4 222.8 226.0 161.4 88.4 47.3 152.0
THIN database by age19
Prevalence (%)
Age group (years)
< 10 10–19 20–29 30–39 40–49 50–59 60–69 70–79 80–89 > 90
0.1 0.6 1.5 1.7 2.1 2.5 3.0 3.0 2.6 1.4
GPRD, General Practice Research Database.
Sources: GPRD by age group and sex (1987–2002);18 THIN database by age.19
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children, the elderly and males may also be affected.28 Lichen sclerosus is a lymphocyte-mediated dermatosis
that occurs in the genital skin and affects both sexes. The incidence is thought to be higher in females
(peak ages of presentation are in prepubertal girls and postmenopausal women) than males.29 Seborrhoeic
dermatitis is a common form of dermatitis affecting areas rich in sebaceous glands such as the face, scalp
and centre of the chest.30 It is thought to affect between 3% and 5% of the global population and is more
common in younger adults.
Impact of the diseases
People with inflammatory skin conditions can experience symptoms including itching (and sometimes pain),
dry skin and changes in skin appearance, to varying degrees of severity and bodily involvement.5,7,29 The
symptoms can be distressing for patients and their carers31,32 and, in some cases, can lead to functional
impairments, particularly when conditions affect the face, genitalia, hands and feet.7 In adults, reduced
levels of employment and income have been noted in psoriasis7 and more severe acne vulgaris.9 Patients can
feel stigmatised by their condition owing to visible skin symptoms and changes in appearance,31,33,34 which
may contribute to distress35 and impact on their social interactions,33,34,36 normal activities (e.g. going to a
public swimming pool or to the hairdressers) and relationships with people, including sexual relationships.34
Sleep quality can also be affected owing to itching and scratching which can be particularly intense at night,
and the sleep of carers can also be disrupted through dealing with symptoms at night.31
Chronic inflammatory skin conditions are associated with high levels of psychological comorbidities,
including depression and anxiety,31,35,37–39 and reduced health-related quality of life (HRQoL),9,33,39,40 which
does not always correlate with disease severity.41–43 Psychological difficulties and stress, along with
symptoms (such as itching), undergoing treatment and concerns about appearance may negatively impact
patients’ HRQoL.33,39,40 Self-managing a long-term skin condition, with a relapsing and remitting course,
is demanding for patients and their carers, and patients may feel that they lack control owing to the
unpredictability of the disease on a weekly, or even daily, basis.31 Poor psychological health can lead to a
vicious cycle in patients where symptoms can be exacerbated by stress44 and reduced HRQoL may lead
to less adherence to treatment regimens, reducing the effectiveness of treatment and resulting in greater
use of health-care resources.45
HRQoL is a commonly used outcome measure in health care to evaluate the impact of disease on patients’
lives. It is defined as a person’s subjective experience and perception of the impact that their health status has
on their physical, psychological and social functioning.46,47 HRQoL instruments measure various dimensions of
these three domains, including physical symptoms, social activity, mental health, ability to carry out normal
activities, life satisfaction and perceived health status,34,46,48 although the specific dimensions measured vary
according to the instrument used.48 HRQoL is a distinct concept from psychological distress (e.g. depression or
anxiety), although, as described above, experiencing psychological distress is associated with poorer HRQoL
in chronic inflammatory skin conditions.
Measurement of disease
A wide range of validated instruments are used to measure HRQoL and disease severity in patients with
chronic inflammatory skin diseases. The Dermatology Life Quality Index (DLQI) is one of the most frequently
used instruments in studies in dermatology. It has been used extensively in studies of over 40 different skin
conditions, although the most common conditions it has been used for are psoriasis, atopic eczema and
acne.49 Other common measures include the Infants’ Dermatitis Quality of Life Index (IDQoL), which is aimed
at children aged 0–4 years old,50 the Children’s Dermatology Life Quality Index (CDLQI), which is aimed at
children aged 4–16 years, the Quality of life in Primary Caregivers of children with Atopic Dermatitis (QPCAD),
and the World Health Organization Quality of Life-26 items (WHOQOL-26). These instruments cover a range
of dimensions of HRQoL, including the severity of the condition, quality of sleep, coping, adherence with
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treatment, satisfaction and the impacts on family members, partners or carers. Some of the instruments that
have been developed specifically for use in children (such as CDLQI and Quality of Life in Children Aged
14–16 Years) use proxy judgements made by someone else, such as a parent or carer.
Some of the common measures of disease severity include the Psoriasis Area Severity Index (PASI), the
Self-Administered Psoriasis Area Severity Index (SAPASI), the Patient-Oriented Eczema Measure (POEM),
the SCORing Atopic Dermatitis (SCORAD) and the Psoriasis Disability Index (PDI).
Appendix 1 gives an overview of some of these common instruments, including definitions of clinically
meaningful changes where this is known (that is, the degree of change that is considered to be of benefit
to the patient and their disease management, regardless of whether the change is statistically significant46).
Impact on the NHS
The need to improve patients’ HRQoL and for clinicians to take a holistic approach to managing patients’
skin conditions has been advocated in the research literature34 and clinical guidelines.5,7 This might benefit
both patients and the NHS through reduced use of health-care resources. It was estimated (using 2005/6
data) that 2.23% of the total NHS expenditure (£140M) was spent on diseases of the skin and
subcutaneous diseases.1 This included prescribing costs, outpatient and inpatient costs, but not primary
care consultations, which could add another £395M.1 In a national statistical report published by the
Health and Social Care Information Centre51 on prescriptions dispensed in the community in England from
2003–13, the costs of emollient prescriptions in the year 2013 were estimated at £105,000, although
these were prescribed for a range of conditions and not just for inflammatory skin diseases.
A UK-based study1 estimated the direct costs of skin diseases to the individual and to the NHS. It reported
a year-on-year increase in over-the-counter (OTC) sales of the skin disease treatments in the UK from 2001
to 2007. The OTC sales for such conditions were £413.9M in 2007; this was 18% of the total OTC sales.
Of the total prescribing budget, 2.85% (£237.7M) was for prescribing costs for skin disease in England in
2007. The study reported an estimated cost of about £395M per year, or 4.4% of the General Medical
Services budget for GP consultations in England and Wales. In the year 2005/6, the overall direct costs
(including medical care and products) of providing care for people with skin diseases was reported as
about £1819M in England and Wales. It was observed that the direct cost of skin disease to the NHS
was relatively low despite the conditions being very common.1
Current service provision
A brief overview of the management of different chronic inflammatory skin diseases with relevance to the
UK is discussed in the context of the relevant national guidelines as outlined below, including the role of
education in the treatment of these conditions. Educational interventions are typically defined as providing
patients with information about, and training in, skills for managing their condition.52 In its simplest sense,
education can be thought of as the provision of information that is intended to influence a specified
outcome. In general, educational interventions involve encounters between teachers and learners for
one or more of the following purposes: to raise awareness, to enhance or improve knowledge, or to
change behaviour.53
Relevant national guidelines
Of all the chronic inflammatory skin diseases prevalent in the UK, national guidelines have been published
on only two of the conditions: atopic eczema5,54 and psoriasis.7 In addition, National Institute for Health
and Care Excellence (NICE) quality standards for psoriasis and atopic eczema are available and these
provide quality statements describing best clinical practice, including pathways for assessment and
treatment. The details of the guidelines are presented below.
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Atopic eczema
Atopic eczema in children: management of atopic eczema in children from birth up to the age of 12 years.
NICE Clinical guidelines, CG57. Issue date: December 2007.5 In addition to covering the management of
atopic eczema in children from birth up to 12 years, this guideline provides guidance on diagnosis and
assessment, management, and providing information and education for children and their parents
and carers.
Management of atopic eczema in primary care: a national clinical guideline. March 2011. Scottish
Intercollegiate Guidelines Network (SIGN) guideline for atopic eczema.54 Similarly to the NICE clinical
guideline, the SIGN guideline also provides recommendations based on current evidence for the
management of atopic eczema in children as well as adults in primary care in Scotland.
Psoriasis
The assessment and management of psoriasis. NICE Clinical guidelines, CG153. Issue date: October 2012.7
This guideline provides evidence-based advice on the assessment and management of psoriasis in adults,
young people and children.
Management of disease
A range of treatment options are available for inflammatory skin diseases and current recommendations
for best practice are summarised here. Although these vary from condition to condition, they typically fall
into topical treatments, which are applied directly to the skin; systemic pharmacological treatments
(intravenous, subcutaneous or oral); bandaging techniques; and, for some conditions, phototherapy.5,7
In addition, patients are encouraged to practise self-care (such as using emollients as indicated, avoiding
known triggers) to minimise environmental triggers of their disease, to monitor their condition, maintain
adherence to treatments, and to seek support groups. Education is an important way to help individuals
manage the symptoms of chronic diseases55 and, in recent years, educational interventions for people with
inflammatory skin disease have been seen as a useful adjunct to usual medical care with topical and
pharmacological therapies.
Atopic eczema
The NICE clinical guideline on atopic eczema5 provides guidance on management of the condition during
and between flares, in children from birth up to the age of 12 years. The guideline suggests that a holistic
approach should be adopted by health-care professionals (HCPs) when assessing a child’s atopic eczema.
Potential trigger factors, such as irritants (e.g. soaps and detergents), skin infections, contact allergens,
food allergens and inhalant allergens should be sought by the HCPs while clinically assessing children
with the condition. With respect to treatment of the condition, NICE recommend the use of a stepped
approach whereby the treatment step was tailored to the severity of the atopic eczema. Emollients are
recommended to form the basis of atopic eczema management.
The current NICE guideline5 states that parents and carers, along with the children with atopic eczema,
should be offered information on how to recognise the symptoms and signs of bacterial infection and how
to access appropriate treatment when a child’s atopic eczema becomes infected. Furthermore, children,
along with their parents and/or carers, should be educated about the health condition and its treatment.
In addition, HCPs should provide both verbal and written information, along with practical demonstrations
on quantity and frequency of the treatment to use. NICE recommends that the information should be
tailored to suit an individual child’s cultural practice relating to skin and the way they bathe. The NICE
guideline acknowledges the impact that the disease can have on a patient’s HRQoL and makes a
recommendation that the effect of the condition on HRQoL should be taken into account at consultations
and treatment decisions.5 Future research recommendations were advocated by NICE to assess the clinical
effectiveness and cost-effectiveness of different models of educational programmes in the management
of atopic eczema in children, as lack of education about therapy could lead to poor adherence, thereby
leading to treatment failure.
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In addition to the above guideline, NICE Quality Standards 4456 include a reference to the provision of
education in Statement 2, that children with atopic eczema should be treated using a stepped-care plan
on the basis of the recorded disease severity and that this care plan should be supported by education. The
NICE pathways for atopic eczema state that quality of life (QoL) should be assessed by practitioners when
making treatment decisions.
The SIGN guideline54 identifies a Cochrane review that examined the effect of parent educational
interventions on severity of eczema in children. This review showed heterogeneity with respect to the
format, content and settings of the interventions and, although two of the four included studies found
the intervention to be effective in reducing clinical severity scores, no recommendations in the SIGN
guideline were made owing to the lack of consistency seen in the trials included.54
The SIGN guideline provides a checklist of information that patients and carers should have access to
at the different stages of diagnosis and treatment. These largely focus on explanation of the condition,
what treatment options there are, how to self-manage their conditions and look for changes in their
condition. There is some limited reference to providing patients and carers with the contact details of
organisations that may be able to provide advice and support. There is no specific advice regarding any
educational interventions.54
There are no published audits of how well the national guidelines are being adhered to in clinical practice
with regard to education. The general impression of our Advisory Group was that this is variable.
From a patient and carer perspective, the need to establish which is the most effective route to manage
eczema has been identified by the James Lind Alliance Eczema Priority Setting Partnership.57 One of the
top research priorities for HCPs identified by the group is to establish which of the following management
approaches is the most effective: education programmes, GP care, nurse-led care, dermatologist-led care
or multidisciplinary care.
Psoriasis
The NICE guideline on psoriasis7,58 provides recommendations on the management of all types of psoriasis
across all age groups: children aged up to 12 years, young people and adults aged 18 years and above.
The NICE guideline7 recommends that for people with any type of psoriasis, disease severity should be
assessed, along with the impact of disease on physical, psychological and social well-being, and whether
they have psoriatic arthritis or presence of comorbidities. The guideline states reasons for referral to a
dermatology specialist for a number of reasons, including uncertainty over the diagnosis, severe psoriasis,
psoriasis that cannot be controlled with topical therapy or psoriasis that has a major impact on a person’s
physical, psychological or social well-being.
It was recommended to discuss risk factors for cardiovascular comorbidities with people who have any type
of psoriasis and with their families and/or carers.
With regard to treatment, practical support and advice about the use and application of topical treatments
should be provided by trained and competent HCPs. For adults with trunk or limb psoriasis, NICE
recommends the use of a potent corticosteroid applied once daily plus vitamin D or a vitamin D analogue
applied once daily for up to 4 weeks as initial treatment. However, people with plaque or guttate-pattern
psoriasis that cannot be treated with topical treatments alone should be offered narrowband ultraviolet B
phototherapy two or three times a week depending on patient preference. Systemic non-biological therapy
should be offered to people with any type of psoriasis if the disease cannot be controlled with topical
therapies, if it has a significant impact on the patient in terms of physical, psychological or social well-being,
or if it is associated with significant functional impairment.7
DOI: 10.3310/hta19860 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 86
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Pickett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
7
In citing the principles of care for patients with the condition and their families or carers, the guideline
recommends the provision of support and information to be provided to meet the requirements of each
individual. Areas of focus for information should be an understanding of their diagnosis, the available
treatments (including their safe and effective use), what the associated risk factors are, when and how to seek
support, and information on strategies to deal with the impact on physical, psychological and social well-being.7
The NICE guideline also recognises the potential impact on a patient’s HRQoL and notes that HRQoL should
be taken into account during patient consultations and when making treatment decisions. The NICE pathways
for psoriasis state that psychological well-being should be assessed by practitioners at diagnosis and when
assessing response to treatments.
Similarly to the situation with eczema guidelines, there are no published audits of how well the NICE
psoriasis guideline is adhered to in clinical practice with regard to education. The Advisory Group to this
review believed that adherence is currently variable.
Overall, although these guidelines for eczema and psoriasis outline to some extent where patient
education, information and advice sit in clinical practice, the guidance tends to focus on education relating
to patients’ use of treatments, self-care and understanding of the disease. It is not currently clear where
educational interventions that more directly address HRQoL could be placed in the clinical pathway,
including which patient groups should be targeted for these kinds of interventions. The guidance also does
not currently clearly state how any type of education is best provided in primary or secondary care, such as
whether it should be provided in a structured, planned way or more informally by practitioners during
routine medical consultations.
Description of the technology under assessment
As stated, educational interventions are typically defined as providing patients with information about and
training in skills for managing their condition (see Current service provision).52 People with chronic skin
conditions and their carers have several educational needs. These include an understanding of the condition
(typically chronic and relapsing, with no cure at present, but in general manageable), an opportunity to try
treatments to find those that suit them best, reassurance that many treatments are generally safe and
effective, guidance on how best to apply topical treatments, and motivation to continue treatment when
the disease is in remission.59 Educational interventions have traditionally been based on what health-care
experts believed patients need to know about their conditions rather than patients’ expressed needs.60,61
Recently, however, there has been a movement in medicine towards greater patient involvement in
treatment and patient-centred care.62 A more patient-empowering subset of educational interventions are
self-management educational interventions, which focus on enabling patients to develop problem-solving
skills and teach patients actions that they can take to resolve issues (including emotional and psychosocial
issues) relating to their condition when they arise.52 Self-management educational interventions will often
involve the creation of patient action plans52 and represent a collaborative approach between HCPs and
patients.60 Patient activation is also an important part of promoting self-management in chronic diseases.63
Patient activation is defined as the extent to which patients believe and have confidence that they can play
an active part in managing their health and the extent to which they carry out and maintain activities which
can positively impact their condition and health more broadly. Patient activation is associated with better
QoL in patients in general64 and potentially could be improved through patient education.
Educational interventions may be delivered in a variety of ways, may include a number of inter-related
elements that either singly or together may bring about change in an outcome and some tailoring to
individual patient or carers’ needs, and therefore could be considered ‘complex interventions’.65 Medical
Research Council (MRC) guidance on the development and evaluation of complex interventions
emphasises the importance of early groundwork in developing an intervention.65 This should include
specification of a clear theoretical basis for the intervention that outlines its rationale and how it might
bring about change in the outcomes of interest, drawing on available evidence and theoretical models.
BACKGROUND
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This is because theory-based interventions tend to be more effective than those that are not theory-based.
The MRC guidance additionally recommends carrying out research, such as qualitative work, with potential
users, deliverers or creators of the intervention to supplement existing theory and evidence, if needed, to
further inform intervention development. The guidance also recommends that systematic reviews of
current evidence for the effectiveness of the intervention and pilot studies (e.g. to evaluate feasibility) are
carried out.
As another consideration in intervention development and delivery, it is also recommended in the wider
literature that educational interventions in dermatology should be sensitive to and take account of
patients’ social and cultural backgrounds, including their education level, literacy and preferred language,
and their favoured learning methods.66,67 Some degree of tailoring of the intervention to individual needs
might also be beneficial, as it has been found in health care generally that tailored interventions result in
better outcomes than more generic ones.68 Consideration might also be given to the characteristics of the
intervention deliverer, because it has been suggested that interventions delivered by people who have
similar characteristics to the intervention participants (such as similar social and ethnic backgrounds) might
be more effective than those delivered by people who differ to the participants.70 Ideally, evaluations of
complex interventions should include process evaluations to gain insight into contextual factors during
intervention delivery that may impact its effectiveness.65
Research studies have investigated a wide variety of approaches for educating patients with chronic
inflammatory skin diseases – mostly those with eczema and psoriasis, and, in some cases, their carers or
families also.2,36,55,70 The existing evidence for educational interventions in general shows variability in
whether these interventions are effective in improving HRQoL, but some studies have shown positive
effects.55,60,71 A systematic review of educational interventions for children with eczema and their parents
suggests that programmes for parents that are delivered by either a nurse or a multidisciplinary team may
lead to improvements in infant and child HRQoL and disease severity.71 However, there is currently little
understanding overall about which elements of educational interventions make them effective in improving
HRQoL and other outcomes.60,61
Our project Advisory Group of patients, HCPs and researchers indicated that educational interventions are
generally not widely used in UK clinical practice to supplement medical treatment for patients with chronic
inflammatory skin conditions. The Group suggested that education in primary care is especially limited and
will generally involve verbal instructions on medication use, provision of information leaflets and sign-posting
to other information sources. The Group stated that educational interventions are more commonplace in
secondary care and are often nurse-led and more likely to be planned and structured. These tend to involve
information giving and advice, combined with paper- or web-based information. The Group stated that,
overall, educational interventions are not sufficiently individualised and the creation of action plans is rare.
As part of educational interventions, patients with chronic inflammatory skin conditions are often provided
with information about their condition and the use of treatments. However, it has been suggested that the
impact of standard education in dermatology on HRQoL could be enhanced by the additional inclusion
of elements that address issues related to HRQoL. This review focuses on these additional elements as per
the commissioning brief. Our Advisory Group was aware of only two UK educational programmes that
specifically aim to improve HRQoL. One is The Eczema Education Programme,72 which is a nurse-led
programme delivered in the community and a specialised centre, which aims to improve parents’ and
carers’ management of their child’s eczema and parents’ QoL. Elements covered in the programme include:
understanding the disease, trigger factors and treatment; enhancing parental confidence in using
treatments; action planning; and practical strategies for reducing itching and sleep problems. A before- and
after- study evaluation of the programme73 found improvements in infant, child and parental HRQoL,
indicating that this may be a potentially successful approach. The other programme is an online intervention
delivered through the Supporting Parents and Carers of Children with Eczema (SPaCE) website for carers of
children with eczema.74
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As with educational interventions in general, it is currently unclear which specific elements of these
interventions may enhance HRQoL or what factors should be targeted to lead to improvements in HRQoL.
Where complex educational interventions for chronic skin diseases involve multiple interacting components
it may not be possible to identify which intervention components are responsible for observed effects on
outcomes.75,76 However, taxonomies of intervention techniques may be used, if appropriate, to map which
intervention components may be related to improved outcomes.69,77 In line with the MRC complex
interventions guidance,65 authors of some studies evaluating educational interventions for childhood
eczema aimed at improving HRQoL have provided information on the underlying theory of change. These
studies have hypothesised that educational interventions may improve HRQoL through enhancing the
ability to manage the disease,72,74,78 increasing self-efficacy72,78 (that is, patients’ or carers’ confidence in
their ability to successfully manage the condition79), promoting positive outcome beliefs and behavioural
capability78 and through the use of a number of other behaviour-change techniques.74 As far as the
authors of this review are aware, however, a clear theoretical basis for such interventions, including
potential underlying mechanisms of change, has not been adequately outlined in the literature.
Based on opinion from our Advisory Group, addressing the following factors may differentiate educational
interventions aimed at improving HRQoL from general educational interventions: unpredictability of the
disease, interaction of multiple factors, impact of everyday life (e.g. family, tiredness and personal and
work life) on the condition, mental well-being, negative thinking, coping skills (e.g. to cope with the
disease or for managing psychological distress), problem-solving and action planning, and management of
medication side effects. Additionally, the Group suggested that it may also be important to cover issues
relating to parental guilt associated with passing on a genetic disease, and parents’ or carers’ empathy and
appreciation of the impact of the disease. The Group also stated that educational interventions that
improve condition management may also result in improvements in HRQoL and emphasised the potential
importance of theory-based interventions in enhancing the effects of an intervention on this (e.g. through
the incorporation of elements hypothesised to improve self-efficacy from social cognitive theory80). The
literature shows that experiencing psychological difficulties, such as depression, is associated with poor
HRQoL in chronic inflammatory skin diseases, among other factors,33,39,40 and patients experiencing a high
psychosocial burden from their disease have been identified as a (psoriasis) subgroup requiring additional
support.81 Based on a model of delivery of psychosocial interventions for skin conditions generally,82
recommended nurse-delivered interventions for patients experiencing mild to moderate psychosocial
distress include training in relaxation techniques, scratching habit reversal, problem solving and ways of
camouflaging skin. It may be reasonable to assume that if these aspects are part of educational
interventions, they may also help enhance HRQoL.
In light of limited existing evidence, there is uncertainty about best practice methods for educational
interventions. Therefore, systematic reviews of clinical effectiveness as well as cost-effectiveness of
educational interventions aimed at improving QoL in people with chronic inflammatory skin diseases
are required.
Overall aims and objectives of assessment
The aim of this health technology assessment is to undertake systematic reviews of the clinical effectiveness
and cost-effectiveness of educational interventions for people with chronic inflammatory skin diseases.
The main objectives are:
1. to conduct systematic reviews of the clinical effectiveness and cost-effectiveness of educational
interventions for improving HRQoL in patients with chronic inflammatory skin diseases
2. if data permit, to adapt an existing economic model or construct a de novo model from the perspective
of the UK NHS to estimate the cost-effectiveness of educational programmes for chronic inflammatory
skin diseases
3. to identify deficiencies in current knowledge and to generate recommendations for future research.
BACKGROUND
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Chapter 2 Methods
The a priori methods for systematically reviewing the evidence of clinical effectiveness andcost-effectiveness were described in a research protocol which was sent to our expert Advisory Group
for comment. Although helpful comments were received relating to the general content of the research
protocol, none of the comments identified specific problems with the methodology of the review.
The methods outlined in the protocol are briefly summarised below.
During data extraction, we made a modification to our protocol to exclude post hoc those papers that
otherwise met our inclusion criteria, but which did not report a study’s results in sufficient detail to be
informative in the review.
Identification of studies
A comprehensive search strategy was developed, tested and refined by an experienced information specialist.
Separate searches were conducted to identify studies of clinical effectiveness and cost-effectiveness. Sources
of information and search terms are provided in Appendix 2. The most recent searches were undertaken in
July 2014.
Literature was sourced from 12 electronic databases, the bibliographies of included articles and relevant
systematic reviews, and our expert Advisory Group were contacted to identify any additional studies.
All databases were searched from inception and limited to the English language. The following electronic
databases were searched:
l The Cochrane Library, including the Cochrane Database of Systematic Reviews (CDSR), the Cochrane
Central Register of Controlled Trials, Centre for Reviews and Dissemination (University of York)
Database of Abstracts of Reviews of Effectiveness (DARE), the NHS Economic Evaluation Database
(NHS EED) and the Health Technology Assessment (HTA) database
l MEDLINE (Ovid)
l EMBASE (Ovid)
l MEDLINE In-Process & Other Non-Indexed Citations (Ovid)
l Cumulative Index to Nursing and Allied Health Literature (CINAHL) Plus with full text (EBSCOhost)
l PsycINFO
l Web of Science: Science Citation Index Expanded (SCIE) and Conference Proceedings Citation Index –
Science (CPCI) (ISI Web of Knowledge)
l Global Resource for Eczema Trials (GREAT) database (University of Nottingham).
A comprehensive database of relevant published and unpublished articles was constructed using Reference
Manager (Thomson ReseachSoft, San Francisco, CA, USA) software. Research-in-progress databases were
searched for any ongoing studies of relevance.
Searches for ongoing studies were undertaken in the following databases: UK Clinical Research Network
(UKCRN), controlled-trials.com, clinicaltrials.gov, World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP), Centre for Evidenced Based Dermatology (University of Nottingham),
UK Clinical Trials Gateway (UKCTG).
Inclusion and exclusion criteria
Studies were eligible for inclusion in the systematic reviews if they met the criteria outline below.
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Population
Adults, young people and children with a chronic inflammatory skin condition and/or their carers.
Intervention
Educational interventions that either specifically aimed to improve HRQoL or could improve HRQoL
[e.g. by targeting patients’ ability to cope with the negative effects of chronic skin disease or by targeting
compliance with therapy (with the aim of reducing the degree of skin affected)]. That is, to be included in
the review, the educational interventions needed explicitly to state that the aim of the intervention was
to improve HRQoL or, in the absence of this, the content of the intervention needed to focus on more
than just information about the specific skin disease and its treatment, and needed to address patients’
ability to cope with the negative effects of the disease (e.g. by providing education on stress management,
coping with itch or addressing the psychosocial effects of the disease, such as feelings of stigmatisation
attributable to changes in skin appearance) or adherence to therapy.
Any type of educational technique was permitted provided that effects of education on outcomes could
be isolated from effects of any non-educational intervention components that may also be present in the
intervention. Therefore, any interventions that were purely psychological approaches (e.g. to manage
distress) and did not seem to include an element of education were excluded.
Comparators
Any comparator was eligible. This could include treatment as usual, waiting-list controls, or other
educational interventions.
Outcomes
l HRQoL: only studies that measured HRQoL as an outcome, using a validated measure, were included.
The following outcomes, where reported in the included studies, were also included:
l disease severity
l disease control
l scratching behaviour (where applicable)
l health-care utilisation
l depression
l anxiety
l patient or carer self-efficacy regarding disease management (self-efficacy is defined as a person’s level
of confidence in their ability to perform particular behaviours to achieve desired outcomes,79 such as
successful self-management of a condition)
l process evaluations, including adherence to therapy, attitudes and knowledge.
Patient-reported outcome measures were included if assessed by validated tools. Reviewers considered that
a measure was validated if the publication stated that it was or, where this information was not available,
if a consultation of the wider literature determined that the measure fulfilled at least one validity criterion.
For the systematic review of cost-effectiveness, studies reporting measures of cost-effectiveness [e.g. cost
per quality-adjusted life-year (QALY), cost per life-year saved] were eligible.
Study design
For each skin disease, relevant randomised controlled trials (RCTs) were sought. If no RCT evidence existed
for a given disease, prospective trials with concurrent control group(s) were eligible.
The identified systematic reviews were used as sources of references only.
METHODS
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Studies were included in the systematic review of cost-effectiveness if they were full economic evaluations
(cost-effectiveness, cost–utility or cost–benefit analyses) that reported both measures of costs and
consequences or if they were cost–consequence or cost analyses.
Studies published as abstracts or conference presentations were only included if sufficient details were
presented to allow an appraisal of the methodology and the assessment of results to be undertaken.
Study selection and data extraction strategy
Studies were selected for inclusion in the systematic review of clinical effectiveness through a two-stage
process using the predefined and explicit criteria specified above. Titles and abstracts from the literature
search results were independently screened by two reviewers to identify all citations that possibly met the
inclusion criteria. Full papers of relevant studies were retrieved and assessed by one reviewer and checked
by a second reviewer using a standardised eligibility form. As far as possible, full papers or abstracts
describing the same study were linked together, with the article reporting key outcomes designated as the
primary publication. Any disagreements between reviewers were resolved by consensus or if necessary by
arbitration by a third reviewer.
Titles and abstracts identified by the search strategy for the systematic review of cost-effectiveness were
assessed for potential eligibility by two reviewers using the predetermined inclusion criteria. Full papers
were formally assessed for inclusion by one reviewer with respect to their potential relevance to the
research question and this was checked by another reviewer. Any disagreements between reviewers were
resolved by consensus or if necessary by discussion with a third reviewer.
Data were extracted by one reviewer using a standard data extraction form and checked by a second
reviewer. At each stage, any disagreements between reviewers were resolved by consensus or, if
necessary, by arbitration by a third reviewer.
In the systematic review of clinical effectiveness, for each study, results for outcomes measured at the
immediate end of the intervention and the longest follow-up time point (where this differed) were
extracted and presented. That is, results for any intermediary time points were not extracted. During data
extraction, a modified version of Schulz and colleagues’69 intervention taxonomy was used to structure
how and which information was extracted about the educational interventions in the included studies. The
taxonomy characterises the different elements of interventions. Based on this, the following intervention
components were extracted for each study: where it was delivered; whether it was a form of self-help;
whether it was individual- or group-based; mode; materials used; provider; duration and intensity; scripting
(use of a protocol guiding interaction between the interventionist and participants); sensitivity to
participant characteristics; interventionist characteristics and training; content and topics (including
educational strategies used); tailoring; and theoretical basis. Reviewers additionally extracted the following:
intervention overview and aims; stated target group; ongoing support provided; and whether individuals’
preferred learning styles were taken into account.
Critical appraisal strategy
The methodological quality and the quality of reporting of the included clinical effectiveness studies were
assessed using risk of bias criteria based on those recommended by Cochrane83 (see Appendix 3). Quality
criteria were applied by one reviewer and checked by a second reviewer, with any differences in opinion
resolved by consensus or by arbitration by a third reviewer.
Quality assessment for the systematic review of cost-effectiveness was based on a checklist for economic
evaluation publications.84
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Method of data synthesis
Studies of clinical effectiveness and cost-effectiveness were synthesised through a narrative review with
tabulation of results of included studies. In the systematic review of clinical effectiveness, studies were
grouped according to the condition being considered and the general age group of the participants.
It was not considered appropriate to combine the studies in a meta-analysis owing to the heterogeneity
between studies in patient characteristics (ages, conditions, duration of disease, severity of disease),
the interventions and the comparators.
Advisory group
The Advisory Group informed the protocol and provided comments on the near complete draft report.
In addition, members of the Advisory Group provided responses to specific questions around the current
use of educational interventions for chronic inflammatory skin disease, which informed the background
section of the report.
METHODS
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Chapter 3 Results of the systematic review of
clinical effectiveness
Quantity and quality of research available
Figure 1 shows the flow of studies through the review. Eight studies74,76,85–90 met the inclusion criteria.
Of these, seven were RCTs74,76,85–89 and one was a controlled clinical trial (CCT).90 The CCT90 evaluated an
educational intervention for psoriasis. In line with our review protocol, which pre-specified that CCTs
would only be included if no RCT evidence existed for a particular condition, the CCT is not discussed
further because RCT evidence was available for psoriasis.
Total identified from searching
(after deduplication)
(n = 2628)
Titles and abstracts inspected
(n = 2628)
Full-text references
retrieved and screened
[n = 63 (2%)]
Studies included in our
review, n = 8
(7 RCTs and 1 CCT)
Not reported in our review:
psoriasis CCT (n = 1),
owing to RCT evidence being
available for psoriasis
(as per review protocol)
References identified
from systematic reviews
and reference lists of
included studies
(n = 3)
Excluded
[n = 2565 (98%)]
Full text unobtainable
[n = 3 (< 1%)]
Full papers excluded (n = 55)
(87%) (listed in Appendix 4),
for the following reasons:
• Did not measure HRQoL, using
   a validated measure, n = 28
• Not a RCT or CCT, n = 2
• Not an educational intervention
   focused on improving HRQoL
   and/or educational and other
   aspects inseparable, n = 14
• Abstract or conference 
   presentation with insufficient
   information, n = 6
• Study protocol, n = 1
• Insufficient reporting of
   results in paper, n = 4
FIGURE 1 Flow chart for the identification of studies in the review of clinical effectiveness. CCT, controlled
clinical trial.
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Searches identified 2628 records, of which 2565 were excluded at title and abstract screening. At the
full-text screening stage of the review, 63 references were reviewed and 55 were excluded. The main
reasons for exclusion were that studies did not measure HRQoL using a validated measure (n= 28) or that
the intervention was not an educational intervention that aimed to, or could, improve HRQoL, and/or the
effect of the educational component of the intervention on outcomes could not be isolated from the effect
of other non-educational components of the intervention (n= 14) (see Appendix 5 for a full list of reasons
for specific exclusions). Three studies, reported in four publications,78,91–93 were excluded for not reporting
results in sufficient detail to be informative in the review. Of these, one reported in Staab and colleagues93
and Wenninger and colleagues78 was a RCT examining a theory-based programme called the ‘Berlin
education programme’ for parents of children with atopic dermatitis, aimed at improving HRQoL and the
disease course, which covered medical, nutritional and psychological issues. The authors reported limited
numerical data in the results. For example, data were reported for only one of the five dimensions of a
disease-specific HRQoL measure. The other two excluded studies were Jaspers and colleagues91 and Lora
and colleagues,92 which were RCTs of a combined psychoeducational and dermatological treatment
programme delivered by a multidisciplinary team for young adults with atopic dermatitis and a
psychoeducation programme for patients with psoriasis, respectively. Jasper and colleagues91 provided
numerical results for only one domain of the Short Form questionnaire-36 items (SF-36) (HRQoL measure) at
10 weeks post intervention and narratively reported changes for other domains at 10, 20 and 40 weeks
post intervention as non-significant. Lora and colleagues92 presented no results for the HRQoL measure they
used. Such exclusions as a result of poor quality reporting are important to note, because these studies
otherwise met the review inclusion criteria and formed around one-third of the relevant evidence-base –
this issue is considered further below (see Discussion).
Characteristics of the included trials
Table 2 provides an overview of the characteristics of the seven included RCTs. Detailed information about
the educational intervention(s) evaluated in each RCT is provided in Table 3, with full details also provided in
Appendix 6. The full data extraction forms are shown in Appendix 4. Two RCTs, by Balato and colleagues85
and Ersser and colleagues,86 assessed the effects of daily text message education over 12 weeks and a
one-off nurse-delivered educational session for adults with psoriasis; one RCT by Matsuoka and colleagues88
focused on instructions in make-up use and skin care from a dermatologist to adult women with acne; and
two RCTS, by Staab and colleagues87 and Santer and colleagues,74 focused on children (and adolescents in
one trial87) with atopic dermatitis and their parents or carers, evaluating a 6-week educational programme
delivered by a multidisciplinary team and an educational website (the ‘SPaCE website’), respectively. The
educational interventions in the remaining two RCTs, by van Os-Medendorp and colleagues89 and Bostoen
and colleagues,76 were delivered to people with a mixture of skin conditions. van Os-Medendorp and
colleagues89 included people with chronic pruritic skin diseases (including eczema, atopic dermatitis,
pruritus, prurigo, psoriasis and chronic urticaria) and evaluated a ‘Coping with itch’ programme, and
Bostoen and colleagues76 included people with either psoriasis or atopic dermatitis in an evaluation of a
3-month programme delivered by a multidisciplinary team.
Five of the included RCTs74,76,86,88,89 compared educational programmes with standard care for the skin
condition. Balato and colleagues85 and Staab and colleagues87 compared the text message education and
3-month educational programme with a ‘control intervention’ and a ‘no education control’, respectively,
but did not provide details about what, if any, treatment was given to the control conditions. In six
RCTs74,76,85,86,88,89 the educational interventions were delivered as an adjunct to standard medical care, and
it was unclear if it was an adjunct in the remaining trial evaluating the 6-week programme including
children with atopic dermatitis and their carers.82 Only one RCT74 compared two different approaches to
the education delivery, in addition to comparing each educational approach with standard care. This trial
compared education delivered through the SPaCE website only with education delivered through the
same website, but with additional support through a one-off appointment with a HCP who promoted
engagement with the website and supported participants in completing some of the modules.
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Only two UK studies were identified.74,86 One examined the effects of a one-off educational session for
patients with psoriasis in primary care86 and the other was also set in primary care, but provided education
mainly through the SPaCE website.74 The other RCTs were conducted in a range of countries and settings,
including secondary care in the Netherlands89 and Japan88 and home-based education in Italy.85 In the
remaining RCT,76 conducted in Belgium, the setting was unclear. The generalisability of these studies to
the UK setting is, therefore, unclear.
No studies of any other chronic inflammatory skin diseases were identified in our searches.
All tables are ordered by condition and then by patient age group within condition.
The largest RCT was of 992 children and adolescents with atopic dermatitis and their parents.87 One other
RCT of mixed skin conditions had a sample size of 120 participants89 and another of children with eczema
and their parents or carers had a sample size of 149.74 Sample sizes in the four remaining trials,76,85,86,88
including all the RCTs of patients with psoriasis, ranged from 40 to 64 participants. One study measured
outcomes at the end of the intervention only,85 with the other six74,76,86–89 employing various lengths of
post-intervention follow-up, ranging from 4 weeks88 to 12 months.87 Three studies76,87,89 had a follow-up of
a reasonable duration to capture the clinical effects of the intervention (≥ 3 months post intervention;
which the review Advisory Group suggested would be the minimum follow-up time necessary in studies to
measure the effect and durability of patient benefits from an intervention).
Aims, content and structure of the educational interventions in
the included trials
During data extraction, a modified version of a taxonomy of elements of interventions developed by Schulz
and colleagues69 was used to structure how information about the interventions in each trial was recorded
(see Methods for more information about this). Following this principle, an overview is provided here of
the educational interventions in each trial, with summary details shown in Table 3. More detailed
information about the interventions, covering all elements extracted, can be found in Appendix 6.
The aims, content and structure of the educational interventions were heterogeneous across the seven
included RCTs. Only one of the included studies,74 of the SPaCE website intervention, explicitly reported
that the aim of the intervention was to improve HRQoL (although another, by Staab and colleagues,87
was in part based on the ‘Berlin education programme’ reported in the excluded Staab and colleagues93
and Wenninger and colleagues78 publications, and these linked publications state that the aim of the
intervention was to improve HRQoL; see Table 3 for more details). The other studies were included in the
review because it was inferred from the content that the intervention could improve HRQoL (e.g. it
included aspects that targeted compliance or patients’ ability to cope with the negative effects of
their disease).
Three of the studies reported that the educational interventions were theory-based. The one-off
educational session for patients with psoriasis in Ersser and colleagues86 and the 6-week programme for
atopic dermatitis in Staab and colleagues87 were based on social cognitive theory. The SPaCE website
intervention in the trial by Sanler and colleagues74 incorporated 20 of the 26 behaviour-change techniques
listed in Abraham and Michie’s77 taxonomy of behaviour-change techniques. The design of the
intervention in Ersser and colleagues86 was additionally informed by findings of previous qualitative
research on the self-management needs of individuals with psoriasis. Similarly, the design and content
of the SPaCE website in Santer and colleagues74 was based on qualitative interviews and input from a
patient support group, as well as evidence-based patient information leaflets, ‘think-aloud’ interviews with
users of a draft version of the website and feedback from other parents and HCPs.
The educational content and strategies used in the interventions varied across the studies. All the trials
except one86 reported that participants were provided with information about the skin disease, its
treatment, skin care, or the causes, consequences and treatment of itch. The interventions also commonly
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included education about stress-reducing or relaxation techniques (reported in five RCTs74,76,86,87,89) and
living a healthy lifestyle and/or nutritional issues (reported in five RCTs74,76,85,87,89). Other psychosocial
aspects included education on coping with the disease and managing itching, scratching and sleep,74,87,89
managing the psychosocial consequences of the disease,85 and provision of information about patient
support groups.89 The SPaCE website for carers of children aged 5 years or younger with eczema also
contained information about how to involve their child in their treatment and guidance for carers on how
to manage a consultation with their GP.74 The intervention in the trial by Matsuoka and colleagues,88
in which patients with acne were provided with instructions on skin care and make-up use, could be
considered to help patients manage appearance concerns and the feelings of stigma associated with their
condition. As well as information provision, the reported education strategies used included encouraging
participants to share experiences,87 discussion of difficulties in transferring newly learnt skills into their
everyday lives,87 individual action planning or creation of (self-)management plans,74,86,87,89 feedback
sessions,76 a 2-week challenge involving short message service (SMS) text alerts for setting goals,
monitoring and rehearsing behaviours,74 and cognitive behavioural therapy, including habit reversal to
reduce scratching.89 Where reported, the duration and intensity of the educational interventions ranged
from two 20-minute compulsory online modules (plus optional additional modules)74 to a 3-month
programme consisting of two 3-hour sessions a week.76
In all the RCTs except one,85 educational interventions were delivered at least in part through face-to-face
sessions, and in three trials it was also delivered in groups. Group sizes across and within the studies
ranged from 5 to 23 participants.76,86,87 In the RCT by Santer and colleagues,74 the intervention was mainly
delivered online (via the SPaCE website), but one group also received additional support from a HCP in a
face-to-face appointment. Participants could also opt to take part in a 2-week challenge, which involved
receiving behavioural prompts by text message. It is unclear if the instructions in skin care and using
make-up were provided to patients individually or as part of groups in the RCT by Matsuoka and colleagues.88
In one trial85 education was provided to individuals solely by daily text messages, over a period of 12 weeks.
The educational interventions were delivered by a multidisciplinary team in two RCTs,76,87 a nurse in another
two RCTs86,89 and a dermatologist in one RCT.88 In the Santer and colleagues RCT,74 the SPaCE website, which
had been developed by medical experts and informed by patient support groups, was the main delivery
mechanism. The HCPs who provided support to one group varied across the general practices taking part and
were the practice nurse in 11 practices, a health-care assistant in one practice and a GP in one practice. Only
one of the HCPs was dermatology trained. In the remaining RCT, of text message education,88 it was unclear
who provided the intervention. Three trials74,86,87 reported information about the interventionist characteristics,
with all stating that the interventionists received training prior to delivering the programmes (although this
was minimal in Santer and colleagues74 and consisted of 1 hour for the HCP to familiarise themselves with
the SPaCE website). None of the RCTs provided information about whether the people delivering the
educational interventions had similar characteristics to the patients taking part, such as similar social and
ethnic backgrounds.
Ersser and colleagues,86 Bostoen and colleagues76 and Staab and colleagues87 reported that the
interventionist was required to follow a protocol, syllabus or content manual, respectively, to standardise
delivery. Delivery of the text message85 and website education74 was also standardised (but with some
optional as well as compulsory modules on the website). In Ersser and colleagues,86 there was flexibility for
the intervention to be tailored to participants’ needs. Another two RCTs74,89 also reported that, to some
extent, the educational interventions were tailored to patients’ individual needs. The interventions in
two trials85,87 were sensitive to participants’ characteristics to some extent, by providing parent and child
education according to age group87 and ensuring that text messages were written in simple language.85
None of the interventions took into account individuals’ preferred learning styles.
Outcomes assessed in the included trials
As per our inclusion criteria, all seven RCTs measured HRQoL using one or more validated measures.
All seven trials also measured disease severity as an outcome. Other measured outcomes were: depression,
stress, lifestyle (measured by a set of unvalidated questions in one trial76), health resource use, medication
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and ointment use, cost-effectiveness, itching behaviour, itch-related coping, skin-related psychosocial
morbidity, general psychosocial morbidity, patient–physician relationship, attitudes and perceptions of
ability to manage the condition, and treatment adherence. Only one trial88 measured adverse events. In
line with our protocol, patient-reported outcome measures were extracted and included in the review only
if assessed by validated tools. HRQoL was a primary outcome in four of the trials76,86,87,89 and a secondary
outcome in one trial.74 The remaining two trials85,88 did not specify if outcomes were primary or secondary.
Three RCTs74,85,86 included process measures that could be regarded as ‘process evaluations’ (e.g. assessing
patients’ perceptions of the usefulness of the intervention).
Four of the included trials76,85,86,88 measured HRQoL using the DLQI, which is a dermatology-specific,
self-report measure.95 van Os-Medendorp and colleagues89 measured HRQoL using the QoL subscale of the
Adjustment to Chronic Skin Diseases Questionnaire (ACS), which measures skin-related psychosocial
morbidity. Staab and colleagues87 measured parents’ HRQoL using the German questionnaire ‘Quality of
life in parents of children with atopic dermatitis’. Santer and colleagues74 measured the impact of the
website for carers on each family’s QoL using the Dermatitis Family Impact (DFI) questionnaire and also
measured the impact on the carers’ children’s HRQoL using the IDQoL (for children aged ≤ 4 years) and the
CDLQI (for children aged ≥ 5 years). Other HRQoL measures used in the RCTs were: Skindex-29,76 PDI,76
Quality of Life Index for Atopic Dermatitis (QoLIAD)76 and WHOQOL-26.88 For more information about the
most commonly used measures and how they are interpreted, please see Appendix 1.
Disease severity was assessed using a range of measures, including the PASI (used in all three trials that
included patients with psoriasis76,85,86), the SCORAD (used in two studies including patients with atopic
dermatitis76,87) and the POEM (used in a study of children with eczema and their carers74). Other measures
used were the Plewig and Kligman’s grade measure of acne severity88 and a patient-reported measure of
the frequency and intensity of itching.89 For more information about the most commonly used measures
and how they are interpreted, see Appendix 1.
Participants’ baseline characteristics
Table 4 shows the baseline characteristics of the participants randomised in each of the trials. Generally,
across the trials, 50% or more of the participants in each study arm were women. The RCT by Matsuoka
and colleagues,88 which evaluated skin care and make-up instructions for patients with acne, focused
exclusively on women. Most carers of children randomised in the trial by Santer and colleagues74 were
women. The overall mean age of participants in the studies of adult patients ranged from 3885 to
59 years,86 except in the trial by Matsuoka and colleagues88 where the mean age of the women was
24 years and 25 years in each arm. In the trial of children and adolescents with atopic dermatitis,87 the
baseline mean ages were around 2 years in the 3 months to 7 years age group, 10 years in the 8–12 years
age group and 15 years in the 13–18 years age group. In Santer and colleagues,74 the majority of carers
were aged between 26 and 40 years and the ages of the children were between 0 to 5 years, as per
the study inclusion criteria. None of the trials reported the participants’ ethnicity. Across the four trials
reporting participants’ socioeconomic characteristics,74,76,85,89 there was a mixture of levels of education and
employment status, see Table 4.
Five trials reported the length of time participants had had their skin condition.76,85,86,88,89 In four trials, the
disease duration ranged from a mean of around 11 to 24 years.76,85,86,89 Patients with acne in the trial by
Matsuoka and colleagues88 had been diagnosed with their condition for a slightly shorter duration (for a
mean of 7 years and 4 years in each study arm). Only two studies reported participants’ comorbidities, and
these included hypertension, dyslipidaemia, type 2 diabetes and unspecified ‘complications’.85,88 Where
measured with the same tool, baseline disease severity was similar across trials of the same condition.
An exception was that participants in the trial by Ersser and colleagues86 had milder psoriasis than the
participants in the two other psoriasis trials (this may be because the participants in Ersser and colleagues
were recruited from primary care).76,85
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Four of the trials,76,85,86,88 including all three of patients with psoriasis,76,85,86 used the DLQI to measure
HRQoL. On this measure, participants’ baseline HRQoL was comparable across three of the studies, with
mean scores in each study arm ranging from 6.24 to 9.7.76,85,88 According to the DLQI website,96 these
scores indicate a moderate disease effect on patients’ HRQoL. In the remaining trial86 of patients with
psoriasis, mean scores were 4.86 and 4.18 in the intervention and control groups, respectively, indicating a
small effect on patients’ HRQoL.96 Participants in this trial therefore had generally experienced less impact
on their HRQoL than the participants in the other psoriasis trials. In addition to the DLQI, Matsuoka and
colleagues88 used the WHOQOL-26 to measure HRQoL in patients with acne. The authors cite a normative
mean score of 3.33 for healthy Japanese women aged 20–29 years, and state that the baseline scores
of the participants were similar to this, suggesting that, on this measure, their HRQoL had not been
extensively adversely affected by their condition. In the three trials using less common methods to assess
HRQoL,74,87,89 the meaning of the baseline scores is unclear, because authors did not provide
this information.
Baseline characteristics and baseline scores for outcome measures were generally similar between the
intervention and comparator groups in all the trials. Exceptions were that in the RCT by Ersser and
colleagues86 there were proportionally more women in the intervention than the control group and that
in the Santer and colleagues trial74 POEM baseline scores were slightly higher in the website and
website+HCP support groups than the usual care group. In the Bostoen and colleagues trial,76 rates of
depression were higher in the intervention group than the control group.
Quality of reporting and methodology of the included trials
The quality of the reporting and methodology of the included trials was generally poor (Table 5), with only
two studies86,88 judged not to be at high risk of bias on at least one domain, and all RCTs including at least
one domain judged to be at unclear risk of bias, with few instances of low risk of bias. Five trials74,76,85–87
reported adequate random sequence generation, but only one of the seven included trials clearly reported
how allocation was concealed and, therefore, the remaining six were judged to be at an unclear risk of
bias. Most trials were judged to be at an unclear risk of performance and detection bias, because they did
not report if participants, study personnel or outcome assessors were blinded to treatment allocation.
Balato and colleagues85 and Staab and colleagues87 were judged to be at high risk of performance bias;
in Balato and colleagues,85 although it was noted that physicians were blinded to group assignment
until the end of the study, no details were provided about the blinding of participants, and in Staab and
colleagues87 it was stated that participants and trainers were not blinded to treatment allocation. The trial
by Staab and colleagues87 was also judged to be at high risk of detection bias (on self-reported measures)
because participants were not blinded, and it was unclear if the investigators who rated eczema severity
were blinded to treatment allocation. However, it may be difficult to blind participants to the fact they are
taking part in an educational intervention rather than just receiving standard medical care, but this
criterion is still appropriate for demonstrating potential risks of bias.
Incomplete outcome data were adequately addressed in three trials85,86,88 either because all participants
completed the trial and were analysed according to their randomised groups,85,88 or because attrition was
balanced across arms with similar reasons for drop-out and was therefore considered unlikely to bias the
results.86 One trial74 was rated as being at an unclear risk of bias on this criterion, because, although
attrition rates were small and balanced across groups, clear reasons were not reported for the attrition,
and, in addition, one participant was randomised and excluded from the analysis because technical
difficulties resulted in baseline data not being available for this participant. The other three trials76,87,89
were considered to be at high risk of attrition bias, either because drop-outs were unbalanced between
groups76,87 or because there was a high overall rate of attrition89 (with no exact reasons provided other
than that participants did not return study measures at particular time points and that four participants in
the control group received the intervention and therefore were excluded) and no intention-to-treat (ITT)
analyses were used. In addition, one participant in the educational intervention group in Bostoen and
colleagues76 was excluded from the analysis owing to experiencing extreme stress at work during the study.
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Two trials were assessed as being at low risk of selective reporting, because the authors reported results
for all the outcome measurements specified in the methods section of the paper.85,86 Four were considered
to be at an unclear risk of bias for various reasons, including narratively reporting results for many of
the outcomes without providing supporting numerical data;76 converting a continuous measure to a
dichotomous measure for a severity of itching and scratching outcome;89 reporting within-group p-values
for two HRQoL outcomes, with between-group p-values reported for only one of the measures;88 and
measuring outcomes at 6 and 12 months’ follow-up, but not reporting the 6-month outcomes.87 The RCT
by Santer and colleagues was considered to be at high risk of selective reporting bias, because results for
the IDQoL and CDLQI measures of HRQoL were not reported.74 Results were also not reported for a
number of other measures [specifically, self-report measure of emollient use; Problematic Experiences of
Therapy Scale (PETS); attitudes measure; and Patient Enablement Instrument].
Other potential sources of bias were identified in three trials where this was rated as ‘unclear’. In Bostoen
and colleagues76 most results were presented as subgroup analyses for atopic dermatitis and psoriasis
patients and it was unclear if these were adequately powered or pre-specified. In Ersser and colleagues86
a statistically significant higher proportion of participants in the intervention group compared with the
control group were women. In Santer and colleagues,74 there were baseline imbalances in disease severity
across groups, with both website groups having slightly more severe disease at baseline than the usual
care group, and it was unclear if this had been adjusted for in the data analysis. In Santer and colleagues,74
TABLE 5 Quality assessment of the included RCTs (Cochrane risk of bias criteria)
Study, skin
condition
(population)
Random
sequence
generation
(selection
bias)
Allocation
concealment
(selection
bias)
Blinding of
participants
and personnel
(performance
bias)
Blinding of
outcome
assessment
(detection
bias)
Incomplete
outcome data
(attrition bias)
Selective
reporting
(reporting
bias)
Other
bias
Balato et al.,
2013,85 plaque
psoriasis (adults)
Low risk Unclear risk High risk Unclear risk Low risk Low risk Low risk
Ersser et al.,
2011,86 psoriasis
(adults)
Low risk Unclear risk Unclear risk Unclear risk Low risk Low risk Unclear
risk
Bostoen et al.,
2012,76 psoriasis
or atopic
dermatitis (adults)
Low risk Unclear risk Unclear risk Unclear risk High risk Unclear
risk
Unclear
risk
Santer et al.,
2014,74 eczema
(children and
parents/carers)
Low risk Low risk Unclear risk Unclear risk Unclear risk High risk Unclear
risk
Staab et al.,
2006,87 atopic
dermatitis
(children,
adolescents and
parents)
Low risk Unclear risk High risk High risk High risk Unclear
risk
Low risk
Matsuoka et al.,
2006,88 acne
vulgaris (adults)
Unclear risk Unclear risk Unclear risk Unclear risk Low risk Unclear
risk
Low risk
van Os-Medendorp
et al., 2007,89
chronic pruritic skin
disease (adults)
Unclear risk Unclear risk Unclear risk Unclear risk High risk Unclear
risk
Low risk
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statistical analyses were also reported inconsistently; specifically, mean change in the POEM score was
presented for the combined website groups versus usual care, not individual website groups versus usual
care (therefore this result was not data extracted or presented in this review).
Completeness of reporting of the interventions
During data extraction, a modified version of a taxonomy of elements of interventions69 was used to
structure how information about the interventions in each trial was recorded. Table 6 shows the elements
extracted and whether or not each trial reported details for each. The seven included trials generally
provided adequately detailed descriptions of the educational interventions, particularly the content and
topics, mode of delivery, providers, materials used and duration and intensity. Few trials explicitly reported
the intervention aim, whether the intervention was theory-based, where it was delivered, whether
elements were tailored to participants’ needs, the extent to which it was sensitive to participants’
characteristics, the interventionist characteristics and training, or whether ongoing support was provided
after the intervention ended.
Statistical issues
All the trials were superiority trials (where the aim is to demonstrate that one treatment is more effective
than another). Only two trials76,87 reported power calculations. Despite this, in both it is unclear if the
analyses that generated the results were adequately powered. In Bostoen and colleagues76 the results were
mainly presented for subgroup analyses of patients with either psoriasis or atopic dermatitis and the power
calculation was for the total sample size on an unspecified outcome [note that the subgroup results are
presented separately below under each condition-specific section; results for two outcomes [stress and
European Quality of Life-5 Dimensions (EQ-5D™) HRQoL measure] were reported for the total group, but
only narratively and, therefore, they have not been included in this review]. In Staab and colleagues,87
the analyses of the results for the 3 months to 7 years age group appeared to be adequately powered
(power calculation was based on the primary outcome, eczema severity), but it is unclear if the analyses of
the results for the 8–12 years and 13–18 years age groups were adequately powered, because fewer
participants per group were analysed than the 125 per group calculated as being needed. Three of the
studies that did not report power calculations, including two psoriasis studies, were pilot studies.74,85,86
Overall, with the exception of the analyses of the 3 months to 7 years age group in the Staab and
colleagues RCT,87 it is unclear if any of the analyses presented in the trials and included in this review were
adequately powered. It should also be noted that all the evidence available for psoriasis was based on
either pilot studies85,86 or subgroup analyses.76
Total attrition rates in five trials ranged from 0% to 26%,74,76,85–88 with four of these74,85,86,88 having no
attrition or low attrition rates. The attrition rate in the remaining trial,89 in which the ‘Coping with itch’
programme was delivered to patients with chronic pruritic skin diseases during a median of three clinic
visits, was particularly high at 58% overall, with 63% and 51% of patients in the education and control
groups, respectively, not completing the trial. None of the trials reported use of ITT analyses, except Santer
and colleagues,74 but reviewers note that the analyses in Santer and colleagues74 were not true ITT
analyses, as not all randomised carers were included in the analyses. As stated above, the analyses in
two trials85,88 can be regarded as ITT, as all patients were analysed according to their randomised groups.
Generally, the trials reported results as point estimates (means) for outcomes in the intervention and
control groups, and provided measures of variability around these as either standard deviations (SDs) or
95% confidence intervals (CIs). In a number of instances, findings were reported only narratively, with no
supporting numerical data provided (see the results sections for each skin condition in Assessment of
effectiveness for specific details of where this occurred). Trials mostly reported the statistical significance of
between-group differences, either narratively or by providing p-values. Only two trials86,87 reported CIs
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around between-group differences. Four of the trials provided some commentary in the publications on
the definitions of clinically meaningful change in particular outcomes (specifically, the DLQI,76 PASI,86
SCORAD87 and POEM74), but only two directly applied these definitions to the interpretation of the results
in the trial. Of these, one study,74 of the SPaCE website, reported the proportion of children with eczema
who had experienced a clinically meaningful improvement in disease severity. The other,87 of a 6-week
programme for atopic dermatitis, commented generally on whether the average improvement in disease
severity among children and adolescents with atopic dermatitis seen in the study could be considered
clinically significant.
Generalisability to UK clinical practice
The majority of the included trials are considered to be of limited generalisability to UK clinical practice,
because most were small-scale studies conducted across a range of countries. The largest UK study was
Santer and colleagues’74 evaluation of education delivered through the SPaCE website to 149 carers of
children with eczema, most of whom were managed in primary care. Reviewers considered this trial to be
of good generalisability to patients treated in primary care in the UK, because participants were recruited
from 31 general practices and a range of socioeconomic areas. The other included UK study86 was a small
pilot study in primary care, conducted in patients with psoriasis. In this study, participants’ baseline
HRQoL scores indicated that their psoriasis had had, on average, a small effect on their HRQoL and the
participants appeared to have, on average, milder disease at baseline compared with participants in the
other psoriasis trials. Given this, it is also of some generalisability to UK clinical practice in primary care and
to patients whose condition has had only a small impact on their HRQoL. The large-scale German trial of
an educational intervention for children and adolescents with atopic dermatitis and their parents87 could be
considered of some relevance to patients with moderate to severe atopic dermatitis seen in secondary care
because it was conducted in seven centres with a range of different age groups and should thus capture a
wider group of patients. However, the health-care system is likely to be different from the UK. In general,
around 50% or more of the patients included in each of the arms of the studies were female, and this is
reasonably representative of the chronic inflammatory skin condition populations in the UK. For example,
psoriasis tends to affect equal proportions of males and females (see Epidemiology).17 Acne also affects
equal proportions of males and females,25 but the one included study of acne focused exclusively on
women aged over 16 years and, therefore, its results may apply only to women in this age group and are
unlikely to generalise to men (given that the intervention is, in part, focused on make-up use) or younger
adolescents, who are commonly affected by this condition (see Epidemiology). Overall, therefore, the
results presented below for educational interventions for children with eczema and their carers are the
most generalisable to the UK.
Assessment of effectiveness
Trials of educational interventions for psoriasis
Three small trials, by Balato and colleagues,85 Bostoen and colleagues (a subgroup),76 and Ersser and
colleagues,86 examined educational interventions that could improve HRQoL in patients with psoriasis, as
an adjunct to standard medical care. Participants in the trial by Balato and colleagues85 were provided with
educational text messages over 12 weeks. In the trial by Bostoen and colleagues,76 patients took part in an
educational programme delivered in twice-weekly, 2-hour sessions over 3 months by a multidisciplinary
team. In Ersser and colleagues,86 a shorter (a single, 2-hour session, supplemented by a 20-minute
follow-up telephone call), theory-based, nurse-delivered self-management programme, targeted at
individuals with mild to moderate plaque psoriasis, was delivered in primary care. The educational
interventions in both Bostoen and colleagues76 and Ersser and colleagues,86 were compared with usual
medical care alone. In the trial by Balato and colleagues,85 the text message education intervention was
compared with an unspecified control intervention.
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Balato and colleagues85 reported results for outcomes at 12 weeks (the end of the intervention), Bostoen
and colleagues76 at 3 months (the end of the intervention), 6 months (although this was not data extracted
and not reported here) and 9 months, and Ersser and colleagues86 at 6 weeks’ follow-up. At baseline,
participants included in the trial by Ersser and colleagues86 had generally milder disease and had
experienced less impact on their HRQoL than the participants in the other two trials.76,85 (see Table 4).
The results presented were from either pilot studies85,86 or subgroup analyses of patients with psoriasis who
were part of a larger trial (see Statistical issues).76
Health-related quality-of-life outcomes
All three trials used the DLQI to measure HRQoL. Bostoen and colleagues76 additionally used the PDI and
Skindex-29. Skindex-29 results were reported only narratively, with no supporting data provided. Balato
and colleagues,85 and Bostoen and colleagues76 found that patients who received the text message
education and the 3-month educational intervention, respectively, had better DLQI scores at the end of the
interventions than those who had received the control interventions (Table 7). However, this effect was
not maintained at 9 months from baseline in Bostoen and colleagues.76 In Bostoen and colleagues, the
3-month educational intervention group also had better PDI scores at the end of the intervention, and
this was maintained at 9 months.76 No statistically significant differences between groups were found
on the Skindex-29. Ersser and colleagues86 found no statistically significant difference between the
one-off education session and usual care alone groups in change in DLQI scores between baseline and
6 weeks’ follow-up.
TABLE 7 Health-related quality-of-life results in studies examining educational interventions for psoriasis (adults)
Study Measure, time point
Score, mean (95% CI) unless otherwise stated
Intervention Control
Difference between
groups
Balato et al.,
201385
DLQI, mean (SD)
Baseline 7.9 (3.2) (n= 20) 7 (3) (n= 20)
12 weeks (intervention end) 4.2a (n= 20) 5.8a (n= 20) p-value< 0.05
Bostoen et al.,
201276
DLQI (n unclear for all
time points)
(n unclear for all
time points)
Baseline 8.4 (5.6, 11.2)a 6.6 (3.9, 9.3)a
3 months (intervention end) 4.4 (1.3, 7.4) 6.4 (3.6, 9.2) p-value= 0.019
9 months 4.0 (0.6, 7.4) 5.8 (2.9, 8.8) p-value= 1.00
PDI
Baseline (SD) [95% CI] 9.0 (6.8)
[5.0 to 13.0]b
7.6 (7.8)
[3.8 to 11.5]b
3 months (intervention end) 4.3 (0.1, 8.4)b 6.7 (2.9, 10.6)b p-value= 0.015
9 months 4.9 (0.3, 9.5) 7.4 (3.3, 11.6) p-value= 0.021
Ersser et al.,
201186
DLQI, mean (SD)
Baseline 4.86 (5.14) (n= 26) 4.18 (3.19) (n= 33)
6 weeks 4.58 (5.05) (n= 26) 3.70 (3.71) (n= 33)
Change from baseline 0.28 (2.16)c (n= 26) 0.48 (3.02)c (n= 33) 95% CI: –1.20 to 1.61;d
p-value=0.772
DLQI scores can range from 0 to 30; a higher score indicates a worse HRQoL.97 A higher score on the PDI indicates
worse HRQoL.95
a Estimated from a figure.
b Note, a variety of baseline and 3-month values were reported for each outcome in Bostoen and colleagues76 with no
explanation about why different values were reported.
c Change (reduction) from baseline; a reduction shows that HRQoL improved. (See Appendix 4 for detailed information
about how measures are interpreted.)
d Point estimate for difference not provided in publication.86
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Disease severity outcomes
All three trials measured disease severity using the PASI. Balato and colleagues85 additionally used the
SAPASI, body surface area (BSA) and physician’s global assessment (PGA). On all the disease severity
measures employed in Balato and colleagues85 and Bostoen and colleagues,76 participants who received
the text message education and 3-month educational intervention, respectively, showed statistically
significant better scores (i.e. less severe disease) than the control groups at the end of the interventions
(Table 8). However, Bostoen and colleagues76 found no statistically significant difference between groups
on the PASI at 9 months after the start of the intervention. Ersser and colleagues86 found no statistically
significant differences in change in disease severity between the one-off education session and usual care
alone groups at the 6-week follow-up assessment.
TABLE 8 Disease severity results in studies examining educational interventions for psoriasis (adults)
Study Measure, time point
Score, mean (SD) (unless otherwise stated)
Intervention Control
Difference between
groups
Balato et al.,
201385
PASI
Baseline 10.64 (4.2) (n= 20) 10.13 (4.7) (n= 20)
12 weeks (intervention end) 5.8a (n= 20) 6.8a (n= 20) p-value< 0.05
SAPASI
Baseline 11 (6.6) (n= 20) 10.90 (5.9) (n= 20)
12 weeks (intervention end) 5.9a (n= 20) 8a (n= 20) p-value< 0.05
BSA
Baseline 16 (7.5) (n= 20) 14.2 (8) (n= 20)
12 weeks (intervention end) 5.8a (n= 20) 8a (n= 20) p-value< 0.05
PGA
Baseline 2.6 (1.04) (n= 20) 2.3 (1.3) (n= 20)
12 weeks (intervention end) 0.7a (n= 20) 1.5a (n= 20) p-value< 0.05
Bostoen et al.,
201276
PASI, mean (95% CI) (n unclear for all
time points)
(n unclear for all
time points)
Baseline 8.4 (6.0 to 10.8)b 7.1 (4.8 to 9.4)b
3 months (intervention end) 6.8 (4.3 to 9.3)b 8.1 (5.8 to 10.4)b p-value= 0.036
9 months 7.0 (3.8 to 10.3) 7.0 (3.8 to 10.3) p-value= 0.116
Ersser et al.,
201186
PASI
Baseline 2.34 (2.66) (n= 26) 3.22 (2.26) (n= 33)
6 weeks 1.78 (1.62) (n= 26) 2.82 (2.20) (n= 33) Not reported
Change from baseline 0.56 (1.42)c (n= 26) 0.40 (1.06)c (n= 33) 95% CI: –0.81 to 0.49;d
p-value=0.619
PASI scores can range from 0 to 72; a higher score indicates more severe disease.
a Estimated from a figure.
b Note, a variety of baseline and 3-month values were reported for each outcome in Bostoen and colleagues76 with no
explanation about why different values were reported (see Bostoen and colleagues76 data extraction in Appendix 4).
c Change (reduction) from baseline; a reduction shows that disease severity improved.
d Point estimate for difference not provided in publication.86
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Other measured outcomes
The RCT by Bostoen and colleagues76 was the only psoriasis trial to measure other outcomes in addition
to HRQoL and disease severity, namely, depression as measured by the Beck Depression Inventory (BDI)
(Table 9) and medication use. The 3-month education programme group had a statistically significantly
higher mean depression score at the end of the intervention (3 months) than the usual medical care group,
but a statistically significant lower mean depression score at 9 months after the start of the intervention.
The end of intervention result for this outcome might be explained by a baseline imbalance in mean
depression scores, which was higher in the education than the control group. Regarding medication use,
Bostoen and colleagues76 narratively reported that there were no differences between the groups at 3 and
9 months in the number of participants using topical, systemic or combined medication or the number
not using any medication (for full results data, see the Bostoen and colleagues76 data extraction form in
Appendix 4). Tests of statistical significance were not conducted for this outcome, because the data were
not suitable for conducting tests of significance.
Process evaluation findings
The trials by Balato and colleagues85 and Ersser and colleagues86 included measures that explored
intervention processes. In the Balato and colleagues85 trial, participants were asked about how useful they
had found the educational text messages. A total of 85% of the participants reported that they found the
text messaging useful, with 75% stating that they would recommend it to a friend and 75% also stating
that they would like to continue using it. Only 15%, however, agreed that they would be willing to pay for
the service.
Ersser and colleagues86 obtained qualitative and quantitative data on participants’ perceptions of the
usefulness of the education programme and recorded attendance. Qualitative data showed participants
thought that the intervention was practical (not too time-consuming), convenient and that it provided
follow-up care. Quantitative data were collected on participants’ perceptions of the usefulness of each
intervention component, including the group learning session, digital versatile disc (DVD), workbook and
telephone consultation. The majority of the participants (54–96%) rated each of these elements to be
either moderately useful or very useful, with few (4–8%) rating them as not useful. A further 8% and
42% of the participants did not provide a response to the questions about the usefulness of the telephone
consultation and DVD, respectively (there was a 100% response rate to the questions about the
usefulness of the group learning session and workbook). There was good attendance at the group
session, with 26 of the 28 randomised participants attending. Only 15 of the randomised participants,
however, watched the DVD. Others reported that they had technical difficulties with it, did not like the
DVD format and/or found that a workbook was more convenient to use periodically. One point of
feedback from the research team also noted by Ersser and colleagues86 was that the smaller group
sessions resulted in more interaction between participants than the larger sessions.
TABLE 9 Depression results in a study examining an educational intervention for psoriasis (adults)
Study
Measure, time point (n
unclear for all time points)
Mean score (95% CI)
Intervention Control
Difference between
groups
Bostoen et al.,
201276
BDI (depression), mean
(95% CI)
(n unclear for all
time points)
(n unclear for all
time points)
Baseline 12.3 (8.3 to 16.4) 7.4 (3.5 to 11.3)
3 months (intervention end) 10.5 (6.1 to 14.9) 6.3 (2.3 to 10.3) p-value< 0.05
9 months 6.1 (1.7 to 10.5) 7.3 (3.2 to 11.3) p-value= 0.029
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Trials of educational interventions for eczema/atopic dermatitis
Adults
One trial, by Bostoen and colleagues,76 examined a group-based educational intervention that could improve
HRQoL in adults with atopic dermatitis. This trial also included patients with psoriasis and results were
reported separately for the two patient subgroups (for psoriasis subgroup results, see Trials of educational
interventions for psoriasis). Twenty-one patients were in the atopic dermatitis subgroup. The baseline
severity of atopic dermatitis was considered ‘moderate’ by the authors. Patients took part in an educational
programme, delivered as an adjunct to usual medical care, and delivered in twice-weekly, 2-hour sessions
over 3 months by a multidisciplinary team. The educational intervention was compared with medical therapy
alone. Outcomes were assessed at baseline, 3 months (i.e. the end of the intervention) and at 9 months
(i.e. 6 months post intervention). Outcomes were mostly described narratively, with no CIs or p-values reported.
Health-related quality-of-life outcomes
Health-related quality of life was specified as a primary outcome. However, apart from QoLIAD scores at
baseline, no quantitative HRQoL results were reported. The authors stated narratively that there were no
significant differences between the educational intervention and control groups for the DLQI or QoLIAD at
3 and 9 months.
Disease severity outcomes
Bostoen and colleagues76 also reported baseline disease severity outcomes in adults with atopic dermatitis,
but did not provide any quantitative data for follow-up assessments. The authors stated narratively that
there were no significant differences between the educational intervention and control groups for the
Eczema Area and Severity Index (EASI) or SCORAD measures of disease severity at 3 and 9 months.
Other measured outcomes
Bostoen and colleagues76 reported medication use and depression outcomes. The numbers of patients in the
intervention and control groups who used each type of medication (topical, systemic, both, none or total
medications) did not differ significantly between the groups (p-values were not reported) (Table 10). The authors
narratively reported that there were no significant differences in depression between groups over time.
Process evaluation findings
No evaluations of process were reported.
Children, adolescents and their parents
Two RCTs included children with eczema/atopic dermatitis and their parents or carers.74,87 One study, by
Staab and colleagues,87 investigated the effectiveness of a group-based educational intervention that could
improve HRQoL in children or adolescents with atopic dermatitis and their carers, which was delivered by a
multiprofessional team. The study included three subgroups with atopic dermatitis: children aged 3 months
to 7 years; children aged 8–12 years; and adolescents aged 13–18 years. Patients’ carers participated in
the interventions for the 3 months to 7 years and 8–12 years age groups, and could participate optionally
in some sessions for the 13–18 years age group. The other study, by Santer and colleagues,74 was a pilot
RCT that evaluated the SPaCE website, which provided education for carers of children with eczema aged
5 years or under recruited from primary care in the UK. There were three groups in this study: website
only, website+HCP support and usual care alone. Both the website intervention groups also received
usual care. Outcomes were measured at 12 months’ follow-up in Staab and colleagues87 and 3 months
following baseline in Santer and colleagues.74 Overall, the trial by Staab and colleagues87 was of a
reasonable size, but it may not have been powered to detect intervention effects in the subgroups,
especially the adolescent subgroup. Similarly, the Santer and colleagues74 trial was of a reasonable size,
but it was unclear if this pilot RCT was adequately powered. The trial by Santer and colleagues was the only
trial included in the review explicitly stating that the aim of the intervention was to improve QoL, although
publications78,93 linked to Staab and colleagues87 provided information that the intervention for 3-month- to
7-year-olds was based on an intervention of which part of the aim was to improve the family’s HRQoL.
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Health-related quality-of-life outcomes
Health-related quality of life was specified as a primary outcome in the study by Staab and colleagues87
and was assessed using the German questionnaire ‘Quality of Life in Parents of Children with Atopic
Dermatitis’ (Table 11). Parental HRQoL results were reported for the two children subgroups (3 months to
7 years and 8–12 years of age) for five questionnaire domains (psychosomatic well-being, effects on social
life, confidence in medical treatment, emotional coping, and acceptance of disease). In both age groups
the scores for all five questionnaire domains increased in both the intervention and control groups, but the
increase was consistently larger in the intervention group than in the control group (the authors did not
provide any guidance on how to interpret this measure). Apart from the psychosomatic well-being and
effects on social life domains in the 8–12 years subgroup, the differences between intervention and control
groups were statistically significant (see Table 11). Overall, these findings suggest that the educational
intervention contributed to improving HRQoL among the parents of children in both age subgroups.
Santer and colleagues74 measured the impact of the online interventions for carers on the family’s QoL
using the DFI questionnaire (Table 12). Across all three arms, DFI questionnaire scores were slightly lower
at 3 months than at baseline (i.e. they had slightly improved), but the authors did not report if there were
any statistically significant differences between groups in DFI questionnaire scores or changes in DFI
TABLE 10 Medication use in a study examining an educational intervention for atopic dermatitis (adults)
Study Measure, time pointa
Number of patients
Intervention (n= 10)b Control (n= 11)b
Difference between
groups
Bostoen et al., 201276 Topical medications
Baseline 8 9
3 months 7 8 Stated NS
9 months 7 7 Stated NS
Systemic medications
Baseline 0 0
3 months 0 0 Stated NS
9 months 0 0 Stated NS
Combination medications
Baseline 2 2
3 months 1 2 Stated NS
9 months 1 1 Stated NS
No medications
Baseline 0 0
3 months 1 0 Stated NS
9 months 0 0 Stated NS
Total medications
Baseline 10 11
3 months 9 10 Stated NS
9 months 8 8 Stated NS
NS, not statistically significant.
a Outcomes reported also for 6 months but not extracted here.
b Not explicitly stated that outcome data are for all participants in each group.
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TABLE 11 Parents’ HRQoL results from the Staab and colleagues87 RCT, examining an educational intervention for
atopic dermatitis (children, adolescents and their parents)
Study: Staab et al., 200687 Questionnaire item
Change in ‘Quality of Life in Parents of Children with
Atopic Dermatitis’ score from baseline to 12 months
(covariance analysis), mean (95% CI)a
Intervention
(n= 274)
Control
(n= 244)
Difference between
groups
Age group: 3 months to
7 years
Psychosomatic well-being 4.4 (3.6 to 5.2) 3.1 (2.2 to 3.9) 1.4 (0.2 to 2.5);
p-value= 0.004
Effects on social life 1.8 (1.4 to 2.3) 1.0 (0.6 to 1.5) 0.8 (0.2 to 1.4);
p-value < 0.0001
Confidence in medical
treatment
4.0 (3.5 to 4.5) 1.9 (1.4 to 2.4) 2.1 (1.4 to 2.8);
p-value< 0.0001
Emotional coping 3.1 (2.7 to 3.5) 1.1 (0.7 to 1.6) 1.9 (1.3 to 2.5);
p-value< 0.0001
Acceptance of disease 1.1 (0.8 to 1.3) 0.5 (0.3 to 0.8) 0.6 (0.2 to 0.9);
p-value< 0.0001
Age group: 8–12 years
Questionnaire item
Intervention
(n= 102)
Control
(n= 83)
Difference between
groups
Psychosomatic well-being 3.2 (1.9 to 4.5) 2.6 (1.4 to 3.8) 0.6 (–1.2 to 2.4);
p-value= 0.36
Effects on social life 1.1 (0.4 to 1.8) 0.9 (0.2 to 1.6) 0.2 (–0.8 to 1.2);
p-value= 0.94
Confidence in medical
treatment
3.1 (2.2 to 3.9) 0.1 (–0.7 to 1.0) 2.9 (1.7 to 4.1);
p-value< 0.0001
Emotional coping 2.7 (2.0 to 3.4) 0.9 (0.2 to 1.6) 1.8 (0.9 to 2.8);
p-value= 0.002
Acceptance of disease 0.8 (0.4 to 1.2) 0.2 (–0.2 to 0.6) 0.6 (0 to 1.2);
p-value= 0.031
a Absolute questionnaire scores at baseline and 12 months were also reported and are given in the data extraction table
for this study (see Appendix 4).
TABLE 12 Families’ QoL results from the Santer and colleagues74 RCT, examining an educational intervention for
eczema (children aged ≤ 5 years and their parents or carers)
Study: Santer et al., 201474 Mean (SD)
Measure, time point
Intervention 1:
website only
(n= 44)
Intervention 2,
website+HCP
support (n= 50)
Control: usual care
alone (n= 50)
Difference between
groups
DFI
Baseline 5.3 (5.3) 6.4 (5.6) 5.2 (5.9)
3 months 4.0 (4.2) (n= 44) 5.9 (5.3) (n= 50) 4.4 (5.5) (n= 50) Not reported
DFI total score can range from 0 to 30, with a higher score indicating worse HRQoL.
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questionnaire scores at 3 months. The authors suggest that, as scores were low at baseline (i.e. showing
reasonably good QoL), the follow-up scores represent floor effects (i.e. there was no room for
improvement). Santer and colleagues74 also measured the impact of the interventions on children’s HRQoL
using the IDQoL and CDLQI measures, but do not report these results.
Disease severity outcomes
Disease severity was assessed by Staab and colleagues87 for all three age groups (i.e. 3 months to 7 years,
8–12 years, and 13–18 years) using the objective and total SCORAD scores and the Skin Detective
subjective score (Table 13). In each of these age groups, the scores on all three severity measures
decreased from baseline to 12 months in both the educational intervention group and the control group.
In all cases, the decreases were statistically significantly larger in the intervention group than in the control
group. These findings suggest that the educational intervention consistently improved (i.e. reduced) disease
severity irrespective of patients’ age. In Santer and colleagues,74 disease severity, as measured by the POEM
score, improved in all three arms at 3 months in comparison to baseline, but the authors did not report
if there were any statistically significant differences between arms (Table 14). The authors also reported the
proportion of children from each trial group who showed a clinically significant change in disease severity
at 3 months (defined as a change in the POEM score of ≤ 2). There were no statistically significant
differences between groups in the proportion of children who showed a clinically significant improvement
in their eczema.
TABLE 13 Disease severity results from the Staab and colleagues87 RCT, examining an educational intervention for
atopic dermatitis (children, adolescents and their parents)
Study: Staab et al., 200687
Change in disease severity score from baseline to 12 months
(covariance analysis), mean (95% CI)a
Age group:
3 months to
7 years
Measure Intervention (n= 274) Control (n= 244)
Difference between
groups
SCORAD: total
severity score
–17.5 (–19.6 to –15.3) –12.2 (–14.3 to –10.1) –5.2 (–8.2 to –2.2),
p-value= 0.0002
SCORAD: objective
severity score
–13.0 (–14.8 to –11.2) –8.7 (–10.5 to –7.0) –4.2 (–6.8 to –1.7),
p-value= 0.0009
‘Skin Detective’
subjective severity score
–3.3 (–3.9 to –2.8) –2.2 (–2.7 to –1.6) –1.1 (–1.9 to –0.3),
p-value< 0.001
Age group:
8–12 years Measure Intervention (n= 102) Control (n= 83)
Difference between
groups
SCORAD: total
severity score
–16.0 (–20.0 to –12.0) –7.8 (–11.4 to –4.3) –8.2 (–13.6 to –2.8),
p-value= 0.003
SCORAD: objective
severity score
–12.3 (–15.6 to –8.9) –5.6 (–8.7 to –2.5) –6.7 (–11.2 to –2.1),
p-value= 0.005
‘Skin Detective’
subjective severity score
–3.7 (–4.6 to –2.7) –1.6 (–2.5 to –0.7) –2.1 (–3.4 to –0.8),
p-value< 0.001
Age group:
13–18 years Measure Intervention (n= 70) Control (n= 50)
Difference between
groups
SCORAD: total
severity score
–19.7 (–23.7 to –15.7) –5.2 (–10.5 to 0.1) –14.5 (–21.2 to –7.9),
p-value< 0.0001
SCORAD: objective
severity score
–15.0 (–18.4 to –11.6) –5.1 (–9.5 to –0.6) –9.9 (–15.5 to –4.3),
p-value< 0.0001
‘Skin Detective’
subjective severity score
–3.1 (–4.1 to –2.2) –1.0 (–2.1 to 0.1) –2.1 (–3.5 to –0.7),
p-value< 0.0002
a Absolute scores at baseline and 12 months were also reported and are given in the data extraction table for this study
(see Appendix 4).
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Other measured outcomes
Santer and colleagues74 measured other outcomes, including adherence to emollient use, adherence to the
intervention, attitudes, and participants’ perceptions of their abilities to manage eczema, but did not report
findings for these outcomes. Staab and colleagues87 assessed itching behaviour in two subgroups using
the Juckreiz-Kognitions-Fragebogen Kinder (JUCKKI) questionnaire for 8- to 12-year-old children and the
Juckreiz-Kognitions-Fragebogen Jugendliche (JUCKKU) questionnaire for adolescents aged 13–18 years.
These measures yielded scores for itching catastrophisation (how the individual experiences the itching)
and coping with itching (Table 15). In both age groups, the scores for itching catastrophisation decreased
(i.e. improved) from baseline to 12 months, both in the educational intervention and control groups, with
the decrease being statistically significantly larger in the intervention group than in the control group. In
contrast, an improvement in coping with itching was only seen in the 8–12 years age group participants.
Overall, these findings suggest that the educational intervention had an effect on reducing itch-related
catastrophising, irrespective of the patient age group, but had less impact on coping with itch, which
appears to have improved only in the 8- to 12-year-old group.
TABLE 14 Disease severity results from the Santer and colleagues74 RCT, examining an educational intervention for
eczema (children aged ≤ 5 years and their parents or carers)
Study: Santer et al., 201474 Mean (SD) (unless stated)
Measure, time point
Intervention 1:
website only
(n= 44)
Intervention 2,
website+HCP
support (n= 50)
Control:
usual care
alone (n= 49)
Difference
between
groups
POEM score
Baseline 10.3 (7.0) 9.4 (6.2) 7.47 (6.2)
3 months 7.6 (6.1) 8.7 (7.0) 7.1 (6.6) Not reported
Clinically significant change in POEM score
between baseline and 3 months, n/N (%)
23/42 (55) 18/47 (38) 16/49 (33) p-value= 0.09
POEM score can range from 0 to 28, with a higher score representing more severe disease. Clinically significant change in
POEM score in a primary care context is a change of at least 2.74
TABLE 15 Other measured outcome results from a study examining an educational intervention for atopic
dermatitis (children, adolescents and their parents)
Study: Staab et al., 200687
Change in score from baseline to 12 months (covariance
analysis), mean (95% CI)a
Age group: 8–12 years
Measure: JUCKKI Intervention (n= 102) Control (n= 83)
Difference
between groups
Itching behaviour:
catastrophisation
–7.0 (–8.9 to –5.1) –1.8 (–3.5 to –0.2) –5.2 (–7.7 to –2.7),
p-value< 0.0001
Itching behaviour:
coping
1.0 (–0.3 to 2.3) –0.4 (–1.6 to 0.8) 1.5 (–0.3 to 3.2),
p-value= 0.047
Age group: 13–18 years
Measure: JUCKKU Intervention (n= 70) Control (n= 50)
Difference
between groups
Itching behaviour:
catastrophisation
–6.8 (–8.6 to –5.0) –2.0 (–3.9 to –0.2) –4.7 (–7.3 to –2.2),
p-value= 0.0002
Itching behaviour:
coping
–0.2 (–1.9 to 1.5) 0.4 (–1.2 to 2.1) –0.6 (–3.0 to 1.7),
p-value= 0.875
a Absolute scores at baseline and 12 months were also reported and are given in the data extraction table for this study
(see Appendix 4).
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Process evaluation findings
Only Santer and colleagues74 carried out what could be considered a process evaluation. Quantitative data
were collected on website use and uptake of the HCP appointment. Qualitative data were obtained
via interviews with and feedback from participants and the HCPs. As Table 16 shows, carers in the
website+HCP support group spent more time using the website than carers in the website only group
and proportionally more made three or more visits to the website. There did not appear to be any other
differences between the two groups in their website use. (Note, however, that differences did not appear
to have been statistically tested and the reviewers’ interpretation of these data differ to the study
authors’,74 who stated that there were no differences between groups.) Overall, the findings show a
reasonably high completion rate of the core modules, and some use of other aspects of the intervention,
but that the median time carers spent using the website in the website only group was less than intended
(median of 34 minutes; it was intended that participants would spend at least 40 minutes completing at
least two compulsory modules). In the website+HCP support group, 23 of the 50 participants (46%)
took up the offer of a HCP appointment. Reasons for non-uptake included the participant declining the
appointment (n= 12), the participant not being contactable, so an appointment could not be arranged
(n= 9), and non-attendance at the appointment (n= 6).
Feedback from the carers about the website included that participants found it easy to use and useful.
Only five of the 26 participants interviewed stated that they did not find it useful, and their reasons
included that they had previously needed more support than now, and that their child’s eczema was mild.
There was more variation in the perceived value of the HCP support from the carers who had received this.
Of those who found the support useful, reasons reported included that it had helped carers engage more
with the website, it had increased their confidence for consulting with HCPs in the future, it had been an
opportunity to discuss other health problems, it had been an opportunity to obtain emollient samples (not
part of the intervention) and they felt more comfortable consulting with an HCP than using the website.
Reasons for not finding HCP support useful included carers feeling that they did not need help in looking
after their child’s eczema and already feeling confident in their ability to source information from the
internet. Feedback from the HCPs included that they felt pleased to play a part in helping carers to
manage eczema, but they had initial reservations about not being knowledgeable enough about eczema,
as most were not eczema specialists. There were some concerns that they had also received minimal
training for the role. However, they reported that the consultations were useful, but perceived that some
carers found it more useful than others and that some did not need HCP support.
TABLE 16 Intervention use in the Santer and colleagues74 RCT, which evaluated a website and website+HCP
support for carers of children aged ≤ 5 years with eczema
Study: Santer et al., 201474 n/N carers (%) (unless stated)
Measure
Intervention 1:
website only
Intervention 2:
website plus HCP support
Time spent on website (minutes), median (IQR) 34 (20–50) 45 (26–70)
Completion of core modules 38/44 (86) 37/49 (76)
Three or more website visits 16/44 (36) 29/49 (59)
Watched≥ 1 video 16/44 (36) 17/49 (35)
Took part in 2-week challenge text alerts 18/44 (41) 18/49 (37)
IQR, interquartile range.
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Trials of educational interventions for acne
One small trial, by Matsuoka and colleagues,88 examined the effects of an educational intervention in
which 25 women with acne received instructions from a dermatologist on skin care and make-up use,
plus acne treatment with topical therapy and/or oral medications. The educational intervention group was
compared with a control group in which 25 women received acne treatment with topical and/or oral
medication with no specific skin care instructions from a dermatologist. Outcomes were measured at
4 weeks post intervention.
Health-related quality-of-life outcomes
Matsuoka and colleagues88 measured HRQoL using the DLQI and WHOQOL-26, and provided results for
the total mean scores for both measures as well as scores for the various subscales of each. Table 17
presents results for the total mean scores, and the findings for the subscales are narratively summarised
here (for the full subscale results, see the data extraction form in Appendix 4). Matsuoka and colleagues88
reported only the statistical significance of between-group differences for the DLQI and only one subscale
of the WHOQOL-26 (the ‘overall quality of life (QoL)’ subscale). No statistically significant differences were
found between the educational intervention and control groups’ DLQI total scores at 4 weeks’ follow-up.
The only statistically significant difference between groups on the DLQI subscales was on the work/school
aspect, with the intervention group showing significantly more disability than the control group at
4 weeks. However, as alpha levels were not adjusted for in multiple comparisons, this may be a chance
finding. On the WHOQOL-26, at 4 weeks, the intervention group had a slightly lower total mean score
than the control group (indicating poorer HRQoL). However, this was also the case at baseline and it was
not reported if the difference at 4 weeks was statistically significant. Differences on the ‘overall QOL’
sub-scale of the WHOQOL-26 at 4 weeks were reported to be non-significant (p-value not provided).
Disease severity outcomes
Disease severity in Matsuoka and colleagues88 was measured by Plewig and Kligman’s grade method,
which assessed the degree of improvement in acne severity on the right and left side of the face.
No statistically significant association was found between trial arm and changes in acne severity at
4 weeks (Table 18).
Other measured outcomes
The only other outcome measured by Matsuoka and colleagues88 was adverse events. The authors
narratively noted that no side effects from using cosmetics or conventional medicine were reported in
either group.
TABLE 17 Health-related quality-of-life results in a study examining an educational intervention for acne (adults)
Study Measure, time point
Mean (SD) score
Intervention (n= 25) Control (n= 25)
Difference between
groups
Matsuoka et al., 200688 DLQI: total mean score
Baseline 8.24 (5.06) 6.24 (6.06)
4 weeks 3.88 (2.79) 3.24 (4.36) NS
WHOQOL-26: total mean score
Baseline 3.27 (0.54) 3.36 (0.44)
4 weeks 3.39 (0.45) 3.44 (0.46) Not reported
NS, not statistically significant.
Interpretation of DLQI: a higher score indicates more disability. Interpretation of WHOQOL-26 score: a lower score indicates
more disability.
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Process evaluation findings
Matsuoka and colleagues88 did not include a process evaluation.
Trials of educational interventions for mixed chronic inflammatory skin conditions
van Os-Medendorp and colleagues89 examined the effects of an educational intervention (the ‘Coping with
itch’ programme) for patients with chronic pruritic skin disease. The focus of the intervention was to
reduce itch and help participants cope with itch. The educational intervention group was compared with a
control group who had normal care, which consisted of outpatient consultations with a dermatologist and
therapeutic interventions such as emollients and topical steroids.
Health-related quality-of-life outcomes
van Os-Medendorp and colleagues89 measured HRQoL through the ‘Impact on QoL’ subscale of the ACS.
Outcomes were reported at 3 and 9 months (the latter time point corresponding with the programme
duration). For the purpose of the present review, the 9-month outcomes are reported. Table 19 presents
the results for the QoL subscale, where lower scores reflect lower skin-related psychosocial morbidity.
The trial authors stated that no statistically significant differences were found between the educational
TABLE 18 Disease severity results in a study examining an educational intervention for acne (adults)
Study Measure, time point
N (%)
Intervention
(n= 25) Control (n= 25)
Difference in change
categories between
groups (chi-squared test)
Matsuoka et al., 200688 Acne severity (Plewig and Kligman’s grade method): degree of improvement in acne severity on
right side of face at 4 weeks
Markedly improved 5 (20) 8 (32)
Improved 10 (40) 8 (32)
Unchanged 10 (40) 9 (36)
Exacerbated 0 (0) 0 (0) p-value= 0.62
Acne severity (Plewig and Kligman’s grade method): degree of improvement in acne severity on
left side of face at 4 weeks
Markedly improved 9 (36) 7 (28)
Improved 8 (32) 9 (36)
Unchanged 8 (32) 9 (36)
Exacerbated 0 (0) 0 (0) p-value= 0.83
TABLE 19 Health-related quality-of-life results in a study examining an educational intervention for mixed chronic
inflammatory skin conditions (adults)
Study Measure, time point
Mean (SD) score
Intervention Control
Difference between
groups
van Os-Medendorp
et al., 200789
ACS QOL subscale
Baseline 12.08 (5.00) (n= 29) 12.56 (4.93) (n= 36)
9 months 13.10 (5.25) (n= 23) 12.68 (4.58) (n= 30) Stated NS
NS, not statistically significant.
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intervention and control groups on this measure (neither p-values nor CIs were not reported). No power
analysis was provided in the publication and there were high rates of attrition, which may have some
relevance to the reported outcome as there were small numbers analysed. Other subscales of the ACS
were reported in the trial; these are discussed separately below as they are not HRQoL subscales.
Disease severity outcomes
Disease severity was measured by two measures in the van Os-Medendorp and colleagues89 trial:
frequency and intensity of itching and scratching. Little detail of the scales was provided except that the
two measures were derived from four factors that had been recorded in diaries (frequency and intensity of
itching, frequency and intensity of scratching), where severity ranged from 0 to 10 (lowest to highest
severity) and the internal consistency was high. The authors subsequently converted these scores into a
dichotomous measure with an arbitrary cut-off (high frequency defined as > 4 and high intensity defined
as > 3) based on averages from the original scale. The paper reports analysis of only the high frequency
between groups. Results are presented in Table 20 where it can be seen that at 9 months there were no
statistically significant differences between the educational intervention and control group. No p-values or
CIs were reported by the study authors and the numbers analysed were small, as there had been a high
drop-out rate.
Other measured outcomes
van Os-Medendorp and colleagues89 measured general psychosocial morbidity using the Symptom
Checklist-90. On this measure, lower scores reflect lower general psychosocial burden. Results can be seen
in Table 21, where it is apparent that there were no statistically significant differences between those in
the educational intervention and control groups.
Other outcomes measured in the van Os-Medendorp and colleagues89 trial included the Itching Cognitions
Questionnaire (ICQ), other subscales of the ACS, medication use, and the proportion of patients visiting
the dermatologist. The results of these various measures and indices are summarised narratively here
(see the data extraction form in Appendix 4 for the full subscale results).
No statistically significant differences were seen between the educational intervention and control groups
on the ICQ subscales of catastrophising and helpless coping, and problem-focused coping. Six subscales of
the ACS were reported (skin-related psychosocial morbidity, social anxiety and avoidance, vicious circle of
itching and scratching, helplessness, anxious depressive mood, and deficit in active coping). No statistically
significant differences were seen on these scales between those receiving the educational intervention
and those receiving the control intervention.
TABLE 20 Disease severity results in studies examining educational interventions for mixed chronic inflammatory
skin conditions (adults)
Study Measure, time point
n (%)
Intervention Control
Difference between
groups
van Os-Medendorp et al., 200789 Patients with high frequency of itching and scratching
Baseline 18 (72) (n= 25) 21 (66) (n= 32)
9 months 12 (50) (n= 24) 15 (52) (n= 29) Stated NS
Patients with high intensity of itching and scratching
Baseline 20 (80) (n= 25) 25 (78) (n= 32)
9 months 12 (50) (n= 24) 16 (55) (n= 29) Stated NS
NS, not statistically significant.
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No statistically significant differences between groups were observed on the use of mild, moderately
potent, potent, or very potent corticosteroids; systemic medication use; or itch-relieving medication use
between groups (see Appendix 4). The proportion of participants visiting the dermatologist was statistically
significantly lower in those in the educational intervention group initially (1–3 months), but by 7–9 months
there were no statistically significant differences between the two groups.
For all of these analyses the numbers of participants in each group were small and it is unlikely that the
analyses were powered to detect a difference between the groups.
Process evaluation findings
The van Os-Medendorp and colleagues89 trial did not report a process evaluation.
Summary of clinical effectiveness
Only seven RCTs, with adequately reported results, were identified that evaluated the effects of
educational interventions that could improve HRQoL in people with chronic inflammatory skin conditions.
Only one study74 explicitly stated in the primary publication that the intervention was aimed at improving
HRQoL (but in one other87 the intervention for one of three age groups of participants in the study was
based on an intervention of which part of the aim was to improve HRQoL78,93), and only three evaluated
theory-based interventions. The current evidence base is mainly limited to small studies (four trials included
between 40 to 64 participants; it was unclear if any of these were adequately powered, and one reported
subgroup results only and two were pilot studies), of generally poor methodological quality, focusing on
psoriasis, atopic dermatitis and acne, and studies including adults. Only two studies included children and
adolescents and their parents or carers; these were the largest trials included in the review (992 and
148 randomised participants, respectively, with the smaller study being a pilot study).
The educational interventions have commonly been delivered face to face (either in a group or
individually), as an adjunct to standard medical care, and have provided participants with information
about their condition and methods for coping with stress or the negative effects of their disease, such as
itch or appearance concerns. There have been some attempts to tailor interventions to individual needs or
participants’ characteristics. The participants included in the trials generally had had their skin condition for
a number of years and no studies were found that specifically targeted newly diagnosed patients. In two
of the seven included studies, participants’ mean baseline HRQoL scores indicated that, generally, their
disease had had a minimal impact on their HRQoL. Three studies had a follow-up of a reasonable duration
to capture the clinical effects of the intervention (≥ 3 months post intervention). Adverse effects were
evaluated in only one trial. The majority of the studies were considered to be of limited generalisability to
UK clinical practice. Exceptions were the two large RCTs examining the effects of an online educational
intervention (the SPaCE website) aimed at the carers of children with eczema in primary care and the
group-based educational programme, delivered by a multidisciplinary team over 6 weeks, aimed at
TABLE 21 Other measured outcome results in a study examining an educational interventions for mixed chronic
inflammatory skin conditions (adults)
Study Measure, time point
Score, mean (SD)
Intervention Control
Difference between
groups
van Os-Medendorp
et al., 200789
SCL-90
Baseline 146.30 (60.02) (n= 29) 151.18 (52.60) (n= 36)
9 months 134.41 (47.68) (n= 23) 159.81 (57.69) (n= 30) Stated NS
NS, not statistically significant.
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children and adolescents with atopic dermatitis and the children’s carers, which was delivered to patients
recruited from secondary care. The UK trial by Ersser and colleagues86 of nurse-led education for psoriasis
may also have some generalisability to patients seen in primary care whose disease has not extensively
affected their HRQoL.
Three trials found statistically significant improvements in HRQoL following the educational interventions.
Of these, two found benefits for adult patients with psoriasis at the end of the text message education
intervention delivered over 12 weeks and the 3-month, group-based, educational programme intervention
delivered by a multidisciplinary team compared with an unspecified control and usual medical therapy,
respectively. The other one found benefits for parents of children with atopic eczema at 12 months’
follow-up (it was unclear if this follow-up time point was from baseline or the end of the intervention)
from a 6-week group-based programme delivered by a multidisciplinary team compared with a no
education control. All these trials also found improvements in patients’ disease severity at these time
points. Only one of these psoriasis trials (of the group-based education) measured outcomes in the
longer-term post intervention (specifically, 6 months after the end of the intervention) and it found that the
improvements on only one of the two HRQoL measures used persisted over time, whereas improvements in
disease severity were not maintained. In one of these studies, the same intervention was delivered to
patients with psoriasis and patients with atopic dermatitis, but it did not improve HRQoL or disease severity
in those with atopic dermatitis despite being effective for psoriasis, and the reasons for this are unclear.
It could have been a chance finding, as the results were from potentially under-powered subgroup analyses,
which were at unclear risk of bias because it was not stated if these were pre-specified. Of the trials
reporting statistically significant improvements in HRQoL and disease severity, only one87 discussed
how clinically meaningful the changes were to patients (suggesting that, on average, a meaningful
improvement in disease severity had occurred in the children with atopic dermatitis in the trial of the
multidisciplinary 6-week programme), but, generally, the clinical significance of the improvements found in
these studies is unclear.
No effects of education on HRQoL or disease severity in comparison with usual care were found in studies
of a one-off nurse-delivered educational session for adults with psoriasis, instructions on skin care and
make-up use to women with acne, the SPaCE website (with or without HCP support) for carers of children
with eczema or in a ‘Coping with itch’ programme for participants with a range of conditions delivered in
a median of three sessions. It was unclear if any of these studies were adequately powered. However,
two were pilot studies, so although they were possibly not powered adequately, they provided useful
information about the feasibility and acceptability of the intervention to inform a more rigorous evaluation,
as recommended by the MRC guidance on complex intervention development and evaluation.65
Furthermore, in two studies, participants’ baseline HRQoL scores indicated that their disease had had
minimal impact on their HRQOL, which may partly explain the lack of effects (e.g. no room for
improvement). The ‘Coping with itch’ study had a high attrition rate, and as no process evaluation was
included in the study, it was unclear why so many participants did not complete the study or what
programme factors may have led to this.
The review findings also indicate that educational interventions may result in improvements in other
outcomes, including decreases in itching catastrophisation, some improvements in coping with itch,
reductions in depression and short-term reductions in consultations with HCPs. No impact on medication
use was found. The one study that reported adverse effects found no negative impact of the intervention.
It is not possible to determine from the studies in this review the educational intervention components or
characteristics that may contribute to improving patients’ and parents’ or carers’ HRQoL. Commonalities
between effective interventions were delivery by a multidisciplinary team and delivery over a longer period
than the interventions in the trials which did not find any statistically significant effects (ranging from
6 weeks to 3 months). However, given the limitations of the evidence, these commonalities should only be
regarded as early indications of factors that may characterise effective interventions.
DOI: 10.3310/hta19860 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 86
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Pickett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
47
Overall, the current evidence base suggests that educational interventions including elements that could
improve HRQoL do show some promise for improving HRQoL and disease severity in adults with psoriasis
directly at the end of the intervention (with some indication that improvements in HRQoL may be
maintained 6 months after the intervention, whereas improvements in disease severity may not
be maintained), as well as for improving the HRQoL of parents of children with atopic dermatitis, and
children and adolescents’ atopic dermatitis disease severity, in the longer term, up to 12 months. There
was no evidence of effectiveness on HRQoL in adults with acne or atopic dermatitis or for an intervention
aimed at improving itch in a mixed skin diseases population or for an online educational intervention (with
or without HCP support) aimed at the carers of children with eczema. Based on the findings of two
studies, there are indications that interventions aimed at mixed populations with different skin conditions
may not be effective or may be more effective for one of the included patients groups than another.
Characteristics of effective interventions may include intensive delivery over a period ranging from 6 weeks
to 3 months (rather than shorter, less intensive interventions of one or a few sessions) and delivery by a
multidisciplinary team, but, overall, at this stage, it is not possible to identify the intervention factors that
may lead to improvements in HRQoL.
Ongoing studies
Six ongoing RCTs were identified that appear to meet the inclusion criteria for the systematic review
(Table 22). Three of the RCTs are being conducted in Europe (excluding the UK), two in the USA and one
in Japan. According to the study dates specified in trial registries, three of the six RCTs should have been
completed, but we have classified these as ongoing trials given that their results have not yet
been published.
Three of the RCTs are being conducted with children with atopic dermatitis, although one also includes
their parents; one RCT includes adults with psoriasis; one RCT includes adults with psoriasis or eczema;
and one RCT includes adults with occupational hand eczema. The interventions are reported to varying
levels of detail in trial registries, but appear to consist mostly of various types of group education. Each of
the RCTs contains two arms, in which an educational intervention is compared with a comparator. In four
RCTs, the interventions are being compared against no education, whereas in two RCTs the comparator
is a different type of education. Four of the RCTs specified HRQoL as a primary outcome and two RCTs
specified HRQoL as a secondary outcome. The target numbers of patients randomised ranges from 50 to
742. The specified completion dates of the RCTs range from August 2011 to December 2015, although no
completion date is specified for the Japanese RCT (see Table 22).
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Chapter 4 Economic analysis
The following section has two parts. First, the methods and findings of the systematic review of thecost-effectiveness of educational interventions as an adjunct to standard medical care in the treatment
of patients with chronic inflammatory skin diseases is presented. The objective of this review is to provide
useful information to inform the development of an economic model. The second part outlines a list of
recommendations on the different aspects that should be considered in the development of any future
health economic model to assess cost-effectiveness of educational interventions for chronic inflammatory
skin conditions, based on the findings of the systematic review.
Systematic review of existing cost-effectiveness evidence
The methods of the systematic review are described above (see Inclusion and exclusion criteria), although
the inclusion criteria were modified slightly from those used in the review of clinical effectiveness. First, the
inclusion criteria for this review were not limited to studies where the effects of education on overall
outcomes had to be isolated from effects of any non-educational intervention components that may also
be present in the intervention. Second, studies that did not specifically aim to improve HRQoL were
also included. The reason for incorporating broader criteria on HRQoL was because the reviewers
anticipated fewer studies at the beginning of this review.
The studies are described in terms of their quality and generalisability to the UK and key issues arising from
each of the studies are discussed.
Quantity and quality of published research
A total of 1394 citations were identified through the systematic searches. Following examination of titles
and abstracts, 13 potentially relevant papers were retrieved for a more detailed inspection. Of these,
10 papers were excluded. The reasons for exclusion were: the nature of the intervention was not educational
as defined within the scope of the project;99–102 the study design was inappropriate;75,93,103,104 the study
was not published in English105,106 (see Appendix 7). Three studies were eligible for inclusion; one was
based on adults with chronic pruritic skin diseases107 and the remaining two studies were on eczema
in children.108,109 In the study on pruritic skin disease, van Os-Medendorp and colleagues107 assessed
health-care costs and costs associated with loss of work in patients with different chronic pruritic skin
diseases (Table 23) enrolled in the nursing programme ‘Coping with itch’ compared with a control group of
patients receiving usual dermatological care. Of the two eczema-based studies, Mason and colleagues108
conducted a cost analysis that examined the effectiveness of an educational support programme to
increase emollient use and reduce atopic eczema symptoms in children, whereas Schuttelaar and
colleagues109 conducted a cost-effectiveness analysis of care provided by nurse practitioners (NPs)
versus dermatologists.
The study by van Os-Medendorp and colleagues107 was included in the review of clinical effectiveness
studies (discussed in Clinical effectiveness, Results), whereas the studies by Mason and colleagues108 and
Schuttelaar and colleagues109 were excluded. This was due to the difference in HRQoL inclusion criteria
between the two reviews as stated above (see Systematic review of existing cost-effectiveness evidence).
In this context, the reviewers deemed the study by van Os-Medendorp and colleagues107 to be the most
relevant of the three studies identified through the systematic searches, given that it also met the inclusion
criteria for clinical effectiveness. As a result, this study107 is discussed in depth (see Description and results
of the published economic evaluations); this is followed by discussion of the remaining two studies108,109
that met the inclusion criteria.
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TABLE 23 Characteristics of economic evaluations
Author van Os-Medendorp et al., 2008107 Mason et al., 2013108 Schuttelaar et al., 2011109
Publication year 2008 2013 2011
Country The Netherlands UK The Netherlands
Study type Economic evaluation based on the
results of a RCT
Cost analysis based on a
before-and-after study
Economic evaluation based
on the results of a RCT
Perspective Not reported NHS Societal
Study population Adults with chronic pruritic skin
diseases including eczema; atopic
dermatitis; pruritus; prurigo;
psoriasis; chronic urticaria; other skin
disease including allergies, mycosis,
fungoides, lichen ruber planus,
Darier disease; unknown and
non-skin diseases
Atopic eczema
(children+ carers)
Children with eczema
Intervention(s) Intervention: nursing care according
to the programme ‘Coping with itch’
consisting of educational and
cognitive behavioural interventions.
It was carried out in a specialised itch
clinic run by dermatology nurses
who provided individual sessions at
the dermatology outpatient
department (see also Clinical
effectiveness, Results)
Comparator: usual dermatologist
care
Educational support
programme for parents and
carers included an educational
DVD, online daily diary and
telephone helpline with
dermatology nurses
Intervention: care provided
in terms of education and
coaching by a NP
Comparator: conventional
care by a dermatologist
Key outcome
measure
Frequency of itching and scratching
as recorded in patient diaries
Emollient use Between-group differences
in the QoL of the child
between baseline and
follow-up at 12 months
measured by IDQoL and
CDLQI
Currency base EUR, currency year not reported GBP, 2011 EUR, 2008
Time horizona 9 months 3 months 1 year
Baseline cohort Patients with chronic pruritic skin
diseases aged 18 years or older,
regardless of the underlying
diagnosis, who visited dermatology
outpatient departments
Eligible children were male
and female, aged 3 months
to 6 years, with mild to
moderate atopic eczema; and
using E45 cream (Reckitt
Benkiser, Slough, UK) as their
primary emollient
Patients aged ≤ 16 years
with a diagnosis of eczema
(‘atopic dermatitis’)
Funding source Dutch College of Health Insurance
(CVZ)
Reckitt Benkiser Healthcare Health Care Efficiency
Research Programme of
the University Medical Centre
Groningen, Groningen,
the Netherlands
NP, nurse practitioner.
a Time horizons of the analyses across the three studies were similar to the trial durations.
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Characteristics of the three included studies107–109 are shown in Table 23 and discussed in more detail
subsequently. The identification process of the included studies is shown in a PRISMA flow chart presented
in Figure 2. Full data extraction forms for the included studies are included in Appendix 8.
Critical appraisal of the studies
The included studies were assessed against a critical appraisal checklist (Table 24) to evaluate their quality
and generalisability to the UK. The checklist was adapted by the review authors from a checklist by
Drummond and colleagues.110 More details of the studies are given below (see Description and results of
the published economic evaluations).
Titles and abstracts inspected
Studies described in our review
(n = 3)
Excluded
(n = 1381)
Total identified from searching
(after deduplication) 
(n = 1394)
Reference for retrieval
and screening
(n = 13)
Excluded
(n = 10)
• Non-English language, n = 2
• Intervention, n = 4 
• Study design, n = 4
FIGURE 2 Flow chart of identification of studies for inclusion in the review of cost-effectiveness.
TABLE 24 Critical appraisal checklist for economic evaluations (based on Drummond et al., 2005110)
Item
van Os-Medendorp
et al., 2008107
Mason
et al., 2013108
Schuttelaar
et al., 2011109
1. Is the decision problem (including interventions
compared and patient group) relevant to the UK?
Yes Yes Yes
2. Is the setting comparable to the UK? No Yes No
3. Is the analytical and modelling methodology appropriate? ? ? ?
4. Are all the relevant costs and consequences for each
alternative identified?
Yes ? Yes
5. Are the data inputs for the model described and justified? Yes ? Yes
6. Are health outcomes measured in QALYs? No No No
7. Is the time horizon considered appropriate? Noa Noa Noa
8. Are costs and outcomes discounted? Nob Nob Nob
9. Is an incremental analysis performed? Yes Yes Yes
10. Is uncertainty assessed? Yes ? Yes
?, unclear.
a The time horizon considered is too short for a chronic disease.
b Discounting was not applicable as the time horizon was < 1 year.
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All three studies clearly defined the decision problem and used a relevant intervention for the purpose of
this review. The nature of the interventions and the comparators varied across the studies. The patient
groups of interest were clearly stated in all the studies. Two studies108,109 stated the perspectives adopted.
However, there remained uncertainty in the adopted analytical methodologies.
The studies did not incorporate a cost–utility analysis; two studies conducted cost-effectiveness analyses107,109
and the other performed a cost analysis.108 This was considered as lacking usefulness from the UK NHS
perspective, where a cost–utility analysis is generally deemed preferable for decision-making purposes.
Methods for estimating resource use and costs varied. van Os-Medendorp and colleagues107 provided
adequate details of all the relevant elements that contributed to the overall costs of both the intervention
and comparator strategies. Schuttelaar and colleagues109 described the resource used and costs in a
detailed manner. Mason and colleagues,108 however, did not present a detailed overview of all the relevant
cost components needed for an accurate estimation of total programme costs.
The studies used different measures to assess outcome. None of the studies reported a preference-based
measure of health to estimate effectiveness in terms of QALYs. This is a potential limitation, as having a
common numeraire such as QALYs would have facilitated comparison of the effectiveness across different
interventions. The quality of the methodology adopted to estimate effectiveness was mixed. Within the
two cost-effectiveness analyses conducted in the Netherlands,107,109 effectiveness in terms of HRQoL was
assessed through condition-specific measures such as IDQoL and CDLQI109 and disease severity was
measured by SCORAD.109 Clinical outcomes such as frequency of itching and scratching were also
estimated107 along with patient satisfaction. The UK-based cost-analysis,108 by contrast, used emollient use,
severity of eczema, use of concurrent medication, parent measures and health-care contacts by patients to
measure outcomes in the before-and-after study periods.
The economic evaluations conducted within the included studies did not involve extrapolating data beyond
study durations. As a result, none of the studies applied discounting as the time horizons were 1 year
or less.
Incremental analyses were conducted in all three studies. Uncertainties were assessed by bootstrapping
methods in two studies;107,109 it is unclear if these analyses were conducted by Mason and colleagues.108
Bootstrapping is a technique of resampling statistical data to derive estimates of summary statistics such as
CIs and standard errors. The technique makes very limited assumptions about the probability distributions
of the data, thereby limiting the introduction of data uncertainty, unlike in probabilistic sensitivity analysis
(PSA) as PSA imposes additional assumptions on the real distribution of the data.111,112 Therefore, even
though the studies did not conduct the standard practice of PSA to assess uncertainty, the methods were
still considered to be appropriate.
In summary, the included studies lacked detail on some aspects of methodology, making it difficult to
assess the validity of the results. Therefore, there is uncertainty on the credibility of the study findings given
the limitations outlined above. The study by Mason and colleagues108 is of most relevance to the UK as the
health-care system in the study was the NHS.
Description and results of the published economic evaluations
van Os-Medendorp and colleagues
van Os-Medendorp and colleagues107 performed an economic evaluation based on a RCT conducted in the
Netherlands that assessed the clinical effectiveness of the nursing programme ‘Coping with itch’ in
patients aged ≥ 18 years with chronic pruritic skin diseases (also included in the clinical systematic review;
see Clinical effectiveness, Results).
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Analytical approach
Statistical analysis was conducted on trial-based outcomes to analyse cost-effectiveness of the intervention
over a period of 9 months for 120 patients.
Assumptions
To estimate costs associated with days off work, the same value based on an overall mean hourly
productivity cost for both men and women was applied. With respect to the frequency of itching and
scratching measured through patient diaries, the authors converted the frequency of itching/scratching to
a dichotomous measure where a high frequency was classed as > 4 and a low frequency as ≤ 4. The cut
off score of 4 was used to discern a clinically relevant decrease after the intervention.
Estimation of effectiveness
Health benefits were expressed in terms of days with a low frequency of itching and scratching. These
outcomes differed from those in the clinical effectiveness review as described in Clinical effectiveness,
Results. Linear interpolation for the period between the measurements at baseline and 3 months and
between baseline and 9 months was used to compute the number of days with a low frequency of itching
and scratching. Data for HRQoL were not presented.
The mean scores of the frequency of itching and scratching declined in the intervention and control groups
after 9 months [5.16 (SD 3.87) and 4.70 (SD 3.53), respectively].
Estimation of costs
Detailed information on the units of resource use across the different cost components was reported.
The authors followed the guidelines for cost studies of the Dutch College of Health Insurance to assess the
costs of visits to health-care workers, days off work and hospitalisations. Medication costs were listed from
a Dutch website113 which represented the market price. The costing year was not reported.
Data on medical consumption were also collected; these included information on:
l visits to the GP
l visits to the dermatology outpatient department
l visits to the other HCPs in or outside the hospital
l days off work
l hospitalisations; and
l medication use.
Intervention costs comprised:
l costs at the dermatology outpatient department, which included the costs associated with:
¢ visits to the dermatologist
¢ visits to the dermatologist nurse
¢ ultraviolet therapy
¢ visits to the medical social worker
l costs of visits to the GP
l costs of visits to other health-care providers
l costs of medication
l costs of hospitalisation; and
l costs of days off work.
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The study reported total costs for two time periods: 1–3 months and 1–9 months. The analysis indicated
significantly higher costs associated with the visits to the dermatology nurse compared with usual care in
the first 3 months (mean difference €107, 95% CI €77 to €137), whereas in the total study period of
9 months the mean difference was €198 (95% CI €131 to €265). This could potentially be due to a
significantly larger number of consultations with the dermatology nurse by the intervention group during
the first 3 months compared with the control group because of the nursing programme. No other
differences were found between the two groups of patients.
Cost-effectiveness results
The cost-effectiveness results are presented in Table 25. The bootstrapped mean differences in total costs
between the two groups were €794 (95% CI –€970 to €2693) and €582 (95% CI –€2730 to €3877)
at 3 and 9 months, respectively. For the first 3 months, the incremental cost per day gained with a low
frequency of itch was estimated at €129.91, which decreased to €16.60 after 9 months, thereby indicating
that the benefits of the intervention in terms of days with little itch increased. The analysis showed that
the intervention group experienced better outcomes in the longer term.
Sensitivity analysis
The bootstrap analysis indicated that patients in the intervention group might expect to gain 6 days
(95% CI –16 to 28 days) with a low frequency of itching and scratching compared with the control group in
the first 3 months and 35 days (95% CI –33 to 96 days) for the entire 9-month period. The authors concluded
that there was 70% certainty that patients experienced benefits from the intervention, whereby in 14%
of the simulations lower costs and favourable effects were observed. Furthermore, there was an 87%
certainty of favourable results for the ‘Coping with itch’ intervention, with lower costs being observed in
31% of simulations. Scenario analysis was conducted to see the impact of a cut-off score of 3 or 5 for the
frequency of itching and scratching on the overall cost-effectiveness results, which was found to be limited
on the overall results.
Relevance in the context of economic modelling
Despite the limitations outlined above, the study was considered to be relevant to informing model
parameters, should a de novo model be developed.
Mason and colleagues
Mason and colleagues108 reported on an educational support programme (ESP) that was provided for
parents or carers of children aged 3 months to 6 years with mild to moderate atopic eczema in the UK.
The programme included an educational DVD, diaries to record eczema condition, daily use of emollients,
TABLE 25 Cost-effectiveness results for ‘Coping with itch’
Costs
Benefits (days with a low frequency of itching
and scratching)
ICERIntervention Control
Difference after
bootstrap analyses
(95% CI) Intervention Control
Difference after
bootstrap analyses
(95% CI)
Months 1–3a
€2602.60 €1808.00 €793.80
(–€970.30 to €2692.70)
34.3 28.4 6.1 (–15.7 to 27.8) €129.90
Months 1–9b
€5040.60 €4476.70 €582.00
(–€2730.00 to €3877.00)
123.0 87.6 35.0 (–33.0 to 96.0) €16.60
ICER, incremental cost-effectiveness ratio.
a Intervention group n= 25; control group n= 31.
b intervention group n= 22; control group n= 27.
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and telephone contact with dermatology nurses for regular and on-demand support. The study assessed
the effectiveness of the ESP in increasing emollient use and reduction of atopic eczema symptoms in the
children. The perspective adopted was that of the UK NHS.
Analytical approach
The study performed a before-and-after incremental within-study cost-analysis over a 12-week period on
135 British children.
Estimation of effectiveness
The support components within the intervention arm aimed to increase the use of emollient with a target
of 250 g per week use per child. Over the study duration, emollient use increased by 87.6 g (95% CI
81.9 g to 119.5 g) on average, with 8.9% children receiving 250 g/week and 61.5% receiving 125 g/week
at 12 weeks. In addition, there was also an increase in prescription of corticosteroids by 20.8% (95% CI
8.9% to 32.1%), although this was not planned as part of the educational support provided.
The POEM and Patient Eczema Severity Time (PEST) measured severity of eczema. Higher POEM and PEST
scores indicate a negative impact from high disease severity. PEST scores are designed for parents to assess
severity in young children who cannot vocalise for themselves.108 The POEM score reduced significantly over
the 3 months, on average by 5.38 (95% CI 4.36 to 6.41). This was a 47% reduction from the baseline score.
The PEST also reduced on average by 0.61 (95% CI 0.47 to 0.75), with a reduction of 48% from the baseline
score. These findings indicate a positive impact of the intervention. Furthermore, the number of nights per
week on which family members experienced sleep disturbance was reduced during the study period by 1.27
nights (95% CI 0.85 nights to 1.68 nights). This was half the baseline level of disturbance. In addition, there
was an improvement by 1.32 points (95% CI 1.16 to 1.48) in parental feelings of control of their child’s
eczema, with 91.5% of parents reporting the highest level of control. Although the study outlined the
statistical outcomes in detail, there was no indication if the results were clinically significant.
The evidence of effectiveness from the ESP should be treated with caution as it was not based on the
evidence from a RCT or a study with a concurrent control group.
Estimation of costs
The cost analysis of the ESP was performed using nationally reported unit costs for 2011. The cost
associated with the emollient [E45 cream (Reckitt Benkiser, Slough, UK) prescription-only medicine (POM)
500 g] was estimated at an average English Prescription Pricing Authority-reimbursement rate of £4.89;
the cost associated with a GP visit was estimated at £36 per visit; and the cost of providing the ESP was
estimated at £32 per child. The study did not report any details of the units of resource use. Owing to this
lack of transparency, the results of the cost analysis should be interpreted with caution.
Cost analysis results
The overall cost of care was estimated as the sum total of costs associated with emollient use and GP visits.
Two methods were applied to estimate emollient use: ‘time-in-use’ (estimated time taken to use a 500-g pot
of emollient) and diary method (programme diaries completed by the participating children). A statistically
significant increase in the cost of emollient by £10 was observed using the diary method and £13 using the
‘time-in-use’ method. There was also a fall in GP visits by about 1 visit per child, on average, resulting in no
overall or significant change in net cost, as the cost per GP visit was £36 compared with the cost of ESP, which
was £32 per child. The results were found to be similar regardless of the method of estimating emollient use.
The mean cost of GP visits decreased from £68.53 in the pre-programme phase to £30.40 in the
post-programme phase. The cost of emollient use, as well as that of care, estimated by the daily diary
and ‘time-in-use’ methods increased in the post-programme phase. However, these increased costs were
not significant, and, as a result, the authors concluded that the current programme, delivered at a distance
using a specialised nurse, might be cost-neutral from a NHS perspective.
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Sensitivity analysis
The study performed subgroup analysis in 117 patients by excluding those children who had visited an
eczema specialist in the 3 months prior to joining the programme. The results of the analysis were similar
to the base case.
Relevance in the context of economic modelling
Despite being based in the UK, the review team did not consider the study to provide any useful
information in informing the development of an economic model, either structurally or in terms of model
parameterisation. This conclusion was mainly driven by the limitations in non-reporting of disease
progression, HRQoL parameters and very limited information on costs.
Schuttelaar and colleagues
Schuttelaar and colleagues109 reported a cost-effectiveness analysis based on a randomised, parallel-group
study for patients aged ≤ 16 years with a diagnosis of eczema, described elsewhere.11 The patients
received either conventional care by a dermatologist or care by a nurse practitioner (NP). The study, based
in the Netherlands, adopted a societal perspective. Care provided by the NP was considered as an
educational intervention by the reviewers, because education and coaching by the NP was a part of the
overall treatment.
Analytical approach
Statistical analysis was performed to assess cost-effectiveness of providing care by a NP compared with
conventional care by a dermatologist for a 1-year period. Details of the design, inclusion criteria and
sample size of the RCT were published elsewhere, reference provided.11 Briefly, 160 participants were
stratified by age and randomised to receive either conventional care from a dermatologist or care from a
NP. The economic analysis was conducted on 147 patients.
Assumptions
Travel costs were estimated based on mean distance to hospital and cost per kilometre travelled. Costs
associated with productivity losses were based on an overall mean hour productivity cost for both men
and women.
Estimation of effectiveness
The HRQoL was assessed by the IDQoL and CDLQI (for descriptions of these measures, see Appendix 1).
The IDQoL was completed by parents for children aged < 4 years. Those aged 4–16 years completed the
illustrated version of the CDLQI. There were improvements in the mean changes of IDQoL scores in both
the intervention and comparator groups from baseline to 12 months. The between-groups difference was
–1.7 (95% CI –4.6 to 1.2; p-value= 0.26), which was not statistically significant. Similarly, there were
significant improvements in the mean CDLQI scores in the two groups from baseline to 12 months.
However, the between-group difference was not statistically significant at –0.7 (95% CI –3.3 to 1.7;
p-value= 0.55).
The Client Satisfaction Questionnaire-8 (CSQ-8) was used to measure patient satisfaction at 12 months;
this was completed by parents. The mean scores were higher in the NP group than the dermatologist
group, with scores being 26.9 (95% CI 25.5 to 28.2) and 24.8 (95% CI 23.6 to 26.0), respectively. There
was a significant difference in scores between groups, with a difference of –2.1 (95% CI –3.0 to –0.3;
p-value< 0.02) favouring the NP group.
Estimation of costs
The study estimated societal costs by aggregating health-care costs (hospital costs and community costs),
family costs and costs in other sectors. Resource-use data relating to visits to dermatologists and NPs,
phone consultations, group education sessions, admission days and laboratory tests were collected at 4,
8 and 12 months. Other resource use relating to absence from work for visits to a dermatologist or NP,
travelling expenses, out-of-pocket expenses, professional help at home and visits to the GP were registered
in cost-diaries completed by parents. Volumes of medication used and refilled prescriptions were obtained
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from registration forms and medical records. Both hospital and community costs were reported. Resources
were measured in natural units and valued using unit costs. The analysis did not include eczema-related
costs, such as costs of visits to the allergologist or dietician.
The estimates for the units’ costs were based on the Dutch guideline process and prices were expressed
for the year 2008. The study reported the methods applied to estimate costs associated with group
education sessions, laboratory costs, medication costs, travel costs including that of parking, and costs
attributable to productivity losses of parents as a result of visits to health-care providers. The mean annual
societal cost per patient in the dermatological group was €1409 and in the NP group was €981, with a
mean difference of –€428 (95% CI –€910 to €197). In children aged < 4 years, the annual societal cost
was €1791 and €1186 in the dermatologist and NP groups, respectively. For those aged 4–16 years,
the costs were €1039 and €778 in the dermatologist and NP groups, respectively.
The mean annual health-care costs were higher in children in the dermatologist group (€801) than those in
the NP group (€658) with a mean difference of –€143 (95% CI –€544 to €299). Other costs, such as costs
of community care, hospitalisation, outpatient visits, laboratory tests and medication, were higher in the
dermatologist group than the NP group; however, costs associated with phone consultations and
protective dressings were higher in the NP group. The mean annual family costs were twice as high in the
dermatologist group (€608) than the NP group (€302) with a mean difference of –€306 (95% CI –€475 to
–€16). Time costs and out-of-pocket expenses were also higher in the dermatologist group (€415 and
€134, respectively) than the NP group (€178 and €83, respectively). By contrast, the mean annual costs for
home help visits paid by the state in the Netherlands were higher in the NP group (€21) than the
dermatologist group (€0.93).
Overall, the study presented comprehensive information on the costs and resource use during the study
period in both the dermatologist and the NP groups. Detailed cost composition by disease severity levels
was also presented. However, there appeared to be miscalculations of the aggregate costs by types, as the
sum total of the individual costs within each of the different types of costs did not match the reported
aggregate costs by a significant margin. Therefore, caution must be assumed when interpreting the cost
analysis by disease severity level.
Cost-effectiveness results
The incremental cost-effectiveness ratios (ICERs) for IDQoL and CDLQI in the NP group compared with the
dermatologist group were €925 and €751, respectively, which lies in the south-west quadrant of the
cost-effectiveness plane, indicating lower costs and lower benefits. For the CSQ-8, the ICER was €251,
which lies in the south-east quadrant, indicating lower costs and more effectiveness in the NP group. The
results of the base-case analyses favoured care provided by an NP over that provided by a dermatologist in
treating young children with eczema.
Sensitivity analysis
For the ICER based on IDQoL score, the cost-effectiveness plane showed that 51% of the cost–effect pairs
were plotted in the south-west quadrant, indicating lower costs and less effectiveness in the NP group.
For the ICER based on CDLQI, the cost-effectiveness plane showed that 59% of the cost–effect pairs were
plotted in the south-west quadrant, indicating lower costs and less effectiveness in the NP group. For the
ICER based on CSQ-8, 92% of the plots fell in the south-east quadrant, which meant that the NP care
dominated the dermatologist group as it was more effective and less expensive. Therefore, the authors
concluded that NP-led care is a cost-effective option when compared with care provided by the
dermatologists, as the associated costs were lower than those provided by the dermatologists with
comparable effectiveness.
Relevance in the context of economic modelling
With regard to model parameterisation, the study provides detailed information on condition-specific
HRQoL as well as resource use and costs, which could be used to inform an economic model.
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Summary of the published cost-effectiveness studies
l Two cost-effectiveness studies based in the Netherlands and one cost-analysis conducted in the UK
were described in our review of cost-effectiveness studies.
l The nature of the interventions and comparators varied in each of the three included studies.
l Statistical analyses were performed on study data in all three studies and bootstrapping was conducted
in two studies to check robustness of the base-case results. None of the studies extrapolated data
beyond study durations and there was no information on disease progression. Omission of long-term
results from extrapolation makes it difficult to draw conclusions from the reported results.
l Although the included interventions measured the impact on the QoL of patients with chronic
inflammatory skin diseases, none reported HRQoL in terms of QALYs. The study by Schuttelaar and
colleagues109 used IDQoL and CDLQI to measure HRQoL.
l The studies, in general, provided detailed information on the resources used and unit costs. Two of the
three included studies could be used to inform model parameters in a de novo cost-effectiveness model.
l The populations of interest across the included studies were children and adolescents in two studies
and in adults in one study.
l The time horizon of the analyses ranged from 3 months to 1 year, which is considered inadequate for
an analysis of chronic inflammatory skin conditions.
l The cost analysis by Mason and colleagues108 is of most relevance to the UK as the health-care system
in the study was the NHS and the study was conducted from UK perspective. However, omission of
reporting details of data inputs in terms of QALYs and costs reduced transparency, thereby making it
difficult to draw conclusions from the results of the analysis.
Owing to limitations in the evidence base, a de novo economic model was not developed as part of this
project. Instead, we discuss recommendations for data that could aid the development of any future
economic evaluation in this area.
Future health economic evaluations
This section aims to identify, discuss and address the issues in the current evidence base for educational
interventions in chronic skin inflammatory diseases that have emerged in the systematic review of
cost-effectiveness studies discussed (see Systematic review of existing cost-effectiveness evidence). The
limitations of the current evidence base are discussed first, followed by a list of recommendations and
reporting guidelines to be considered for future health-economic analyses of educational interventions in
such conditions.
Limitation of current evidence base
The systematic review highlighted the following gaps in existing evidence of literature.
Limited information on educational intervention
The literature identified in the systematic review indicates that there is no clear definition of an educational
intervention. The scope of such an intervention could vary considerably with respect to the type and level
of the intervention needed at different points in a clinical pathway to have an impact on overall QoL.
The broad and diverse nature of such an intervention, reflected in the studies included in the review,
means that it is difficult to compare the findings of the studies owing to their wide variability. In addition,
limited literature in this domain further confines the comparison and interpretation of the study findings.
Poor effectiveness data and lack of relevant health-related quality-of
life measures
As observed in the systematic review, no consistent measure was used to estimate effectiveness of
educational interventions. Only one study109 used validated condition-specific measures to estimate
effectiveness data. None of the included studies reported any information on HRQoL measure to express
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outcome in terms of QALYs, which is the main outcome measure in the decision-making context of the
UK NHS.
The primary outcome measures reported in the three included studies were discussed above (see Systematic
review of existing cost-effectiveness evidence) and the tools used to measure these outcomes are presented
in Table 26. The studies reported a number of outcomes, including frequency of itching and scratching,
emollient use, disease severity, use of concurrent medication, condition-specific health outcomes and
patient satisfaction. The tools used to measure and report the health outcomes varied, with variations in the
dimensions of health accounted for in each of the instruments. This heterogeneity in the reported outcomes
and the tools used to measure health benefits has restricted the degree of comparability of the results
across the studies. In addition, this also raises questions relating to the clinically relevant differences across
different instruments.
Lack of information on relevant costs and resource use
In general terms, all three studies included in the review provided a detailed overview of the resources
used and/or the cost components. However, the nature of the resource use/costs varied. This was
potentially driven by the difference in the nature and settings of the intervention.
The resources used and/or costs reported across the three included studies were reviewed to explore the
breadth of the various costs and resource utilisation covered in the economic evaluations in chronic
inflammatory skin diseases. Studies that did not meet one or more of the inclusion criteria in the screening
stage were also reviewed to provide a broad overview of the range of resources and/or costs used in the
economic evaluation of such interventions (see Other studies). Table 27 reports the resources used
and/or costs reported within each of the studies.
The studies reported a range of resources used. Except for Schuttelaar and colleagues,109 none of the
studies provided any information on resource use associated with the intervention. Only two studies107,109
presented detailed information regarding service use and only van Os-Medendorp and colleagues107
provided information on the types ands physical units of resources used. This was considered a limitation,
as the studies did not meet the requirement of reporting both physical units, as well as costs,
as advocated by Drummond and colleagues.110
Limited information on disease pathway
Across all the three studies included in the systematic review (see Systematic review of existing
cost-effectiveness evidence), statistical analyses were conducted based on trial data where the time-period
of the analyses ranged from 3 months to 1 year. There was no information about patient progression
TABLE 26 Instruments used to measure health outcomes
Study Instrument used to measure health outcomes
Mason et al., 2013108 l Patient diaries (itching and scratching measure)
Schuttelaar et al., 2011109 l IDQoL (health outcome measure)
l CDLQI (health outcome measure)
l SCORAD (severity measure)
l CSQ-8 (patient satisfaction measure)
van Os-Medendorp et al., 2008107 l Patient Oriented Eczema Measure (POEM) (severity measure)
l Patient Eczema Severity Time (PEST) (severity measure)
No single instrument was used to measure health benefits;
different aspects of health benefits were measured separately
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through disease pathways among those suffering from different chronic inflammatory conditions. As a
result, it is difficult to conceptualise a comprehensive disease progression encompassing all the pathways
associated with different chronic inflammatory skin conditions as a whole.
Other studies
This section summarises four additional studies that were identified through the systematic searches. These
studies were excluded from the review at the full paper screening stage because they did not meet the
inclusion criteria owing to the nature of the interventions (for details, see Appendix 7). Nonetheless, they
report useful information with respect to resource utilisation and QoL measures that could be used to
inform the list of recommendations to aid the development of future economic analysis. A brief overview
of these studies is outlined below for context.
Hartman and colleagues99
This study conducted a cost-effectiveness analysis of moderate to severe psoriasis patients receiving
dithranol short contact therapy in a care instruction programme (short contact therapy) with ultraviolet B
phototherapy (UVB) and inpatient dithranol treatment (inpatient treatment). The study was based in the
Netherlands and the analysis was conducted from a societal perspective. Both medical and non-medical
costs were included. Disease severity was quantified with the PASI and the area of involved skin. Clinical
effectiveness was measured in terms of the clinical response rate and the number of clearance days. The
study concluded that short contact treatment with dithranol in a care instruction programme was an
attractive alternative. However, given the associated higher costs this strategy was not a first choice when
compared with UVB.
Parsi and colleagues101
A cost-effectiveness analysis was conducted to assess conventional in-office care with a patient-centred,
online model for follow-up treatment of patients with psoriasis. The setting of the analysis was the USA
and the analysis adopted a societal perspective. The study accounted for both medical and non-medical
costs. The DLQI was used to measure outcome and the scores were mapped to the EQ-5D to obtain
utility-based HRQoL scores. The results of the study indicated no significant difference in the mean change
in DLQI scores between the two strategies, or the mean improvement in quality-adjusted life expectancy.
However, costs associated with online visits during follow-up psoriasis care were 1.7 times lower than the
cost associated with in-office visits. Based on their findings, the authors concluded the patient-centred
online care model to be cost-saving, as both the strategies were similar in terms of effectiveness.
Kernick and colleagues100
Kernick and colleagues100 conducted a cost–consequence analysis on patients with psoriasis or eczema to
assess whether a primary care dermatology liaison nurse should be introduced by the NHS in the UK.
The analysis was conducted based on a limited economic perspective and, therefore, included the costs
associated with nurse and GP care only. DLQI was the primary outcome measure. There was no significant
improvement in DLQI scores between the intervention and control groups. The authors concluded that there
were difficulties involved in attaining relevant information necessary to assist decisions on resource allocation
in primary care. It was acknowledged that large multicentred trials could not answer all the questions and,
therefore, the authors concluded that local resource decisions should be based on satisfactory partial
evidence-yielding solutions rather than optimum decisions taken on the basis of no evidence.
van Gils and colleagues102
This analysis, based on a Dutch setting, was conducted to examine the cost-effectiveness of an integrated
care (IC) programme compared with a usual care programme for patients with moderate to severe chronic
hand dermatitis. A societal perspective was adopted in collecting cost data. The difference in clinical
severity of hand dermatitis, measured with the Hand Eczema Severity Index (HECSI), was the primary
outcome measure. The EQ-5D measure was used to estimate QALYs. On the basis of the findings, the
study found the IC programme to be neither cost-effective nor clinically effective compared with usual care
after a follow-up of 12 months.
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Recommendations for the future
As has already been outlined, with the complexity involved in defining and implementing educational
interventions, there has been considerable variation in the nature and type of services provided by them.
Although some guidelines exist on the management of inflammatory skin diseases in the UK, no guideline
has specified best practice for implementing educational interventions. In light of this wide heterogeneity
and evidence gap, we list the following recommendations to address the limitations discussed earlier
(see Limitation of current evidence base).
Characteristics of the intervention
One of the fundamental bases for developing an economic model is to have clear boundaries for the
characteristics of the intervention in question. This would facilitate two objectives: first, to follow a systematic
approach in understanding the key components of the intervention and, second, to enable feasibility to
compare and contrast the findings of different studies for the same intervention. It is, therefore, important
to understand the components of the intervention, its target at-risk groups; the characteristics of the
target population with respect to their physical and/or emotional needs, age, sex and ethnicity, and the
characteristics of the settings of the intervention, such as where and how it is delivered and if the programme
is delivered as a single initiative or incorporated within the existing health and social services.114,115
The nature and setting of the educational interventions can vary widely and can be categorised in a
number of ways according to: (1) the theoretical approach employed including educational, behavioural,
and/or psychological; (2) who provides the education (e.g. self-help, nurse, dermatologist, multiprofessional
group, support group); (3) to whom it is delivered (e.g. patient or carer; individual or group); (4) where the
education takes place (e.g. at home or in a clinic); (5) how the education is delivered (e.g. using booklets,
face-to-face sessions, lectures, workshops, or the internet); (6) the intensity of education (number, duration
and frequency of sessions); and (7) the duration of follow-up.2,36,55,70 It is important to consider these
different aspects when defining an educational intervention.
Methodological approach
One of the key features of the existing evidence that has come to light through the findings of the
systematic review is the methodological approaches adopted to assess the cost-effectiveness of educational
interventions. Statistical analyses conducted over time, ranging from 3 months to 1 year were performed in
the three studies included in the systematic review (see Systematic review of existing cost-effectiveness
evidence). However, it is unclear what evidence is needed to account for behaviour change in primary
studies in order to assess the persistence of effect of an intervention beyond the trial duration.
Resource use/cost
The Drummond checklist for economic evaluation110 points out that all the important and relevant costs of
each alternative in question should be identified and measured in appropriate physical units. To do so in
educational interventions for chronic inflammatory skin diseases, the resources used can be grouped under
three categories for providing a comprehensive resource use framework:
l interventional
l service use
l non-service use.
Interventional and service use groups include resources that have a direct impact on government budget or
decision-making bodies. For example, decisions regarding allocation of resources used in the programme
delivery, the budget for equipment used to deliver the programme, such as books, online tools, resources
required during follow-up services, staff training along with services received in the primary, secondary and
tertiary care from the health-care providers are directly influenced by government budgets or that of the
health service provider. The primary care setting includes use of outpatient services by the GPs, nurses and
alternative medical provider, whereas secondary care includes resources used in inpatient settings. Tertiary
care, however, includes all resource use associated with specialised consultations.
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Resources within non-service use that mainly consists of indirect costs have a wider societal impact. Within
this category, costs associated with productivity loss, travel expenses, family costs, costs associated with
patient and/or family time can be included. Such classifications aim to provide a reference base of the
resources that should ideally be considered and reported in economic evaluations of such complex
multidimensional educational interventions.
Table 28 outlines the items of resource use that should be considered while conducting economic
evaluations of educational interventions in chronic inflammatory skin diseases. Table 27 presents a detailed
overview of the resource use items from the three included and four additional studies and shows the
variability in reporting and gaps in resource coverage. Of the seven studies tabulated, five included
information on non-service use.99,101,102,107,109 These findings indicate that there is no clear pattern of the
resources accounted for in the economic analyses. Such inconsistencies in accounting and reporting of key
input parameters across the studies limit their comparability.114
Health outcomes
Preference-based generic measures of health include multidimensional questionnaires that include
questions on a person’s mental, physical, social and functional dimensions to assess overall QoL which
enable comparisons across different health conditions. Disease-specific measures of health, however,
are more sensitive to change in QoL specific to the conditions.116 Because of the advantages of both
disease-specific and generic HRQoL measures, the majority of current research endorse the combined
use of the two measures to assess QoL.116
The findings of the systematic review (see Systematic review of existing cost-effectiveness evidence) have
indicated wide variability in reported health outcomes. To address this issue, the common health outcome
measure of QALYs could be obtained from the reported health outcomes in the primary studies through
process mapping the reported outcomes to the associated dimensions of a preference-based measure of
health, such as EQ-5D. The process mapping would need to relate the outcomes to both direct and
indirect effects that a reported health condition might impact upon, as the two effects might not be
mutually exclusive.114 For example, a person experiencing itching and scratching might, in turn, suffer from
psychological symptoms (such as depression) and difficulties in mobility as a result of pain and/or
discomfort. In this case, if the outcome measure considers only pain and/or discomfort, and does not
account for the person’s mental state, then such a measure will reflect only a partial effect on the overall
health state of the individual.114 Another way is to conduct mapping from condition-specific measures of
health in skin diseases such as IDQoL to preference-based measures, as done by Parsi and colleagues.101
None of the three studies included in the review assessed causal questions such as why and how
educational interventions could be expected to positively influence the overall health of the patients with
chronic inflammatory skin diseases.114,117 One way to explore this could be by segregating the contribution
of each element in the educational intervention to the overall health outcome. This, however, could be
challenging given the complex nature of such an intervention by definition and the possibility of intricate
TABLE 28 Items for resource use
Interventional Service use Non-service use
l Delivery of the programme/intervention
l Equipment used
l Training provided
l Follow-up services
l Primary care
l Secondary care
l Tertiary care
l Patient and/or family time
l Days off work/productivity loss
l Travel expenses
l Other family costs
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links between direct and indirect impacts of the health conditions with the dimensions of a preference-based
measure of health.114 The studies included in the review used condition-specific instruments which could
possibly be explained by the assumption that generic measures may be insensitive. One disadvantage of this
approach, as has been implicit in the discussion above, is that these instruments limit the generalisability and
comparability of the study findings. Therefore, future studies should:
l use a generic, preference-based measure to assess QoL; or
l choose a condition-specific measure that can map to a preference-based measure; or
l use both, test the sensitivity of the preference-based measure and develop (then publish) the mapping
as a basis for future research.
Summary
l There are a number of gaps in the current economic evidence of educational interventions in improving
QoL of patients with chronic inflammatory skin conditions, as identified through the systematic review.
These include limited information on the type of intervention and clinical pathways of the different
conditions and poor-quality data on economic costs and QoL.
l Based on the gaps identified, it is recommended that future studies consider a wide range of aspects
(see Recommendations for the future) to define an educational intervention, use appropriate
methodological approaches, consider a broad range of intersectoral costs and resource use, and use
either a generic preference-based measure of QoL to assess effectiveness or condition-specific measures
that could be used to map to a preference-based measure to assess cost-effectiveness in the
UK context.
ECONOMIC ANALYSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
72
Chapter 5 Discussion
Statement of principal findings
Clinical effectiveness
Seven RCTs74,76,85–89 met the inclusion criteria for the systematic review of the clinical effectiveness of
educational interventions that aim to, or could, improve HRQoL in people with chronic inflammatory skin
conditions. Of these, two focused on adult patients with psoriasis,85,86 two focused on children (and
adolescents in one study87) with eczema or atopic dermatitis and their carers,74,87 and one focused on
women with acne aged over 16 years.88 The remaining two included adult patients with mixed skin
conditions, with one focusing on patients with atopic dermatitis or psoriasis76 and reporting subgroup
results for each condition, and the other focusing on adults with chronic pruritic skin diseases.89 In six
RCTs,74,76,85,86,88,89 the educational interventions were delivered as an adjunct to usual care, and it was
unclear if this was the case in the remaining trial of group education for children with atopic dermatitis
and their carers.87 The quality of the reporting and methodology of the included trials was judged to be
generally poor. The studies were considered to have some generalisability to UK clinical practice, including
both studies of education for children with atopic dermatitis and/or their carers.74,87 Overall, there was
heterogeneity in the types of interventions evaluated and patient populations included, precluding
meta-analysis and allowing for a narrative synthesis of findings only.
Three of the seven included RCTs found statistically significant greater improvements in HRQoL among
patients taking part in the educational interventions than patients in the control group comparisons
following the interventions.76,85,87 Of these, two studies76,85 found evidence of efficacy among adults with
psoriasis and one study87 found evidence of efficacy among the carers of children with atopic dermatitis.
Among adults with psoriasis, once-daily educational text messages delivered over 12 weeks85 and an
intensive group-based educational programme delivered by a multidisciplinary team twice a week over
3 months76 significantly improved HRQoL by the end of the interventions in comparison to an unspecified
control condition and medical therapy alone, respectively. Of these psoriasis studies, the one study utilising
a longer-term follow-up period76 found that improvements in one of the two HRQoL measures used were
maintained 6 months after the intensive educational programme. Among parents of children with atopic
dermatitis taking part in a group-based education programme delivered by a multidisciplinary team over
6 weeks,87 there were significant improvements in their HRQoL at 12 months (it was unclear if this was
from baseline or the intervention end) compared with a no education control. In the three studies, greater
improvements in patients’ disease severity in the educational intervention groups compared with the
control groups were also found at these time points, with the exception that the patients with psoriasis
who took part in the intensive educational programme76 did not maintain the improvements seen at the
end of the intervention by 6 months post intervention.
Only the authors of the study of the educational intervention for children with atopic dermatitis and their
parents87 suggested that a clinically meaningful improvement in disease severity had occurred at 12 months.
The authors of the other studies finding statistically significant effects did not measure or discuss how
clinically meaningful changes in outcomes were. The reviewers note that the minimally clinically important
difference has been defined for some of the measures used in the three trials finding statistically significant
effects (e.g. the DLQI, PASI and SCORAD – see Appendix 1), and recommend that future trials report how
clinically meaningful changes in outcomes are (see Suggested research priorities).
No effects of education on HRQoL or disease severity in comparison with usual care were found in studies
of a one-off nurse-delivered educational session in primary care for adults with psoriasis (a pilot study),86
instructions on skin care and make-up use provided by a dermatologist to women with acne,88 the SPaCE
website (with or without HCP support) for carers of children with eczema (a pilot study)74 or in a ‘Coping with
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itch’ programme, incorporating educational and cognitive behavioural interventions, for adults with chronic
pruritic skin diseases.89 Overall, no effective interventions were found for acne or atopic dermatitis in adults.
Commonalities between the effective interventions were delivery by a multidisciplinary team and delivery
over a longer period (ranging from 6 weeks to 3 months) than the non-effective interventions. However,
this was inferred by the reviewers and not tested in any way and it is not possible to say with confidence
from the current evidence whether particular elements of educational interventions and how they are
delivered may be associated with improvement in HRQoL.
Cost-effectiveness
Three studies were included in the cost-effectiveness review. Two of these were economic evaluations
based on controlled trials conducted in the Netherlands and the remaining study was a cost-effectiveness
analysis conducted in the UK. The study populations in two of the three included studies had atopic
eczema. One of these studies108 included children with the condition and their carers, whereas the other
study109 focused on children alone. Adults with chronic pruritic skin diseases, including a range of skin
conditions, were studied in the remaining study, which was the only trial meeting the inclusion criteria
for the cost-effectiveness review that was also included in the review of clinical effectiveness. The nature of
the interventions and comparators varied in each of the three included studies. The interventions provided
nursing care consisting of educational and cognitive behavioural interventions carried out in a specialised
itch clinic (the ‘Coping with itch’ programme), an educational support programme for parents and carers,
and support in terms of education and coaching by a HCP. None of the studies reported HRQoL in terms
of QALYs and only one study measured HRQoL, using the IDQoL and CDLQI. Omission of reporting such a
QoL measure limits study comparability. Furthermore, none of the studies reported any adverse events or
comorbidities. None of the studies conducted their analyses beyond 1 year. As a result, it is difficult to
draw conclusions on the long-term effects from the reported results. Overall, based on the findings of the
review of the cost-effectiveness studies, it is unclear if educational interventions are cost-effective in the
treatment of patients of chronic inflammatory skin diseases from the perspective of the UK NHS.
Other relevant factors
Gaps in the clinical effectiveness evidence base
The findings of this review highlight a number of gaps in the current clinical effectiveness evidence base.
Given how few studies were identified, there is, overall, a lack of evidence for the effectiveness of
educational interventions that aim to or could improve HRQoL across all chronic inflammatory skin
conditions, although there are some indications of promise of effectiveness in adults with psoriasis and
children with atopic dermatitis and their carers. In particular, no studies focused on some of the rarer
chronic inflammatory skin conditions, such as lichen planus, lichen sclerosus and hidradenitis suppurativa,
so the effectiveness of educational interventions aimed at HRQoL in these populations is unknown.
Only two studies74,87 of children (one of which also included adolescents87) were included in the review, and
both focused on atopic dermatitis and eczema, with one providing education to older children, in addition
to their carers, and adolescents. It may be important for future studies to focus on age-appropriate
education for children and young people themselves, particularly as children grow older and transition to
taking on more responsibility for disease management from their carers. Such early intervention, for
example in eczema or atopic dermatitis, may help improve prognosis and prevent further damage to the
skin. There were no studies including children or adolescents affected by other conditions, including acne,
which is common in adolescents, with around 50% of 14- to 16-year-olds being affected.25 However, this
may be a hard-to-reach group, as acne may commonly be treated with OTC medications.
Part of the remit of this review was to include studies focusing on carers of people with chronic
inflammatory skin conditions. Two of the included studies74,87 assessed education for carers of children
with atopic dermatitis or eczema. However, we identified no studies that considered carers of adults with
disabilities or other conditions who may also be involved in supporting patients’ self-care.
DISCUSSION
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None of the included studies focused exclusively on patients newly diagnosed with a chronic inflammatory
skin condition, which may be a group with particular needs. Indeed, the process evaluation included in the
trial by Santer and colleagues,74 which examined the SPaCE website for carers of children with eczema,
found a minority of carers did not perceive value from education at this stage in their child’s disease and
commented that it had previously been more of a need than it was at the time of the intervention.
In terms of study design and outcome measurement, only the acne trial of instructions in make-up use and
skin care88 measured adverse events, and this showed no negative impact of the intervention in a small
sample of 25 participants in intervention arm. It may be desirable for studies to include measures of
adverse effects or any undesirable or unintended effects of treatment, both of the education and any
medical therapy included in either the intervention or comparator arms. There was also a lack of
longer-term follow-up data, with only three of the seven trials76,87,89 measuring outcomes at or beyond
3 months post intervention (the review Advisory Group suggested ≥ 3 months would be the minimum
follow-up time necessary in studies to measure the effect and durability of patient benefits from an
intervention). Only one study compared two different kinds of educational intervention (the SPaCE website
with or without HCP support for carers of children with eczema).74 Comparisons of different approaches
would be useful for identifying which intervention factors may be associated with effectiveness.
Target groups for education
It is not clear from the studies included in this review or the NICE guidance5,7 which groups of patients may
particularly benefit from education and, more specifically, education aimed at improving HRQoL. NICE
guidance5,7 suggests education should be provided at all stages of care and be reiterated in each medical
consultation, and from this point of view it could be considered an ongoing need for all patients. However,
the place for more structured and planned education in the clinical pathway, such as the more intensive
group-based education delivered in some of the studies included in this review, is not clear. These
interventions are likely to be costly in terms of resource use and may therefore need to be targeted at
particular groups. In all the effective interventions found in this review, the patients targeted and included
had more severe psoriasis and atopic dermatitis at baseline than those who took part in the non-effective
interventions, providing some indication that those with more severe disease may benefit the most;
however, owing to the low number of studies included and their poor quality, this conclusion is tentative.
However, HRQoL has not always been found to correlate with disease severity,41–43 so other factors
could be considered in how interventions are targeted. For example, the literature has identified that
experiencing psychological distress (e.g. depression)38,44 is associated with poor HRQoL, and a subgroup of
patients with psoriasis who experience a high psychosocial burden from their disease and who may require
additional support has been identified.86 One consideration is whether patients experiencing psychological
distress may particularly benefit from educational interventions aimed at improving HRQoL and which
include elements that help patients cope with and address these feelings. Another consideration is
whether education may be best targeted at patients who have recently been diagnosed with a condition
(when HRQoL scores may not necessarily show a negative impact of the condition) to help patients
develop effective self-care behaviours and strategies for enhancing their HRQoL which they can then
endeavour to maintain in the future. As well as benefiting patients, this may help prevent costly referrals to
secondary care and decrease health-care resource costs for these conditions.
A related issue is whether education should be targeted generically, that is, the same intervention should
be used for patients with a range of skin conditions or whether it should be targeted at particular
conditions. The studies included in this review indicate that a ‘one-size-fits-all’ model may not be the best
approach. Two studies included patients with a mixture of skin conditions and one of these found no
benefits for a ‘Coping with itch’ programme for patients with pruritic skin diseases,89 whereas the other
found that an intensive group-based programme delivered over 3 months was effective in improving
HRQoL in patients with psoriasis, but not those with atopic dermatitis.76 Given that conditions differ in their
disease processes and, potentially the factors that may negatively affect HRQoL, it may be better to target
specific conditions, although more generic approaches that focus on particular symptoms or issues
common to a range of conditions could be considered.
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Quality of reporting and methodology
Generally, the quality of reporting and methodology of the included RCTs was judged to be poor. Three
studies (reported in four publications78,91–93), around one-third of the relevant evidence base, met our initial
inclusion criteria for the review, but at data extraction it was found that the studies did not provide sufficient
adequate information about the results to be included in the review and they were, therefore, excluded. This,
along with the poor quality of the included studies, indicates a need for better reporting in this research area.
Reporting of the interventions was generally good, but reporting of the intervention aims, theoretical basis,
where the intervention was delivered, any tailoring to participants’ needs, sensitivity to participants’
characteristics, and any ongoing support provided post intervention could be improved, as these elements
were less commonly reported in the included studies. Overall, this suggests that more attention needs to
be given to reporting and theorising about intervention aims, underpinning theories and hypothesised
mechanisms of change, and ensuring (and reporting) that interventions are sensitive to the target groups’
needs and characteristics.
Most of the analyses, with the exception of those of the 3 month to 7 years age group in the trial by
Staab and colleagues of group education for children and their carers,87 were potentially underpowered.
However, three of these included studies were pilot studies,74,85,86 and, therefore, it is not essential that
they are adequately powered, as they will provide information that can inform a power calculation for a
larger, more rigorous trial and, as outlined in the MRC guidance on the development and evaluation of
complex interventions,65 such pilot studies are an important part of intervention development in offering
insight into the feasibility and patient acceptability of an intervention.
Intervention development
As outlined in the Background section of this report, the MRC guidance on the development and evaluation
of complex interventions65 underscores that intervention development work is crucial. In line with the MRC
guidance, three of the seven included studies reported the underpinning rationales and theoretical bases to
the interventions,74,86,87 with two of these, both UK studies,74,86 additionally using qualitative research with
patients and/or HCPs to develop the intervention. Two of these studies, both investigating eczema or atopic
dermatitis in children, aimed to improve HRQoL through promoting better disease management by the
use of behaviour-change techniques in the intervention.74,87 The other study aimed to improve patients’
self-management through incorporation of techniques addressing constructs from social cognitive theory
(e.g. self-efficacy).86 There is a need for studies to specify more carefully how the interventions may bring about
changes in HRQoL and other outcomes, and to make the aims of, and rationale behind, the intervention
explicit when reporting findings. Overall, there is a need to clarify in the literature what factors may need to
be targeted in an educational intervention to improve HRQoL. Although improving self-management of
disease has been put forward as a hypothesised mechanism and may give patients or carers a greater sense of
control over the disease (which in itself could be beneficial for HRQoL33), as mentioned above, HRQoL does
not always correlate with disease severity. This suggests that target factors other than disease severity that are
associated with poor HRQoL in chronic inflammatory skin conditions, such as psychological distress33,39 or
feelings of stigmatisation owing to changes in skin appearance,39 may need to be considered as possible
mechanisms of change. Intervention developers and investigators could also give consideration to how more
informal aspects of educational intervention, such as social contact with other people with or caring for
someone with the same condition during educational sessions, may also enhance HRQoL.
There were some reported attempts in the interventions in the included studies to tailor interventions to
individual needs and design interventions to be sensitive to participants’ characteristics. However, more
attention could be given to these aspects of intervention. Ensuring that interventions are sensitive to
participants’ needs may be particularly important when interventions include participants with English as
an additional language or people with low levels of literacy. Little consideration seemed to be given in the
interventions to the characteristics of the intervention provider, in terms of ensuring they had adequate
training for the role or how similar they were in characteristics such as social and ethnic background to the
participants, which are also important considerations in intervention delivery.66,67,69
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The MRC guidance on the development and evaluation of complex interventions65 recommends that pilot
studies are undertaken to inform further development and evaluation. Three of the seven included studies
were pilot studies,85–87 and provided some information on possible effectiveness and the feasibility and
acceptability of the interventions. For example, one indicated that daily text message education over
12 weeks reminding patients with psoriasis to use their medications and providing them with general
educational statements, used as an adjunct to usual medical care, may result in improvements in HRQoL
and disease severity at the end of the intervention compared with an unspecified control condition.85 The
remaining pilot studies, both including patients with more mild eczema74 and psoriasis86 recruited from
primary care in the UK, did not find evidence of effectiveness. However, both found that, on the whole,
the interventions (a one-off nurse-delivered educational session for patients with psoriasis, supplemented
by a follow-up phone call,86 and the SPaCE website for carers of children with eczema74) were feasible and
generally perceived as useful by the patients, although a DVD and HCP support provided in each of these
interventions, respectively, were perceived as less useful than other aspects, suggesting that inclusion of
these approaches may not be needed in follow-on RCTs.
Three studies – all the pilot studies74,85,86 – included process measures. There is a need for more studies to
include process evaluations, as recommended by the MRC guidance on complex interventions,65 to identify
the contextual factors in intervention delivery which may help explain why an intervention is found to be
effective or not. Such process evaluations may offer insight into the best way such interventions could be
delivered to patients and carers. For example, if evening meetings may be more suitable for those who
work, if allowing patients to bring along relatives or friends for support might encourage better
attendance or impact effectiveness, if having easily accessible additional support outside the sessions
(e.g. from a specialist nurse) to ask questions patients or carers forgot to ask or were reluctant to ask in
the more formal educational session or medical consultation may be beneficial, and the best location for
the intervention to be delivered (e.g. at local hospital venues).
Intervention developers could also draw on evidence about what has worked in educational interventions
for other long-term conditions that require long-term self-management, such as diabetes, when designing
interventions. For example, the Diabetes Education and Self Management for ONgoing and Diagnosed
(DESMOND) programme and the Diabetes X-PERT programme for people with diabetes in the UK have
been criticised for not adequately addressing the needs of people in particular communities,118 and this
points to the need for programmes to be sensitive to the local context. Involvement of patients, family
members or carers, general practitioners and Clinical Commissioning Groups could be useful for
determining these needs. Additionally, involvement of a lay educator in delivering the DESMOND
programme alongside a HCP has been found to be successful,119 and this is an approach that could
be considered in educational interventions for chronic inflammatory skin conditions (e.g. patients,
family members or carers could be involved as educators). This may also have implications for the
cost-effectiveness of interventions, as those delivered with lay person involvement may be less costly than
those delivered solely by HCPs.
Educational intervention studies that did not measure health-related quality
of life
At the full-text screening stage of the review, we excluded 28 references because the studies either did not
report a HRQoL outcome or use a validated HRQoL measure. This was the first criterion studies were
screened against at this stage and so not all of the references excluded for this reason were studies of
educational interventions (as it was not always clear at the title and abstract screening stage that the
studies were about education). Of the 28 references excluded for this reason, 18 were studies of
educational interventions for chronic inflammatory skin conditions. It is a notable finding that so many of
these studies either did not measure HRQoL or did not use a validated measure. This suggests that studies
of educational interventions for these conditions in general may need to give more attention to HRQoL
outcomes and, when HRQoL is measured, ensure that validated measures are used.
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Strengths and limitations of the assessment
Strengths
l Thorough searches of a range of literature databases were conducted for both the clinical and cost-
effectiveness reviews, including the Global Resource for Eczema Trials (GREAT) database which contains
all atopic dermatitis RCTs and systematic reviews. Additionally, the reference lists of included studies
and relevant systematic reviews were searched and experts were asked about studies of which they
were aware. This means that the review is unlikely to have missed relevant studies.
l The systematic reviews were conducted in line with good practice principles of conducting systematic
reviews in health care.120
l The review methods were set out in a protocol prior to the start of the review and published on the
PROSPERO website (PROSPERO reference number: CRD42014007426).
l Both the development of the protocol and the project were informed by an Advisory Group including
clinicians, researchers in the field and patient representatives.
l The use of a taxonomy of intervention elements69 during data extraction to ensure that detailed
information about the content and characteristics of the educational interventions was included in
the review and to help evaluate the completeness of reporting of the intervention characteristics in the
included studies.
l The systematic reviews of both the clinical effectiveness and cost-effectiveness studies have been
carried out independently of any vested interest and the results of both the reviews are presented in a
consistent and transparent manner.
Limitations
l Owing to the nature of the intervention and to many of the studies retrieved for full-text screening not
explicitly reporting the aims of the interventions, the reviewers found it challenging to infer if the
interventions were aimed at improving HRQoL or could improve HRQoL, in accordance with the review
inclusion criteria. Therefore, this was sometimes a judgement call and there was some disagreement
between pairs of reviewers, which was resolved through arbitration by a third reviewer. To resolve
these disagreements, reviewers considered whether the interventions included elements that targeted
compliance with therapy or patients’ ability to cope with the negative effects of the chronic skin
disease, as per the examples given in our a priori inclusion criteria. As mentioned above, this highlights
that what defines such interventions generally needs more consideration and theorising in the
literature. We consider our approach satisfactory, given that intervention aims were not well reported
and given the lack of definition of these kinds of interventions in the literature.
l Meta-analysis could not be conducted owing to heterogeneity of studies and interventions and the
limited evidence-base for each skin condition.
l The review was limited to English-language studies only.
l When determining if a HRQoL or patient-reported outcome measure was validated, the reviewers relied
on statements in the included publications that these were validated and, if this was not reported, they
then checked the general literature to see if a measure met at least one validation criteria. Therefore,
some measures included were more validated than others. However, the studies used a range of
commonly used and well validated measures in this area, such as the DLQI and PASI, so this is likely to
be only a minor issue in the review.
l Outcomes for the end of intervention and longest follow-up period only were data extracted in this
review, owing to limited resources and time and consideration that the longest follow-up time point
would be the most informative. Given the episodic nature of skin diseases and impact of seasonal
changes, however, it may have been useful to data extract interim time points too.
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l The main focus of this review was on the effect of educational interventions that aim to, or could,
improve HRQoL. As such, the data presented on other outcomes from education, such as improved
disease severity, are drawn only from studies of this particular type of education and, therefore, do not
represent all data on how these outcomes may change following patient education in general for
chronic inflammatory skin conditions.
l Three studies of educational interventions that aimed to or could improve HRQoL were excluded from
the review for not reporting results in sufficient detail to be informative. Owing to time and resource
limitations for the review, we were unable to contact study authors to request them to provide the
missing information.
l Length of follow-up of the studies included in the cost-effectiveness review was inadequate to assess
the long-term costs and outcomes of educational interventions in patients with chronic inflammatory
skin diseases.
l There were a number of limitations in the evidence base for the cost-effectiveness of educational
interventions, including limited information, lack of relevant HRQoL measures and information on costs
and resources and, as such, we were able only to make recommendations for future economic
evaluations rather than undertake a de novo economic model.
This review builds on previous systematic reviews of RCTs of educational interventions for chronic
inflammatory skin conditions55,71,121 through its focus on those interventions that specifically aim to improve
HRQoL or those that include aspects which could improve HRQoL. In line with the other reviews of
educational interventions in general, we found that some studies showed statistically significant positive
impacts on HRQoL and other outcomes, whereas some did not. Therefore, even when considering only
interventions that focus on some way on HRQoL, it is still uncertain from the evidence if educational
interventions for people with chronic inflammatory skin conditions can improve HRQoL. Ersser and
colleagues71 suggested from a review of educational interventions in children with atopic dermatitis that
nurse-led or multidisciplinary interventions may be the most effective in improving outcomes. In our
review, we similarly found that delivery by a multidisciplinary team was a commonality between the
effective interventions in comparison with those that were not effective.
Uncertainties
There is overall uncertainty about the effectiveness of educational interventions aimed at improving HRQoL
in all chronic inflammatory skin conditions, particularly over whether beneficial effects are maintained in
the longer term. This is due to the limitations of the evidence base (i.e. studies are generally small, of a
poor quality, likely to be underpowered, lack long-term follow-up and there is a lack of consistent
evidence for a positive effect on HRQoL). The characteristics and content of educational interventions that
may be associated with improvements in HRQoL remain uncertain. The effectiveness of such interventions
in rarer chronic inflammatory skin diseases, such as lichen planus, lichen sclerosus and hidradenitis
suppurativa, is unknown, as no evidence is available. There are no indications from the evidence reviewed
or current clinical guidelines about the best place for such interventions in the clinical pathways for chronic
inflammatory skin conditions, about which patients may benefit the most from such interventions, or the
settings in which they should be implemented.
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Chapter 6 Conclusions
Implications for service provision
There is overall uncertainty over whether educational interventions that include components that could
improve HRQoL are effective in improving HRQoL and other outcomes among people with chronic
inflammatory skin conditions. However, there are some indications of effectiveness in patients with
psoriasis and children and adolescents with atopic dermatitis and their carers. Among patients
with psoriasis, when used as an adjunct to usual care, text message education improved patients’ HRQoL
in the short term at the intervention end compared with an unspecified control condition (based on one
RCT), and intensive group-based education delivered over 3 months by a multidisciplinary team improved
HRQoL at the intervention end and possibly up to 6 months post intervention compared with medical
therapy alone (based on one RCT). Among carers of children with moderate to severe atopic dermatitis,
a 6-week, group-based, education programme delivered by a multidisciplinary team may improve their
HRQoL in the long term (i.e. up to 12 months), in comparison with no education (based on one large
RCT). These interventions also had positive impacts on patients’ disease severity, compared with usual care
or the control conditions, with the authors of the trial of education for atopic dermatitis in children
suggesting that the average improvements in disease severity found were clinically significant. Other than
in this trial, it is unclear how clinically meaningful these improvements are, as authors of these trials did
not comment on this. No effective interventions have yet been evaluated for adults with atopic dermatitis
or acne, and no evidence exists for rarer conditions or acne in young people.
The best approach to delivering these kinds of interventions is yet to be established and there is much
uncertainty around this, but face-to-face, group, sessions or delivery by text messages may be effective.
There are some early indications that delivery over a long period (ranging from 6 weeks to 3 months) and
delivery by a multidisciplinary team may be associated with positive outcomes. Other than these structural
elements, it is not clear what intervention content may be associated with improvements in HRQoL.
Owing to the limitations of the included studies, there is uncertainty over whether educational
interventions aimed at improving QoL are cost-effective in the treatment of chronic inflammatory
skin diseases.
Suggested research priorities
There is a need for high-quality, adequately powered RCTs in all chronic inflammatory skin conditions,
including rarer conditions, in adults, children and adolescents and carers. These should evaluate
theory-based interventions that are sensitive to patients’ needs and characteristics, measure adverse events
or undesirable effects of both the educational intervention and treatment it is supplementing, and include
an adequate long-term follow-up (of at least 3 months post intervention – as recommended by the review
Advisory Group – but preferably 12 months or more as these are long-term conditions which require the
maintenance of self-care behaviours, disease control and positive HRQoL over time). Ideally, such RCTs
should include an economic evaluation, ITT analyses and a process evaluation, define and measure
clinically meaningful changes in outcomes, and follow good reporting standards (e.g. the Consolidated
Standards of Reporting Trials statement). Ideally, process evaluations should be included and it would be
useful to include measures of hypothesised mechanisms and carry out mediation analyses to explore
theoretical explanations about how such interventions may work.
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Prior to carrying out rigorous RCTs, in line with the MRC guidance on complex intervention development
and evaluation, careful intervention development work should be carried out. This could include reviews of
existing evidence and theory to define more accurately the theoretical basis of such interventions and what
content should be included to help improve HRQoL in chronic inflammatory skin conditions, supplemented
by qualitative work with relevant stakeholders, such as patients and HCPs, where needed. For example,
investigators could carry out reviews of the factors associated with HRQoL in specific skin conditions to
help inform the factors that could be targeted in the intervention to improve HRQoL. Our brief literature
review (see Impact of the disease) suggests that psychological distress and stress, along with symptoms,
such as itch, and concerns about appearance may negatively impact patients’ HRQoL.33,39,40 Additionally,
the authors of some of the included studies hypothesised that the effects of education on HRQoL may be
mediated by improved disease self-management. It could be argued that improved patient activation from
education might also increase HRQoL, as it has been found to be associated with improvements in
HRQoL in patients in general.64 These are among the target factors that could be identified in reviews,
qualitative work and in consultation with stakeholders, and which then could be considered in the design
of future interventions. In particular, our review suggests that there is a paucity of studies of educational
interventions that include components addressing the psychosocial issues experienced by people with
chronic inflammatory skin conditions, so this may be a useful focus in future educational interventions.
Given the paucity of current evidence for this kind of intervention in chronic inflammatory skin diseases,
investigators could also draw on evidence about what has been successful in educational interventions
for improving HRQoL in other long-term conditions where patients need to self-manage their condition
(e.g. diabetes and asthma) when designing interventions. Pilot studies should also be conducted to inform
the development of the intervention, its feasibility and acceptability to patients.
RCTs examining the effectiveness of different approaches to intervention delivery would be useful, such as
comparing face-to-face sessions or online interventions, or comparing the effectiveness of shorter
educational sessions with more intensive programmes or comparing delivery by a multidisciplinary team
with delivery by other kinds of intervention providers (e.g. a specialist nurse).
Future studies of educational interventions aimed at improving HRQoL could include measurements of, and
clearly report the resources and costs used to deliver, the intervention, to help inform future economic
evaluations. It would also be ideal if future economic evaluations used a generic, preference-based measure
to assess HRQoL or a disease-specific one that could then be mapped to a preference-based measure.
CONCLUSIONS
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Appendix 1 Common health-related quality-of-life
and disease severity measures
Health-related quality-of-life measures
Dermatological Life Quality Index
The DLQI was developed as a dermatology-specific QoL measure because generic HRQoL instruments,
for example the SF-36, were not specific enough to capture aspects of QoL related to dermatological
conditions. The DLQI is widely used in clinical practice and clinical trials across the world, and has been
particularly used in psoriasis, atopic dermatitis and acne.122,123
The questionnaire is used in adults aged over 16 years. The DLQI consists of 10 questions and provides a
total HRQoL score, as well as scores for six aspects of QOL: symptoms and feelings; daily activities; leisure;
work and school; personal relationships; and treatment. Question responses range from ‘not at all’,
‘a little’, ‘a lot’ to ‘very much’. The DLQI score is calculated by adding the scores together, with a
maximum score of 30 and a minimum score of 0. A higher score reflects a worse HRQoL. A minimally
clinically important difference on the DLQI is generally defined as a score change of at least four points,
with studies estimating that this ranges from 2.2 to 6.9 across specific inflammatory skin conditions.49 The
time frame of DLQI is one week (i.e. it focuses on the QoL in the previous week because it is easy to recall
accurately).49 Lewis and Finlay123 reported that DLQI has been validated against a number of other
dermatology and health measures.
An advantage of the DLQI is that it is simple and quick to complete. Furthermore, there is a very high
success rate of accurate completion of the measure.123 The DLQI is accepted by dermatology professionals,
researchers and regulatory authorities as a standard by which HRQoL can be reliably measured. Despite
being a valid and reliable measure, there are a few limitations. There is a focus on physical limitations as
a result of the skin condition and few items address the possible implications to psychological health.
Evidence suggests that the measure is, therefore, most valid in assessing HRQoL in those with more severe
disease.124 The DLQI is also affected by some bias in terms of factors such as age, sex, diagnosis and
nationality ,which can affect responses on more than half of the questions. Therefore, caution in the
interpretation is recommended when using the measure in a heterogeneous patient population, for
example in international studies, as these factors may impact on the scores seen across patients.124
The Infants’ Dermatitis Quality of Life Index
The IDQoL Index questionnaire is designed to assess QoL in infants with atopic dermatitis aged between
0 and 3 years. This widely used questionnaire is completed by the children’s parents or their carers. It has
wide international use, having been translated into 21 languages.125
The questionnaire consists of two main domains: dermatitis severity and life quality index. Within the life
quality index, there are 10 questions relating to: itching and scratching; mood of the child; how long it
takes for the child to sleep; has the eczema interfered with their playing; swimming or participation in
other family activities; problems during meal times; problems caused by treatment; level of comfort while
dressing or undressing the child; and problems during bath times. Each question is scored between 0 and
3 and these are then totalled to generate the IDQoL score, which therefore ranges from 0 to 30. Higher
scores reflect greater impact.125
Basra and colleagues reported that, despite available evidence across 11 countries on IDQoL sensitivity to
change, there is currently no means by which to estimate what score change is clinically meaningful.125
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The IDQoL measure has several positive aspects of psychometric performance. The measure has shown
high specificity, thereby indicating that it can distinguish between infants with disease and infants without
disease well. As it is simple to use it has been considered to be the ‘gold standard’ to measure HRQoL in
infants with atopic dermatitis. Some validation factors have not been fully researched however, such as
factor analysis, and the test–retest reliability and internal consistency across the different adaptations of
the measure.125
Children’s Dermatology Life Quality Index
The CDLQI questionnaire was designed as a tool to allow assessment of QoL in children aged 4 to 16 years
with skin conditions.126,127 It is a simple questionnaire, which is self-explanatory and very quick to complete
in 1 or 2 minutes. Children are asked to fill it with the help of their parents or guardian.126 This
questionnaire has been a widely used tool and is available in 44 languages. It has been applied in a range
of different skin conditions. It is available in two versions: text only and text with cartoons.127
There are six headings in CDLQI covering 10 questions.126 These are:
l symptoms and feelings (Questions 1 and 2)
l leisure (Questions 4, 5 and 6)
l school or holidays (Question 7)
l personal relationships (Questions 3 and 8)
l sleep (Question 9)
l treatment (Question 10).
Each question is scored on a scale of 0–3, which ranges from ‘Very much’; ‘Quite a lot’; ‘Only a little’;
‘Not at all’; ‘Question unanswered’; and ‘Prevented school’ for Question 7. A score of 3 is assigned to a
question if it is scored ‘very much’ or ‘prevented school’ for Question 7. ‘Quite a lot’ is assigned a score of 2;
‘Only a little’ is assigned a score of 1; and for questions answered as ‘not at all’ or unanswered is given a
score of 0.126
The CDLQI score is calculated when each score is added together, with a range of 0 to 30. Higher scores
represent greater impairment with suggested severity bandings as follows:126
l Score 0–1: No effect on child’s life.
l Score 2–6: Small effect.
l Score 7–12: Moderate effect.
l Score 13–18: Very large effect.
l Score 19–30: Extremely large effect.
In addition, the overall CDLQI score can be expressed as a percentage of the maximum possible score.126
Holme and colleagues128 conducted a study to validate the cartoon-based questionnaire and suggested
that it was equivalent to the written questionnaire (which was previously validated). The authors point
out that the cartoon version was beneficial because it was easier for children to use and both the children
and their parents felt that it was the preferred method.
Salek and colleagues127 tested internal consistency, test–retest reliability and responsiveness to change and
concluded that the measure met these criteria well. The minimally clinically important difference in those
with psoriasis has been suggested to be 2.5; however, this was based on results of one study only and
the authors suggest that further research is warranted. The CDLQI is for use in children aged from 4 to
16 years, which may limit the validity of the measure, as it is likely that adolescents’ responses to the
disease will differ from those of very young children.127
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Quality of life in Primary Caregivers of children with Atopic Dermatitis
The QPCAD is a self-reported questionnaire developed to evaluate the QoL of primary caregivers of a child
with atopic dermatitis. The questionnaire was developed in Japan.129
The QPCAD includes 19 items within the following four categories: ‘exhaustion’ (seven items), ‘worry
about atopic dermatitis’ (six items), ‘family cooperation’ (three items), and ‘achievement’ (three items).
Responses to these items are made on a five-point scale. The overall score is calculated by summing all
scores, with a higher score indicating a worse health state. The questionnaire only takes into account the
QoL of the carer(s) in the past week.129
The QPCAD is simple and quick to complete and it addresses both positive and negative aspects of life
in children with atopic dermatitis (there are six items relating to positive influences out of the total of
19 items).129 Kondo-Endo and colleagues129 reported that the QPCAD is internally consistent, has good
retest reliability and also has reasonable validity. With respect to responsiveness, the study stated that
QPCAD was better in detecting severity change compared with the other well-being instruments.
However, it was pointed out that there was a need for further study to examine the responsiveness of the
subscales to improvements in disease severity over longer periods.129 Some limitations to this study are that
it was based in a Japanese setting, data were based on caregivers of patients with mild to modest disease,
and participants were a relatively homogenous group.129
Skindex
Skindex is a self-report questionnaire with 61 items in eight scales: cognitive effects; social effects;
depression; fear; embarrassment; anger; physical discomfort; and physical limitations. The item responses
range from 0 to 100, with 0 indicating no effect and 100 indicating maximum effect.130
Skindex scales have been shown to have good internal reliability, to be reproducible and to be valid.130 In
the analysis by Chren and colleagues,130 the measure also demonstrated responsiveness to clinical change
and demonstrated both content validity and construct validity. However, the scores were found to be
inconsistent with judgements made by physicians about the severity of the condition.
The earlier version of Skindex was refined into a 29-item Skindex-29, which comprised three domains,
namely: symptoms (constituting 7 items), emotions (constituting 10 items) and functioning (constituting
12 items). Like the previous version, all the item responses were converted to a linear scale, ranging from
0 to 100.131 This version was further refined to develop a shorter version comprising 16 items (Skindex-16)
across three domains: symptoms (4 items), emotions (7 items) and functioning (5 items). Like the two
parent measures, in this version, responses are summed across the three domains and scores range from
0 (for no effect) to 100 (maximum effect). Based on analyses performed over 500 patients, the authors
assessed Skindex-16 to be reliable, valid and responsive to clinical change.131
Both Skindex-29 and Skindex-16 have advantages and the choice between the two instruments depends
on the nature of the research question.131 For instance, Skindex-26 could be better suited to examine and
understand the impacts of a condition on QoL owing to its comprehensive nature, whereas Skindex-16
addresses many other relevant aspects of skin diseases that are not covered by Skindex-29. Despite the
advantages, there is room for further exploration and interpretation in future research.131
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Other measures
The studies included in the review of clinical effectiveness also included other HRQoL measures, apart from
the ones discussed above. These are:
l ACS, reported by van Os-Medendorp and colleagues,89 using one sub-scale
l German questionnaire ‘Quality of life in parents of children with atopic dermatitis’, reported by
Staab and colleagues87
l PDI, reported by Bostoen and colleagues76
l QoLIAD, reported by Bostoen and colleagues76
l WHOQOL-26, reported by Matsuoka and colleagues.88
Disease severity measures
Psoriasis
Psoriasis Area Severity Index
The PASI is the gold-standard measure used by doctors and nurses to assess the severity of psoriasis or the
progress of patients receiving treatment for the condition. It is a measure of the average redness, thickness
and scaliness of the lesions. Each criterion is graded 0–4, and weighted by the area of involvement.132
The questionnaire consists of four sections, covering the head, arms, trunk and legs. Within each of these
four areas, the percentage of area of skin involved is estimated and then transformed into a grade
from 0 to 6:132
l grade: 0; 0% of involved area
l grade: 1; < 10% of involved area
l grade: 2; 10–29% of involved area
l grade: 3; 30–49% of involved area
l grade: 4; 50–69% of involved area
l grade: 5; 70–89% of involved area
l grade: 6; 90–100% of involved area.
Disease severity is assessed by three clinical signs: erythema (redness), induration (thickness) and
desquamation (scaling). Each of these signs is graded on a scale of 0–4, where 0 represents none;
1 represents mild; 2 represents moderate; 3 represents severe and 4 represents maximum severity.133
Psoriasis Area Severity Index is measured by adding the three severity parameters weighted by the area
of involvement. It provides a total score of disease severity, taking into account both coverage and
intensity.134 A clinically meaningful change in clinical trials is a 75% improvement, although there is also
evidence of a 50% improvement being clinically meaningful.132
One of the key advantages of PASI is that it is widely used and has been shown to correlate with QoL.
It has been accepted as a valid measure of disease severity by approving agencies. However, it has a few
limitations: it has poor sensitivity to change when there is only a small area of involvement, despite being
the most widely used instrument for assessing severe psoriasis; there have been a few validation studies;
and the construct validity, face validity and sensitivity to change are not well characterised.132
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Self-Administered Psoriasis Area Severity Index
The SAPASI is a structured instrument that allows patients to assess accurately the severity of their
psoriasis. As a patient-administered measure, the SAPASI requires the patient to shade on an anatomic
sketch, which is then assigned values from an investigator, with a value of 0–6. The scoring is similar to
that used in the PASI as described above. When used as a measure of treatment effectiveness, the patient
is required to grade a sketch of a typical psoriasis plaque and grade the colour, thickness and scaling.
There tool also uses visual analogue scales (VASs) which describe the strength of colour, thickness and
scaling. The scoring range of SAPASI is 0–72.134
Two studies tested the validity of SAPASI.132,134 In their comparison study, Henseler and colleagues134
found a good correlation between the PASI and the SAPASI. This could be a potential advantage of the
instrument in research, as the SAPASI can be used in situations where the investigator is unable to see
the patient. The study also noted that there was good regression between the two instruments, which
suggests that there is equivalent value between both tools.134 However, one limitation of SAPASI as
outlined by Feldman and Krueger132 was that, despite the high correlation between the PASI and SAPASI
across a broad range of severity tested, for any given PASI score there was a wide range of corresponding
SAPASI scores. This indicates that the SAPASI score may not accurately determine the severity of psoriasis
in some individual patients.132
SCORing Atopic Dermatitis
The SCORAD can be used to assess the extent and severity of eczema or atopic dermatitis and can be used
as a marker of treatment effectiveness. The extent of the disease is estimated as a percentage of the
whole body by applying the proportions shown below for different sections of the body affected in an
individual and these are then summed up to a maximum of 100 (classed as ‘A’):135
l head and neck: 9%
l upper limbs: 9% each
l lower limbs: 18% each
l anterior trunk: 18%
l back: 18%
l genitals: 1%.
Intensity of the disease is assessed based on redness, swelling, oozing/crusting, scratch marks, skin
thickening and dryness. These are rated as: none (0); mild (1); moderate (2); or severe (3) and, when
added, give a maximum score of 18 to give ‘B’.135
Finally, patients or representatives are asked to rate on a VAS their subjective symptoms, such as itch and
sleeplessness, using a score of 0 to 10 (where 0 means none and 10 is the worst imaginable symptom).
The scores are summed to give ‘C’ (maximum 20).135
Total SCORAD for that individual is then estimated as: A/5+ 7B/2+C.
The SCORAD combines objective assessments of the extent and intensity of disease made by investigators
with subjective patient or carer ratings of severity (subjective ratings are specifically made for pruritus and
sleep loss over the past 3 days). The objective SCORAD is also available, which does not include the
subjective ratings. On the SCORAD, a higher score indicates more severe disease.136 A minimal clinically
important difference on the SCORAD is defined as a score change of 8.7 points (8.2 points for the
objective SCORAD).137
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Appendix 2 Search strategy
MEDLINE search strategies for clinical effectiveness are shown here. These were adapted for otherdatabases and the cost effectiveness searches (and are available on request).
1. exp acneiform eruptions/ or exp dermatitis/ or exp dermatomyositis/ or exp facial dermatoses/ or hand
dermatoses/ or leg dermatoses/ or exp lupus erythematosus, cutaneous/ or nephrogenic fibrosing
dermopathy/ or prurigo/ or exp pruritus/ or exp rosacea/ or exp skin diseases, eczematous/ or psoriasis/
or exp skin diseases, bacterial/ (159,684)
2. (eczema* or dermatitis or dermato* or acne or psoriasis or pruritus or prurigo or erythem* or rosacea
or rozacea or “cutaneous lupus erythematosus” or “lichen sclerosus” or “lichen planus” or
“hidradenitis suppurativa”).tw. (214,088)
3. (chronic* and inflam* and skin).tw. (5447)
4. 1 or 2 or 3 (289,612)
5. Patient Education as Topic/ (68,477)
6. exp Health Education/ (132,310)
7. Health Promotion/ (50,756)
8. Health Behavior/ (31,842)
9. Life Style/ (41,162)
10. Health Knowledge, Attitudes, Practice/ (68,962)
11. Self Care/ (22,573)
12. "Continuity of Patient Care"/ (13,997)
13. consumer participation/ or patient participation/ (30,827)
14. Telemedicine/ or Teledermatology/ (10,676)
15. Webcasts/ (291)
16. Internet/ (46,581)
17. Cellular Phone/ or Telephone/ (12,862)
18. Counseling/ (27,044)
19. Behavior Therapy/ (22,902)
20. Physician-Patient Relations/ or Nurse-Patient Relations/ (87,702)
21. exp Mind-Body Therapies/ (40,139)
22. ((educat* or train or learn* or teach* or instruct* or knowledge or support*) adj3 (patient* or self* or
program* or model* or system*1 or intervention*)).tw. (158,193)
23. (patient* adj3 information*).tw. (23,746)
24. ((program* or intervention* or instruction* or teach* or learn* or educat* or plan* or strategy or
strategies) adj10 (literature or handout* or leaflet* or inform* or video* or audiovisual or “AV” or
internet or web or website* or telecare or telemedicine or teledermatology or telephone or phone or
mobile or teleconferenc* or telehealth or transtelephonic* or podcast or broadcast*)).tw. (106,105)
25. (self* adj3 (care or monitor* or help or management)).tw. (25,940)
26. exp Psychotherapy/ (146,141)
27. psychotherap*.tw. (29,205)
28. (psychosomatic and therap*).tw. (1513)
29. Cognitive Therapy/ (14,733)
30. Family Therapy/ (7499)
31. (“health promotion” or “health education” or “patient education” or “patient
information”).tw. (49,573)
32. (educat* and intervention*).tw. (41,292)
33. (intervention* adj3 (group* or study or studies or trial*)).tw. (50,074)
34. (“e-consult*” or “e-health” or “e-learn*”).tw. (1790)
35. (“patient teaching” or “patient training” or “patient learning”).tw. (862)
36. or/5-35 (873,959)
37. 4 and 36 (6230)
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38. (psychosocial* and (intervention* or educat*)).tw. (16,709)
39. (psychological* and (intervention* or educat*)).tw. (23,824)
40. (psychosomatic* and (intervention* or educat*)).tw. (821)
41. Stress, Psychological/ed, pc, th [Education, Prevention & Control, Therapy] (9164)
42. or/38-41 (46,080)
43. 4 and 42 (428)
44. 37 or 43 (6430)
45. exp Randomized Controlled Trial/ (359,500)
46. Randomized Controlled Trials as Topic/ (88,564)
47. randomized controlled trial.pt. (359,493)
48. controlled clinical trial.pt. (86,909)
49. Controlled Clinical Trial/ (86,909)
50. placebos/ (31,924)
51. random allocation/ (78,664)
52. Double-Blind Method/ (122,243)
53. Single-Blind Method/ (18,296)
54. (random* adj2 allocat*).tw. (19,059)
55. placebo*.tw. (145,886)
56. ((singl* or doubl* or trebl* or tripl*) adj (blind* or mask*)).tw. (119,800)
57. crossover studies/ (32,896)
58. (crossover* or (cross adj over*)).tw. (54,490)
59. Research Design/ (75,676)
60. ((random* or control* or compar*) adj5 (trial* or stud*)).tw. (750,980)
61. Clinical Trials as Topic/ (166,646)
62. Comparative Study/ (1,647,117)
63. or/45-62 (2,601,095)
64. 44 and 63 (1222)
65. limit 64 to english language (1116)
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Appendix 3 Quality assessment criteria
TABLE 29 Cochrane ‘risk of bias’ tool
Criteria Judgement of risk of biasa Support for judgement
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
a High risk, unclear risk, low risk.
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Appendix 4 Data extraction tables:
clinical effectiveness
Reference and
design Intervention Participants Outcome measures
Author and year:
Balato et al., 201385
Study ID: 51
Source: published
Country/location:
Italy
Setting: home
Trial design: RCT
Includes process
evaluation: yes
Number of study
centres: 1 (assumed)
Funding: none
Conflicts of interest:
none
Trial/study number:
not reported
Study dates:
September 2011–not
stated
Was the educational
intervention an
adjunct to standard
medical care? Yes
Treatment intervention
Overview: text message
education
Intervention aims: not stated
explicitly but implicit from the
paper that aim was to use
text messaging to improve
treatment adherence and
patient outcomes including
HRQoL
Where delivered: via mobile
phone
Self-help, individual- and/or
group-based? (state group
size): individual-based
intervention
Mode: text messaging
Materials: text messages
Provider: not stated who the
‘investigators’ were but
physicians enrolled
participants
Duration and intensity: 1 text
message per day for a period
of 12 weeks
Scripting (level of detail
guiding interaction between
interventionist and
participants): general
educational statements and
reminders sent in a random
order with four educational
and three reminders sent each
week. Details of the types of
information provided in the
paper but no details of the
coverage of these (i.e. if all
were eventually sent to each
participant)
Sensitivity to participant
characteristics: text messages
were created using simple
language
Skin condition: plaque psoriasis
Diagnostic criteria: not reported
Specify if patients, parents
and/or carers: patients
Patient general age group
(specify if children, young
adults and/or adults): adults
Stated target group: no details
How recruited: consecutive
patients
Eligibility criteria: aged between
18 and 65 years, current
systemic and topical treatment,
PASI between 5 and 15, owner
of a mobile phone capable of
receiving text messages and
the ability to use it. The
presence of comorbidities was
not an exclusion criteria
Numbers involved (randomised/
allocated): total 40;
intervention: 20; control: 20
Numbers (%) completing,
attrition and reasons: attrition:
intervention group= 0; control
group= 0
Reasons: not applicable
Completing: 100%
Sample cross-overs: none
Baseline characteristics
Comorbidities, n (%) as
reported in paper is percentage
of those with any comorbidity,
reviewer also calculated % of
total group [%]:
Hypertension
Intervention: 3/6 (50) [15];
Control: 4/7 (57) [20]
Primary outcomes: not
reported as primary or
secondary outcomes. PASI,
PGA, BSA, SAPASI; HRQoL
(DLQI)
Other outcomes: evaluation
of patient–physician
relationship; treatment
adherence
Secondary outcomes: adverse
events: not reported
Process evaluation measures:
usability and satisfaction with
the text messaging education
Individual preferred learning
style addressed? No
Any sub groups: none
reported
How outcomes assessed?
DLQI, SAPASI and adherence
are self-report; PASI, BSA
and PGA are clinician
reported but not clear who
assessed. Unclear for the
patient–physician relationship.
DLQI, PASI and SAPASI details
of measure not stated;
patient–physician relationship
was a scale of 0–10;
treatment adherence through
a multiple-choice question
about how often they forgot
to use products/medications
in days per week in the past
week. Also a 7-day calendar
marking days when they were
adherent as outlined in a
cited reference. States the
PASI, BSA and PGA were
used to support the results of
the self-reported adherence
Normal range(s) for outcomes/
clinically meaningful
improvement defined: not
reported
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Reference and
design Intervention Participants Outcome measures
Interventionist characteristics
and training: no details
Content and topics:
summary – covered frequently
asked questions about
psoriasis drugs (e.g.
administration and adverse
effects) and general
recommendations to take
care of overall health. All text
messages between one and
three sentences. Educational
topics included daily care
statements (e.g. use
moisturisers, wear light
clothes), healthy lifestyle
statements (e.g. avoid
smoking, pay attention to
your diet), prompts about the
use of treatments (e.g. do not
abuse steroids, common
side effects of certain drugs)
and one statement about
the psychosocial effects of
psoriasis (e.g. do not feel
ashamed or guilty, psoriasis is
not contagious). Reminders
reinforced many of the same
principles
Tailoring: does not appear to
be tailored
Ongoing support: none
reported
Theory: none reported
Control intervention:
Description: no details of the
control intervention
Duration and intensity: not
reported
Dysplipidemia
Intervention: 2/6 (33) [10];
Control: 2/7 (28.5) [10]
Type 2 diabetes
Intervention: 1/6 (17) [5];
Control: 1/7 (14.5) [5]
Co-medications/interventions:
Intervention group: acitretin 2
(10%); biologics 10 (50%);
ciclosporin 3 (15%);
methotrexate 5 (25%)
Control group: acitretin 3
(15%); biologics 11 (55%);
ciclosporin 2 (10%);
methotrexate 4 (20%)
Duration of disease, mean (SD):
Intervention 10.7 (5.3) years
Control 12.1 (5.8) years
Sex (M/F) n/N:
Intervention 10/10
Control 12/8
Average age: mean (SD) age,
years
Intervention 38.4 (9.5); Control
39.3 (10.2)
Ethnic groups: not reported
Socioeconomic characteristics:
Education, n (%)
Intervention: middle school
5 (25); high school 12 (60);
college graduate 3 (15)
Control: middle school 6 (30);
high school 10 (50); some
college 1 (5); college graduate
3 (15)
Currently employed, n (%)
Intervention: 16 (80)
Control 15 (75)
Validated? Yes for
all measures except
patient–physician relationship
and adherence (therefore not
data extracted)
Timing of outcomes same for
both groups: yes
Length of follow-up:
12 weeks
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
106
Methods
Statistical analysis, including how missing data dealt with: minimal details about statistical approaches used, data
presented as means (SDs). No missing data
Power calculation: not reported. Described as a pilot study
Study adequately powered? Unclear
ITT used? No missing data or drop outs so ITT (although not described as such by authors)
Groups comparable at baseline? Yes
Subgroup analyses: none reported
Process evaluation methods (if relevant): in the treatment group only, usability and satisfaction with the text
messaging intervention were assessed using a series of questions
Outcome evaluation results
HRQoL Outcomes Intervention (n= 20) Control (n= 20) p-value/CIs
DLQI, mean (SD) baseline 7.9 (3.2) 7 (3)
DLQI, mean 12 weeks 4.2 5.8 p< 0.05
Comments: 12 weeks scores estimated from figure by reviewer
Other relevant outcomes Intervention (n= 20) Control (n= 20) p-value/CIs
PASI, mean (SD) baseline 10.64 (4.2) 10.13 (4.7)
PASI, mean 12 weeks 5.8 6.8 p< 0.05
SAPASI, mean (SD) baseline 11 (6.6) 10.90 (5.9)
SAPASI, mean, 12 weeks 5.9 8 p< 0.05
BSA, mean (SD) baseline 16 (7.5) 14.2 (8)
BSA, mean 12 weeks 5.8 8 p< 0.05
PGA, mean (SD) baseline 2.6 (1.04) 2.3 (1.3)
PGA score 0.7 1.5 p< 0.05
Comments: all 12 weeks’ data estimated from figure by reviewer
Treatment adherence scores and patient–physician relationship scores not data extracted as not validated measures
Adverse events Intervention Control p-value/CIs
Comments:
Subgroup analysis results
Comments: no subgroups reported
Outcome Intervention Control p-value/CI
Comments:
Process evaluation results
Usability and satisfaction with the text messaging education:
85% found text messaging useful
75% would recommend to a friend
75% would like to continue using the text messaging
15% would be willing to pay a small fee for the service
Comments:
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Outcome Intervention Control p-value/CI
Generalisability: Italian population all with plaque psoriasis of moderate-to-large effect based on baseline PASI
scores (reviewer observation). Participants on a range of different treatments, unclear how generalisable these
are to UK standards of care
Other: no details of the control group so unclear whether they were seen as usual care or not seen at all
Quality criteria (Cochrane ‘risk of bias’ tool) randomised
controlled trials
Criteria
Judgement of
risk of biasa Support for judgement
Random sequence generation
(selection bias)
Low risk Allocation by a computer-generated random number list
Allocation concealment
(selection bias)
Unclear risk States group assignment was stored electronically and that
investigators performing randomisation had no contact with
participants, but no other details
Blinding of participants and
personnel (performance bias)
High risk Physicians were blinded to group assignment until the end
of the study. No details of blinding of participants, which
would be difficult to do
Blinding of outcome assessment
(detection bias)
Unclear risk No details
Incomplete outcome data
(attrition bias)
Low risk No attrition
Selective reporting (reporting bias) Low risk All outcomes stated were reported
Other bias Low risk
a High risk, unclear risk, low risk.
Reference and
design Intervention Participants Outcome measures
Author and year:
Bostoen et al., 201276
Study ID: 84
Country/location:
Belgium
Setting: unclear,
assume outpatient
Trial design: RCT
Includes process
evaluation: no
Number of study
centres: unclear,
assume one
Treatment intervention
Overview: educational
programme for patients with
psoriasis and atopic dermatitis
Intervention aim(s): not
explicitly stated. Study aimed
to examine if the educational
intervention ‘added value to
medical therapy’ (p. 1025) and
examine the effects on disease
severity and QoL
Where delivered: not reported
Self-help, individual- and/or
group-based? (State group size):
group-based intervention.
Group sizes differed and were
14, 23 and 13
Skin condition: psoriasis or
atopic dermatitis
Diagnostic criteria: not
reported except that diagnosis
was checked by a
dermatologist at study entry
Specify if patients, parents
and/or carers: patients
Patient general age group
(specify if children, young
adults and/or adults): adults
Stated target group: adults
with psoriasis or atopic
dermatitis
Primary outcomes: disease
severity (PASI; SCORAD, EASI).
HRQoL (DLQI; Skindex-29;
PDI; QoLIAD)
Secondary outcomes:
depression (BDI); lifestyle
(set of questions un-validated)
Stress (EPC)
Medical consumption
Cost-effectiveness (states used
costs of medical consumption
and EQ-5D for health
outcomes to assess cost per
EQ-5D gain in Euros)
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Reference and
design Intervention Participants Outcome measures
Funding: grants from
various pharmaceutical
companies
Conflicts of interest:
states none
Trial/study number:
NCT01077882
Study dates: February
2010–11
Was the educational
intervention an
adjunct to standard
medical care? Yes
Mode: face-to-face workshop
Materials: secondary
publication99 of a before-and-
after study. Used the same
intervention notes as the
syllabus that was offered to
participants
Provider: dermatologist,
dermatology nurse,
pharmacists, dietician, training
expert, psychiatrist, psychologist,
philosopher, and a sports, yoga
and mindfulness teacher
Duration and intensity:
3-month programme, with
two, 2-hour sessions a week
Scripting (level of detail
guiding interaction between
interventionist and
participants): secondary
publication99 refers to a
syllabus
Sensitivity to participant
characteristics: not reported
Interventionist characteristics
and training: none reported
apart from job title noted
above
Content and topics:
information on specific skin
disease, and skin care sessions,
healthy lifestyle (diet, sleep
hygiene, smoking, substance
abuse) and stress-reducing
techniques (physical training,
psychodermatology, practical
philosophy and mindfulness),
feedback sessions. Further
details of the intervention
provided in a separate
publication99
Tailoring: not reported
Ongoing support: not reported
Theory: not reported
All patients continued with
medical therapy
How recruited: recruited from
Ghent University Hospital,
patient advocacy groups and
dermatologists
Eligibility criteria: aged
18 years or older, psoriasis or
atopic dermatitis
Excluded if other severe
illnesses, psychiatric disorders
or cognitive disorders
Numbers involved
(randomised/allocated):
Total: 50 (29 psoriasis; 21 AD)
Intervention (intervention):
25 (15 (60%) psoriasis,
10 (40%) AD)
Control (control): 25 (14 (56%)
psoriasis, 11 (44%) AD)
Numbers (%) completing,
attrition and reasons (by study
end, reports rates for each
follow-up period but not data
extracted):
Attrition: N (%) 13 (26%)
[intervention 8 (32%); control
4 (16%)] In addition, one
participant in the intervention
group was excluded from the
analysis
Reasons: range of reasons
provided but not linked to
number of individuals
dropping out for each reason.
These included lack of time,
too intensive programme
and moving house in the
intervention group and
worsening of disease and loss
of motivation in the control
group
Completers: N (%)
[intervention: 16 (64%);
control 21 (84%)]
Sample cross-overs: none
reported
Baseline characteristics
Co-morbidities: not reported
Adverse events: not reported
Process evaluation measures:
none reported
Individual preferred learning
style addressed? No
How outcomes assessed?:
Severity measures assessed by
two clinicians, having been
trained at the start of the trial,
level of agreement was
good (intraclass correlation
coefficient 0.86 (95% CI 0.72
to 0.94) for PASI, 0.89 (95% CI
0.74 to 0.96) for SCORAD,
0.92 (95% CI 0.82 to 0.97) for
EASI)
Normal range(s) for outcomes/
clinically meaningful
improvement defined: yes for
BDI and EPC and DLQI
Validated?
Severity, HRQoL measures, BDI
and EPC validated
Lifestyle questionnaire not
validated and not data
extracted
Timing of outcomes same for
both groups: yes
Length of follow-up: 9 months
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Reference and
design Intervention Participants Outcome measures
Control intervention
Description: received medical
therapy alone
Duration and intensity: no
details
Co-medications/interventions,
n:
Topical therapies
Intervention: 17 (psoriasis 9,
AD 8); control: 21 (psoriasis 12,
AD 9)
Systemic therapies
Intervention: 0; control: 1
(psoriasis 1)
Combination
Intervention: 4 (psoriasis 2,
AD 2); control: 3 (psoriasis 1,
AD 2)
None
Intervention: 4 (psoriasis 4);
control: 0
Total
Intervention: 25 (psoriasis 15,
AD 10); control: 25 (psoriasis
14, AD 11)
Duration of disease, mean
(SD) years:
Intervention: 18.9 (11.0);
control: 20.1 (11.4)
Disease severity: see below
Sex (M/F),%:
Intervention: 48/52; control:
48/52
Average age, mean (SD) years:
Intervention: 38.5 (12.3);
control: 40.6 (12.2)
Ethnic groups: not reported
Socioeconomic characteristics:
Education: low/medium/high
(%)
Intervention: 4/22/74; control:
4/52/44
AD, atopic dermatitis; EPC, Everyday Problem Checklist.
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Methods
Statistical analysis, including how missing data dealt with: reports how data were analysed including mixed
modelling to identify differences in time between the intervention and control groups for each outcome variable
Power calculation: power calculation showed that 34 patients were required. There was an 80% probability that the
study would detect a treatment difference at a two-sided 0.05 significance level if the mean difference between treatments
is 2 with a SD of 2
Study adequately powered? Yes for total sample; however, analyses presented are essentially subgroup analyses and
unclear if the sample is adequately powered
ITT used? No details reported; paper does suggest that those dropping out were included in the analysis with the
exception of one participant in the intervention group who was excluded from the analysis (p. 1027). However,
the reporting of the results suggests that different numbers may have been analysed at each follow-up point because the
baseline scores are different in each case
Groups comparable at baseline? Not reported but appear to be well matched
Subgroups analyses: all analyses were subgroup analyses of psoriasis and atopic dermatitis patients
Process evaluation methods (if relevant): none reported
Outcome evaluation results
Total group, psoriasis and AD combined
HRQoL outcomes Intervention (n= 25) Control (n= 25) p-value/CI
DLQI, mean (SD) baseline 9.7 (6.0) 7.5 (5.0)
Skindex-29 total, mean (SD) baseline 45.5 (16.1) 43.3 (17.7)
Skindex-29 symptoms, mean (SD) baseline 58.1 (15.4) 55.8 (18.4)
Skindex-29 emotions, mean (SD) baseline 48.9 (19.6) 49.0 (22.7)
Skindex-29 functioning, mean (SD) baseline 35.2 (20.4) 30.8 (21.4)
BDI, mean (SD) baseline 11.3 (8.2) 8.4 (6.5)
PDI, mean (SD) baseline 9.0 (6.8) 7.6 (7.8)
Comments: paper does not specify which outcomes were reported for the total group and which for the two subgroups,
so reviewer has assumed generic instruments at baseline are reporting the total group. However, these measures are also
presented for baselines within the two disease subgroups (see below) and there are no end-point measurements for these
in the total group
DLQI, Skindex-29, PDI, QoLIAD: higher scores indicate a greater negative impact of the skin disease on QoL. In another
publication, the same authors state that the minimal clinical important difference of the DLQI is reported to be between
2.2 and 6.9 depending on the skin disease
BDI: self-administered questionnaire with 21 questions. Patients categorised as minimal (score 0–9), mild (score 10–18),
moderate (score 19–29) or severe (score 30–36) depression
Paper states the EPC was applied to 27 participants but it is not clear which group these participants were allocated to.
Reports that there were no significant differences between groups during the study, no further details
Paper states EQ-5D values were not significantly better than in the control group at 6 months. Cost–utility analysis taking
into account programme cost per patient and medical resource use per individual patient did not show cost-effectiveness at
6 months
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Psoriasis subgroup
Other relevant outcomes Intervention (n=unclear) Control (n=unclear) p-value/CI
DLQI, mean (95% CI) baseline 8.4 (5.6 to 11.2)a 6.6 (3.9 to 9.3)b
DLQI, mean (95% CI) 3 months 4.4 (1.3 to 7.4) 6.4 (3.6 to 9.2) p-value= 0.019
DLQI, mean (95% CI) 9 months 4.0 (0.6 to 7.4) 5.8 (2.9 to 8.8) p-value= 1.00
PASI, mean (SD) baseline 8.4 (CI 6.0 to 10.8)c 7.1 (CI 4.8 to 9.4)d
PASI, mean (95% CI) 3 months 6.8 (4.3 to 9.3) or
6.5 (3.6 to 9.4) or
6.5 (3.3 to 9.8)
8.1 (5.8 to 10.4) or
8.1 (5.6 to 10.7) or
8.1 (5.3 to 10.9)
p-value= 0.036
PASI, mean (95% CI) 9 months 7.0 (3.8 to 10.3) 7.0 (3.8 to 10.3) p-value= 0.116
PDI, mean (SD) [95% CI] baseline 9.0 (6.8) [5.0 to 13.0]e 7.6 (7.8) [3.8 to 11.5]f
PDI, mean (95% CI) 3 months 4.3 (0.1 to 8.4) or
4.5 (0.1 to 9.0) or
4.5 (–0.1 to 9.1)
6.7 (2.9 to 10.6) or
6.7 (2.7 to 10.7) or
6.7 (2.6 to 10.8)
p-value= 0.015
PDI, mean (95% CI) 9 months 4.9 (0.3 to 9.5) 7.4 (3.3 to 11.6) p-value= 0.021
Skindex-29
g
No data No data Not significant
BDI, mean (95% CI) baseline 12.3 (8.3 to 16.4) 7.4 (3.5 to 11.3)
BDI, mean (95% CI) 3 months 10.5 (6.1 to 14.9) 6.3 (2.3 to 10.3) p-value< 0.05
BDI, mean (95% CI) 9 months 6.1 (1.7 to 10.5) 7.3 (3.2 to 11.3) p-value= 0.029
Comments: 3-month and 9-month outcomes extracted – 3 month relates to the end of the intervention, 9 months was the
longest period of follow-up. Also reports 6-month data, not extracted
a In the reporting of the results the baseline DLQI was also reported to be 8.0 (CI 5.0 to 11.0) and 8.0 (CI 4.9 to 11.1)
with no explanation. This suggests that the numbers analysed differed at different time points and the baselines were
recalculated on the basis of different participant numbers.
b In the reporting of the results the baseline DLQI was also reported to be 6.6 (CI 3.8 to 9.4) and 6.6 (CI 3.7 to 9.5) with
no explanation, see above.
c In the reporting of the results the baseline PASI was also reported to be 8.9 (SD 4.3) or 8.4 (CI 5.6 to 11.6) or 8.6
(CI 5.8 to 11.4) which is not explained, see above.
d In the reporting of the results the baseline PASI was also reported to be 7.1 (SD 3.8) or 7.1 (CI 4.6 to 9.7) or 7.1
(CI 4.3 to 9.9) which is not explained, see above.
e In the reporting of the results the baseline PDI was also reported to be 8.8 (CI 4.5 to 13.0)/CI 4.3 to 13.2), see above.
f In the reporting of the results the baseline PDI was also reported to be 7.6 (CI 3.7 to 11.6)/(CI 3.6 to 11.7), see above.
g Paper reports no significant differences between groups but no data presented.
EPC categorised as having a low (score for men of ≤ 6, for women of ≤ 4), normal (score for men of 7–36, for women of
5–33) or high (score for men of ≥ 37, for women of ≥ 34) stress level. No data reported for EPC, states not significant
across groups during the study.
Paper reports different mean scores and 95% CI for 6-month outcomes in different places.
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Medical therapy use Intervention (n= 14) Control (n= 14)
At 3 months
Topical
Systemic
Combination
None
Total
5
–
2
2
9
12
–
–
1
13
At 9 months
Topical
Systemic
Combination
None
Total
3
–
2
3
8
10
1
1
1
13
Comments: paper states no major differences between groups (could not test for significant differences)
AD subgroup
HRQoL Intervention (n= 10) Control (n= 11)
QoLIAD, mean (SD) baseline 9.1 (5.6) 9.6 (6.1)
Disease severity
SCORAD, mean (SD) baseline 38.9 (18.0) 38.8 (15.5)
EASI, mean (SD) baseline 11.9 (10.9) 10.4 (8.1)
Comments: paper states no significant differences between intervention and control groups for EASI, SCORAD, DLQI,
Skindex-29 or QoLIAD. No data presented
Paper also reports no statistically significant differences on the BDI but no data presented
Medical therapy use Intervention (n= 10) Control (n= 11)
For baseline see above
At 3 months
Topical
Systemic
Combination
None
Total
7
–
1
1
9
8
–
2
–
10
At 9 months
Topical
Systemic
Combination
7
–
1
7
–
1
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Medical therapy use Intervention (n= 10) Control (n= 11)
None
Total
–
8
–
8
Comments:
Paper states no significant differences between groups
Adverse events Intervention Control p-value/CI
Comments:
Process evaluation results
Not reported
Comments:
General comments
Generalisability: psoriasis patients classified on average as mild at baseline, atopic dermatitis moderate
Other: patients recruited from three different sources, a university hospital, patient advocacy groups and peripheral
dermatologists. There were three runs of the educational programme, one in spring 2010, one in autumn 2010 and one in
spring 2011 – unclear how uniform the delivery of these was between the three groups
Quality criteria (Cochrane ‘risk of bias’ tool) randomised
controlled trials
Criteria
Judgement of
risk of biasa Support for judgement
Random sequence generation
(selection bias)
Low Randomised on 1 : 1 basis using computer-generated
randomisation list, allocation was indicated and stratified by
diagnosis using a block size of two
Allocation concealment
(selection bias)
Unclear Sequentially numbered envelopes were used to assign patients
to the two study groups, does not state is opaque envelopes
Blinding of participants and
personnel (performance bias)
Unclear Not reported
Blinding of outcome assessment
(detection bias)
Unclear Clinicians performing the assessments of disease severity were
blinded to randomisation, unclear who assessed other outcomes
Incomplete outcome data
(attrition bias)
High risk Numbers and general reasons provided but high drop-out in
intervention group, no ITT analysis and there are different data
reported for many outcomes for the same time points. Also one
in intervention group excluded from analysis owing to extreme
stress at work
Selective reporting (reporting bias) Unclear risk Paper appears to report all outcomes but in many cases no data
were presented and the reviewer has to rely on statements
which state there were no significant differences
Other bias Unclear All results are essentially subgroup analyses and unclear if
powered adequately
a High risk, unclear risk, low risk.
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Reference and
design Intervention Participants Outcome measures
Author and year:
Ersser et al., 201186
Study ID: 135
Country/location: UK
Setting: primary care
Trial design: cluster
RCT (pilot)
Includes process
evaluation: yes
Number of study
centres: 8 (health
centres)
Funding: Psoriasis
Association, UK
Conflicts of interest:
none
Trial/study number:
not reported
Study dates:
June–September 2009
Was the educational
intervention an
adjunct to standard
medical care? Yes
Treatment intervention
Overview: a theory-based
self-management educational
intervention for individuals
with psoriasis. Patients also
received usual care (only
mentioned in abstract)
Intervention aim(s): to support
self-management in psoriasis
Where delivered: not reported
Self-help, individual- and/or
group-based? (State group
size): group-based face-to-
face session (maximum of
9 participants), with
supporting information
and follow-up telephone
consultation
Mode: face to face, written
and audio-visual materials,
individual telephone
consultation
Materials: supporting written
and audio-visual materials
provided; DVD and
workbook, including
relaxation material
Provider: nurse-led group
sessions, with supporting
materials provided
(see Materials)
Duration and intensity: group
session: one-off 2-hour
session
Telephone consultation:
one-off 20-minute session
Scripting (level of detail
guiding interaction between
interventionist and
participants): in delivering the
intervention, the nurse was
expected to follow the
intervention protocol,
but with flexibility for
individualisation. Outline
script was used for follow-up
telephone consultation
Sensitivity to participant
characteristics: not reported,
but intervention allowed
flexibility for individualisation
Skin condition: psoriasis
Diagnostic criteria: not
reported
Specify if patients, parents
and/or carers: patients
Patient general age group
(specify if children, young
adults and/or adults): adults
Stated target group:
individuals with mild-to-
moderate plaque psoriasis
How recruited: from primary
care, with CLNR support
Eligibility criteria: aged
≥ 18 years; mild to moderate
plaque psoriasis (defined as
patients using only topical
therapies and having had no
secondary care contact in
preceding 3 months)
Numbers involved
(randomised/allocated):
total: 64
Intervention: 28; control
(control): 36
Numbers (%) completing,
attrition and reasons:
Attrition: 5 (8%) [intervention
2 (7%); control (8%)]
Reasons: all lost to follow-up
Completers: 59 (92%)
[intervention 26 (93%);
control 33 (92%)]
(All percentages calculated
by reviewer.)
Sample cross-overs: none
Baseline characteristics
Comorbidities: not reported
Comedications/interventions
(n):
Current topical therapies:
None: intervention 2;
control 2
Primary outcomes:
HRQoL (DLQI)
Secondary outcomes: disease
severity (PASI)
Adverse events: not reported
Process evaluation measures:
participant questionnaire
assessing perceived value,
accessibility and extent
to which intervention
met individual needs
(operationalised as a single
rating of usefulness for each
intervention delivery mode)
(see Methods and Results
below)
Individual preferred learning
style addressed? No
How outcomes assessed?
DLQI (designed as self-report;
not reported if used as
a self-report measure in
this study). PASI (unclear if
self-report or scored by
assessors)
Normal range(s) for outcomes/
clinically meaningful
improvement defined: yes
(in discussion)
PASI score ranges:
< 7 mild
7–12 moderate
> 12 severe
Clinically meaningful
improvement:
Typically defined as PASI 75 if
used as a primary outcome in
a trial (defined as a 75%
reduction in PASI at the end
of the intervention), but some
also regard PASI 50 (i.e. 50%
reduction) to be a clinically
meaningful improvement
(though this is opinion and
has not been formally
defined)
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Reference and
design Intervention Participants Outcome measures
Interventionist characteristics
and training: nurse attended
training on self-efficacy-based
education
Content and topics: practical
element (no details provided),
individual action planning,
stress reduction (through
provision of relaxation
materials), feedback on action
plans (through telephone
consultation)
Tailoring: intervention
included individual action
planning
Ongoing support: nurse
provided one 20 minute
follow-up telephone
consultation one month after
the group session (based on
outline script)
Theory: based on social
learning theory – specifically
self-efficacy theory.
Intervention incorporated
elements designed to address
the four sources of self-
efficacy (mastery, verbal
persuasion, vicarious
experience, emotional
regulation). Intervention was
also informed by the findings
of previous qualitative
research into the
self-management needs of
individuals with psoriasis
Control intervention
Description: continued with
their usual treatment (topical
therapies only), with access to
primary care as needed
Duration and intensity:
not reported
Emollients only: intervention 6;
control 2
GP prescribed active therapies:
intervention 20; control 32
Mean duration of disease:
Intervention 22.68 (SD 17.99)
years; control 24.17 (SD
18.63) years
Disease severity:
Described as mild-moderate
Sex (M/F):
Intervention 8 (29%)/20
(71%); control 20 (55%)/16
(45%)
Mean age: Intervention 56.86
(SD 12.67) years; control
59.03 (SD 13.53) years
Ethnic groups: not reported
Socioeconomic characteristics:
not reported
Validated? Yes (for both DLQI
and PASI)
Timing of outcomes same for
both groups: yes
Length of follow-up: 6 weeks
CLNR, Comprehensive Local Research Networks.
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Methods
Statistical analysis, including how missing data dealt with: unpaired t-tests used to assess differences in changes from
pre–post intervention scores between the intervention and control groups. Multilevel modelling also used to take into
account the cluster RCT design, but not reported as results were similar to those of the t-test. No imputation of missing
data for those lost to follow-up – those lost to follow-up were excluded from the analysis as they had incomplete
information
Power calculation: not reported
Study adequately powered? Pilot study to test feasibility of intervention, not expected to have enough power to detect
statistically significant differences
ITT used? No, completers only
Groups comparable at baseline? Yes, on all baseline characteristics reported (only sex, age, duration and current topical
therapies reported), except sex (proportionally more women in the intervention than the control group; p-value= 0.031)
Subgroups analyses: post hoc subgroup analyses conducted for both outcomes for patients with more severe disease and
worse HRQoL at baseline (participants with DLQI or PASI scores of > 6) – not data extracted
Process evaluation methods (if relevant): assessment of the feasibility of the intervention (participant feedback); participant
completion of a questionnaire post intervention assessing perceived value, accessibility and extent to which intervention
met individual needs (rated on a scale of 1 (not useful at all) to 10 (very useful); score interpretation: 1–3= not useful,
4–7=moderately useful, 8–10= very useful); participants’ views of the intervention obtained through written feedback at
their 6-week follow-up visit; research team also assessed intervention practicality and value. Feedback analysed through
qualitative data analysis and descriptive statistics
Outcome evaluation results
HRQoL Outcomes Intervention (n= 26) Control (n= 33) p-value/CI
DLQI, mean (SD)
baseline 4.86 (5.14) 4.18 (3.19)
at 6 weeks 4.58 (5.05) 3.70 (3.71)
change from baseline 0.28 (2.16)a 0.48 (3.02)a p= 0.772 (95% CI: –1.20 to 1.61)
Comments: DLQI scores can range from 0–30, a higher score indicates worse HRQoL
Other relevant outcomes Intervention (n= 26) Control (n= 33) p-value (95% CI)
PASI, mean (SD)
baseline 2.34 (2.66) 3.22 (2.26)
at 6 weeks 1.78 (1.62) 2.82 (2.20)
change from baseline 0.56 (1.42)b 0.40 (1.06)b 0.619 (–0.81 to 0.49)
Comments: PASI scores can range from 0–72, a higher score indicates more severe disease
Adverse events Intervention Control p-value/CI
Not reported
Comments:
Subgroup analysis results:
Subgroup: no pre-specified subgroup analyses reported
Outcome Intervention Control p-value/CI
Comments:
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Process evaluation results
Patient perspective:
Qualitative data – participant feedback:
Participants found the intervention practical (not too time-consuming), convenient (because it was partly home-based),
and felt it provided follow-up care
Qualitative data on how useful participants found each intervention component and their perceptions on the difference it
has made to how they manage their psoriasis are presented (not data extracted; see Table 4)
Quantitative data:
Rated usefulness of intervention components, % (n= 26)
(Data were derived from the questionnaire where participants rated the usefulness of the intervention)
Group learning: 3.8 not useful; 30.8 moderately useful; 65.4 very useful; 0 no response
DVD: 3.8 not useful; 26.9 moderately useful; 26.9 very useful; 42.3 no response
Workbook: 3.8 not useful; 38.5 moderately useful; 57.7 very useful; 0 no response
Telephone consultation: 7.7 not useful; 30.8 moderately useful; 53.8 very useful; 7.7 no response
Educational intervention attendance (n/N):
Group-learning session: 26/28
Watched DVD: 15/28 (others had technical difficulties, did not like DVD format and/or found workbook more convenient to
intermittently consult)
Research team perspective: noted that smaller group learning sessions resulted in more interaction between participants
Comments:
General comments
Generalisability: patients’ baseline HRQoL and disease severity scores were very low, suggesting many participants had
only mild disease and that their HRQoL had not been extensively affected by their disease. This may have impacted
outcomes, e.g. less room for improvement, participants’ need for support and education may have been less than for
people more severely affected by their disease
a Change (reduction) from baseline; a reduction shows that HRQoL improved.
b Change (reduction) from baseline; a reduction shows that disease severity improved.
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Quality criteria (Cochrane ‘risk of bias’ tool) randomised
controlled trials
Criteria
Judgement of
risk of biasa Support for judgement
Random sequence generation
(selection bias)
Low risk ‘Randomisation was performed by the flip of a coin by a colleague
independent of the study’ (p. 740)
Allocation concealment
(selection bias)
Unclear risk Randomisation of clusters performed independently of the study
team, but unclear how allocation of clusters to intervention or control
group was concealed from participants
Blinding of participants and
personnel (performance bias)
Unclear risk No information about blinding provided
Blinding of outcome assessment
(detection bias)
Unclear risk No information about blinding or who conducted the PASI
assessment provided
Incomplete outcome data
(attrition bias)
Low risk Missing outcome data balanced in numbers across intervention and
control groups, with similar reasons for missing data across groups
Selective reporting (reporting
bias)
Low risk All outcomes specified in the methods section of the paper were
reported. Paper does not report if a protocol is available
Other bias Unclear risk A statistically significant higher proportion of participants in the
intervention than control group were women; unclear whether this
might bias outcomes
a High risk, unclear risk, low risk.
Reference and
design Intervention Participants Outcome measures
Author and year:
Matsuoka et al.,
200688
Study ID: 543
Country/location:
Kagawa, Japan
Setting: Outpatient
clinic
Trial design: RCT
Includes process
evaluation: no
Number of study
centres: 1
Funding: not reported,
but sample cosmetics
prescriptions provided
by a pharmaceutical
company
Conflicts of interest:
stated no relevant
financial interests
Treatment intervention
Overview: women with acne
vulgaris were instructed on
skin care and how to use
make-up by a dermatologist.
The women also received
acne treatment (topical
therapy and/or oral
medication)
Intervention aim(s): not
explicitly stated, but part of
the aim of the study was to
examine if instructions in
make-up use from a
dermatologist could affect
female acne patients’ QoL
Where delivered: outpatient
clinic based in a university
dermatology department
Self-help, individual- and/or
group-based? (State group
size): not reported
Mode: face to face, with
supporting videotape
instructions and detailed
leaflets/prescriptions
Skin condition: acne vulgaris
Diagnostic criteria: not
reported
Specify if patients, parents
and/or carers: patients
Patient general age group
(specify if children, young
adults and/or adults): adults
(age > 16 years)
Stated target group: women
How recruited: not reported
Eligibility criteria: pregnant or
lactating women were
excluded
Numbers involved
(randomised/allocated):
Total: 50
Intervention (intervention): 25
Control (control): 25
Primary outcomes: outcomes
not specified as either primary
or secondary
Outcomes measured: acne
severity (Plewig and Kligman’s
grade method)
HRQoL (WHOQOL-26 and
DLQI)
Secondary outcomes:
see above
Adverse events:
dermatologists evaluated
safety in both groups
Process evaluation measures:
not applicable
Individual preferred learning
style addressed? No
How outcomes assessed?
WHOQOL-26 and DLQI both
self-report
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Reference and
design Intervention Participants Outcome measures
Trial/study number:
not reported
Study dates: April 2004–
November 2005
Was the educational
intervention an
adjunct to standard
medical care? Yes
Materials: videotaped
instructions; leaflets and
make-up prescriptions with
more detailed instructions;
sample cosmetics provided
Provider: dermatologist
Duration and intensity: not
reported
Scripting (level of detail
guiding interaction between
interventionist and
participants): not reported
Sensitivity to participant
characteristics: not reported
Interventionist characteristics
and training: not reported
Content and topics:
summary – patients received
instructions on use of skin
care and make-up products.
Instructions included general
skin care and how to use
‘point make-up’ (e.g. eyeliner
and lipstick)
Tailoring: not reported
Ongoing support: not
reported
Theory: not reported
Control intervention
Description: acne treatment
(topical and/or oral
medication), with no specific
instructions from a
dermatologist. Patients were
told to use cosmetics in the
same way they usually do
Duration and intensity: not
reported
Numbers (%) completing,
attrition and reasons:
Attrition: none
Reasons: not applicable
Completers: 50 (100%)
[intervention 25 (100%);
control 25 (100%)]
Sample cross-overs: not
reported
Baseline characteristics
Comorbidities:
Complications (%):
Intervention: yes/no: 28/72
Control: yes/no: 24/76
Comedications/interventions:
not reported. Study is
Japanese; assumed
predominantly Japanese
patients
Duration of disease:
intervention 7 (SD 4) years;
control 4 (SD 4) years
Disease severity: data
provided on number and
proportion of patients in each
of eight different severity
categories for both right and
left side of face; not data
extracted
Sex (M/F) (n): 0/50
Average age: intervention
24 years (SD 3 years) years;
control 25 years (SD 5 years)
Ethnic groups: not reported
Socioeconomic characteristics:
not reported
Dermatologist rated disease
severity using the Plewig and
Kligman’s grade method
although reference provided
Normal range(s) for outcomes/
clinically meaningful
improvement defined:
WHOQOL-26: Authors cite a
normative total mean score
of 3.33 (SD 0.49) in healthy
Japanese women aged 20–29
(based on Nakane et al., 1999)
Validated? Yes
(for WHOQOL-26 and DLQI)
Unclear for Plewig and
Kligman’s grade method
Timing of outcomes same for
both groups: yes
Length of follow-up: 4 weeks
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Methods
Statistical analysis, including how missing data dealt with: authors detail statistical tests used to analyse HRQoL data.
Alpha level was not adjusted for multiple comparisons. A p-value of < 0.05 was considered to be statistically significant
Power calculation: not reported
Study adequately powered? Unclear
ITT used? Yes – not explicitly stated, but all randomised patients were included in the analyses
Groups comparable at baseline? Yes – no statistically significant differences between groups on age, duration of disease,
complications, severity of disease, HRQoL or medication use (although data not reported)
Subgroups analyses: none reported
Process evaluation methods (if relevant): no process evaluation
Outcome evaluation results
HRQoL outcomes
Cosmetic instructions
(n= 25)
No instructions control
(n= 25) p-value/CI
WHOQOL-26, mean (SD)
Physical domain
Baseline 3.23 (0.62) 3.45 (0.55) Not reported
4 weeks after 3.35 (0.46) 3.54 (0.45) Not reported
Psychological domain
Baseline 3.09 (0.69) 3.21 (0.62) Not reported
4 weeks after 3.26 (0.59)* 3.29 (0.60) Not reported
Social relationships
Baseline 3.65 (0.55) 3.68 (0.50) Not reported
4 weeks after 3.65 (0.49) 3.64 (0.61) Not reported
Environment domain
Baseline 3.35 (0.53) 3.42 (0.49) Not reported
4 weeks after 3.42 (0.51) 3.45 (0.49) Not reported
Overall QoL
Baseline 3.04 (0.88) 2.78 (0.76) NS
4 weeks after 3.38 (0.77)** 3.18 (0.72)** NS
Total mean score
Baseline 3.27 (0.54) 3.36 (0.44) Not reported
4 weeks after 3.39 (0.45) 3.44 (0.46) Not reported
DLQI, mean (SD)
Symptoms, feelings
Baseline 3.16 (1.49) 2.60 (1.58) NS
4 weeks after 1.52 (1.08)*** 1.52 (1.16)*** NS
Daily activities
Baseline 1.76 (1.81) 1.20 (1.73) NS
4 weeks after 0.56 (0.77)** 0.64 (1.25)** NS
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Outcome evaluation results
HRQoL outcomes
Cosmetic instructions
(n= 25)
No instructions control
(n= 25) p-value/CI
Leisure
Baseline 1.20 (0.96) 1.12 (1.48) NS
4 weeks after 0.72 (0.84)* 0.52 (1.08)** NS
Work/school
Baseline 0.68 (0.69) 0.48 (0.67) NS
4 weeks after 0.48 (0.51) 0.20 (0.65)** Statistically significant
difference
Personal relationships
Baseline 0.68 (0.90) 0.48 (1.19) NS
4 weeks after 0.24 (0.44)** 0.16 (0.55)* NS
Discomfort of treatment
Baseline 0.76 (0.83) 0.40 (0.65) NS
4 weeks after 0.36 (0.49)** 0.20 (0.50) NS
Total mean score
Baseline 8.24 (5.06) 6.24 (6.06) NS
4 weeks after 3.88 (2.79)*** 3.24 (4.36)*** NS
Comments: p-values only reported for within-group changes from baseline. WHOQOL-26 analyses: no between-group
p-values reported, except that it is stated that the QOL score was not statistically significant between groups either before
or after the intervention. DLQI analyses: statistically significant differences between-groups reported narratively only;
p-values not provided
Statistically significant within-group changes: *p< 0.05, **p< 0.01, ***p< 0.001
Interpretation of WHOQOL-26 score: a lower score indicates more disability. Interpretation of DLQI: a higher score indicates
more disability
Other relevant outcomes
Cosmetic instructions
(n= 25)
No instructions control
(n= 25) p-value (CI)
Degree of improvement in acne severity on right side of face at 4 weeks, n (%)
Markedly improved 5 (20) 8 (32) 0.62
Improved 10 (40) 8 (32)
Unchanged 10 (40) 9 (36)
Exacerbated 0 (0) 0 (0)
Degree of improvement in acne severity on left side of face at 4 weeks, n (%)
Markedly improved 9 (36) 7 (28) 0.83
Improved 8 (32) 9 (36)
Unchanged 8 (32) 9 (36)
Exacerbated 0 (0) 0 (0)
Comments:
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Adverse events
Cosmetic instructions
(n= 25)
No instructions control
(n= 25) p-value/CI
Reported side effects of cosmetic
and conventional medicine use
None None
Comments:
Subgroup analysis results:
Comments: no subgroups reported
Outcome Cosmetic instructions No instructions control p-value/CI
None
Comments:
Process evaluation results
No process evaluation
Comments:
General comments
Generalisability: small-scale study conducted in one study centre in Japan examining the impact of instructions in
make-up and cosmetic use in women, so results are likely to be of limited generalisability
Other: none
NS, not statistically significant.
Quality criteria (Cochrane ‘risk of bias’ tool) randomised
controlled trials
Criteria
Judgement of
risk of biasa Support for judgement
Random sequence generation
(selection bias)
Unclear risk No details provided
Allocation concealment
(selection bias)
Unclear risk No details provided
Blinding of participants and
personnel (performance bias)
Unclear risk No details provided
Blinding of outcome assessment
(detection bias)
Unclear risk No details provided
Incomplete outcome data
(attrition bias)
Low risk All randomised patients were included in the analyses
Selective reporting (reporting bias) Unclear risk All outcomes specified in the methods section of the
paper are reported in the results, but p-values for
between-group differences are only reported for one
domain of the WHOQOL-26 measure
Other bias Low risk
a High risk, unclear risk, low risk.
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Reference and
design Intervention Participants Outcome measures
First author and Year:
Santer et al., 201474
Study ID: 42 (update
searches)
Country/location: UK
(South West England)
Setting: participants
recruited from primary
care and intervention
delivered online
Trial design: RCT
(pilot)
Includes process
evaluation: yes
(includes measures
that could be
regarded as a process
evaluation; not
described as a process
evaluation by authors)
Number of study
centres: recruitment
from 31 general
practices, but one
centre for evaluation
Funding: National
Institute for Health
research (NIHR)
Research for Patient
Benefit programme
(ref. number
PB-PG-0110–20243)
Conflicts of interest:
none declared
Trial/study number:
ISRCTN 98560867
Study dates: not
reported
Was the educational
intervention an
adjunct to standard
medical care? Yes
Treatment intervention 1:
website only+usual care
Overview: online intervention
delivered through the SPaCE
website (see ‘usual care alone’
description below for what usual
care consisted of)
Intervention aim(s): aimed to
improve carers’ management
of their child’s eczema by
increasing regular use of
emollients. Ultimate aim of
intervention was to improve
HRQoL through enhancing
carers’ management of the
condition
Where delivered: internet
(website)
Self-help, individual- and/or
group-based? (State group size):
individual-based
Mode: online intervention
Materials: delivered through a
website. Some modules on the
website contained videos
(e.g. demonstrating techniques
for emollient application)
and print sheets of information.
Both of these could also be
accessed from a menu bar at
the bottom of the website.
2-week challenge involved SMS
text alerts
Provider: medical experts
developed the website; website
delivered through LifeGuide
software. HCPs (practice nurses,
a health-care assistant and a GP)
provided support to participants
in one group
Duration and intensity: two
20-minute compulsory modules,
and then participants could
complete other modules of their
choice from a selection of 14,
watch videos, download print
sheets and take part in a 2-week
challenge (see below) involving
SMS alerts
Scripting (level of detail guiding
interaction between
interventionist and participants):
delivery of website intervention
the same for all participants,
except that participants could
choose optional modules after
completing the compulsory ones
Skin condition: eczema
Diagnostic criteria: GP
diagnosis of eczema
Specify if patients, parents
and/or carers: parents/carers
and patients
Patient general age group
(specify if children, young
adults and/or adults):
children (aged ≤ 5 years)
Stated target group: carers
of children aged ≤ 5 years
with mild to moderate
eczema
How recruited: primary care
(31 general practices)
Eligibility criteria
Inclusion criteria: Parent/
carer of child aged ≤ 5 years
with GP diagnosis of eczema
and who had received a
prescription for eczema in
past year
Exclusion criteria: child aged
older than 5 years, severe
mental distress, experienced
recent bereavement,
unwillingness to be involved
in research, parent could not
give informed consent,
English language skills not
advanced enough to use
website or complete study
measures
Numbers involved
(randomised/allocated):
Total: 148 (with useable
data; 1 additional participant
was randomised but
technical difficulties meant
no useable baseline data,
no details about which
condition they were
randomised to)
Intervention 1
(intervention 1 – website): 46
Intervention 2
(intervention 2 – website+
HCP): 51
Control (control – usual care):
51
Primary outcomes: disease
severity (POEM; measures
eczema symptoms over past
week)
Secondary outcomes: HRQoL
(DFI, measures impact on
family’s QoL)
Other outcomes (not
specified if primary or
secondary): HRQoL (IDQoL,
measures HRQoL in children
aged ≤ 4 years; CDLQI,
measures HRQoL in children
aged ≥ 5 years)
Adherence (self-report
measure of emollient use)
Adherence to intervention
(PETS)
Attitudes (measure not
stated)
Participants’ perceptions
about if they understand
and can manage treatment
better (Patient Enablement
Instrument)
Adverse events: not reported
Process evaluation measures:
interviews with/feedback
from participants and HCP
(see Methods below)
Intervention use (amount
of time website used;
completion of core modules;
website visits; video use, took
part in 2-week challenge SMS
text alerts; uptake of HCP
appointment)
Individual preferred learning
style addressed? No
How outcomes assessed?
POEM, use emollients
(adherence) and Patient
Enablement Instrument:
self-reported, completed by
carers online. No details in
publication about who
completed the DFI, IDQoL,
CDLQI, PETS and attitudes
measure
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Reference and
design Intervention Participants Outcome measures
Sensitivity to participant
characteristics: not reported
Interventionist characteristics and
training: HCPs received minimal
training (one hour to familiarise
themselves with the website)
Content and topics: first stage of
intervention: participants
completed two compulsory
modules: ‘What is eczema?’ and
‘Emollient moisturisers’. Then 14
other modules were available to
complete, which covered
‘common concerns of carers of
children with eczema’ (p. 3)
including: diet and allergy;
topical steroids, talking to your
GP, starting school, sleep
problems, bath time, washing
clothes, eczema in the winter,
eczema in the summer,
swimming, going on holiday,
avoiding stress for parents,
involving your child in treatment,
managing scratching (extracted
from screenshot of SPaCE
website in publication).
Participants could access videos
and print sheets on website,
covering, for example, use of
emollients, how to bath their
child, action plan to use during
GP consultation, and details on
how to manage eczema to pass
to relatives, school or nursery.
Intervention strategies used are
detailed in table 1 of the
publication, but not data
extracted. Participants could take
part in a 2-week challenge
involving SMS text alerts for
setting goals, monitoring and
rehearsing behaviours
Tailoring: intervention was partly
tailored – after completing the
two compulsory modules,
participants could choose to
complete other optional modules
that they were interested in
(from a menu of 14 modules)
Ongoing support: not reported
(assume none)
Numbers (%) completing,
attrition and reasons:
Attrition: 5 (3%) [website: 2
(4%); website+HCP: 1 (2%);
usual care: 2 (4%)]. (Ns and
%s calculated by reviewer)
Reasons: not reported (but
states that these participants
did not complete primary
outcome measures)
Completers: 143 (97%)
[website: 44 (96%);
website+HCP: 50 (98%);
usual care: 49 (96%)] (Total
N and all % calculated by
reviewer)
Sample cross-overs: not
reported
Baseline characteristics
Comorbidities: not reported
Comedications/interventions:
not reported
Duration of disease: not
reported
Disease severity: see ‘results’
below for continuous POEM
score at baseline
Sex (M/F) of carer, n (%):
Website: 2 (4)/44 (96)
Website+HCP: 1 (2)/50 (98)
Usual care: 1 (2)/50 (98)
Average age: age of carer:
detailed information
provided across six
categories for each of the
three groups; not data
extracted. The majority of
participants (72–84%) across
each arm were aged
between 26 and 40
Age of child: detailed
Normal range(s) for
outcomes/clinically
meaningful improvement
defined: yes, for POEM:
authors state change in
score of ≥ 2 in primary care
is clinically significant.
Authors also provide score
classifications: 0–2= clear/
almost clear, 3–7=mild,
8–16=moderate,
17–24= severe,
25–28= very severe
Validated? POEM, DFI,
IDQoL and CDLQI: yes,
authors provide evidence of
validation/state measures are
validated
PETS and Patient
Enablement Instrument: yes,
wider literature confirms
these are validated measures
No details provided in
publication about if the
measures of self-reported
emollient use and attitudes
were validated
Timing of outcomes same
for both groups: yes
Length of follow-up:
3 months (from baseline)
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Reference and
design Intervention Participants Outcome measures
Theory: theory-based: used
PRECEDE–PROCEED model to
develop the intervention. The
intervention incorporated 20
of the 26 behaviour-change
techniques listed in Abraham and
Michie’s taxonomy of behaviour-
change techniques.83 Full list of
exact intervention techniques used
is provided in table 1 of the
publication, but not data
extracted. The development of the
modules about ‘common concerns
of carers of children with eczema’
(p. 3) were informed by qualitative
interviews and input from patient
support groups. Intervention also
informed by ‘evidence-based
patient information leaflets’ (p. 1),
think-aloud interviews with users
of a draft version of the website
and feedback from other parents
and HCPs
Treatment intervention 2:
website+plus HCP
support+usual care
Website intervention: same as
above
HCP support: one-off 20-minute
appointment with HCP to
promote engagement with the
website intervention and to go
through the 2 compulsory
modules and 2-week challenge
with participants if they had not
already completed them/if
participants had completed
them, HCP helped them choose
other modules to work through
together. HCP varied across the
general practices taking part:
practice nurse in 11 practices,
health-care assistant in 1 practice
and GP in 1 practice. HCPs were
not dermatology trained, except
for one. All spent one hour
familiarising themselves with the
website (see ‘usual care alone’
description below for what usual
care consisted of)
Control intervention: usual
care alone
Description: usual care alone –
participants consulted with GPs
or attended secondary care
dermatology appointments as
needed. Most participants were
being managed in primary care
Duration and intensity: N/A
information provided across
six categories for each of the
three groups; not data
extracted
Ethnic groups: not reported
Socioeconomic characteristics:
age carer left education:
detailed information provided
across four categories for
each of the three groups; not
data extracted. Across study
arms, between 12–16% left
school between the ages of
15 and 16
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Methods
Statistical analysis, including how missing data dealt with: methods of statistical analysis reported
Power calculation: none reported, but study was intended to be a pilot RCT
Study adequately powered? Unclear
ITT used? States yes – but no details provided about how missing data were imputed. States that ‘follow-up questions not
asked by phone received response rates below 60%; therefore they will not be presented here’ (p. 5); it is unclear to which
questions this relates. Also, Ns reported for outcomes are not the ITT population
Groups comparable at baseline? No comment provided on this by authors. Reviewer notes that POEM baseline scores
were slightly higher in the website and website+HCP groups than the usual care group
Subgroups analyses: subgroup analysis conducted of participants with a higher baseline eczema severity score (≥ 5),
but not clear if pre-specified or post-hoc, so results are not data extracted below
Process evaluation methods (if relevant): interviews with HCPs, covering their experiences of the study and details
about the appointments they had with carers (e.g. use of the website during the appointment, any difficulties, perceived
usefulness of the appointments with carers). Feedback interviews with 26 carers (plus e-mail feedback from one carer).
Qualitative data were analysed thematically. Quantitative data: see ‘Process evaluation methods’ above for details about
quantitative measures used
Outcome evaluation results
HRQoL outcomes
Website
(n= 44)
Website+HCP
(n= 50)
Usual care alone
(n= 49) p-value/CI
DFI score, mean (SD)
Baseline 5.3 (5.3) 6.4 (5.6) 5.2 (5.9) Not reported
3 months 4.0 (4.2) 5.9 (5.3) 4.4 (5.5) Not reported
Comments: DFI total score can range from 0–30, with a higher score showing worse HRQoL. Authors suggest that because
baseline scores were low, follow-up scores represent floor effects. Results for IDQoL and CDLQI measures not reported
Other relevant outcomes
Website
(n= 44)
Website+HCP
(n= 50)
Usual care alone
(n= 49) p-value/CI
POEM score (disease severity), mean (SD)
Baseline 10.3 (7.0) 9.4 (6.2) 7.47 (6.2) Not reported
3 months 7.6 (6.1) 8.7 (7.0) 7.1 (6.6) Not reported
Clinically significant change in POEM
score between baseline and 3 months,
n/N (%)
23/42 (55) 18/47 (38) 16/49 (33) p-value= 0.09
Comments: POEM score can range from 0–28, with a higher score representing more severe disease. Clinically significant
change in POEM score in a primary care context is a change of ≥ 2. Mean change in POEM score between baseline and
3 months and associated mean difference and 95% CIs also reported for the website groups combined and compared
with usual care, but not data extracted
Adverse events Intervention Control p-value/CI
Not reported
Subgroup analysis results:
Comments: no subgroups reported
Outcome Intervention Control p-value/CI
No pre-specified analyses reported
DOI: 10.3310/hta19860 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 86
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Pickett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
127
Process evaluation results
Quantitative data
Parents/carers
Intervention use, measured by time spent on website (minutes), median (IQR):
Website only: 34 (20–50)
Website+HCP: 45 (26–70)
Completion of core modules, n/N (%):
Website only: 38/44 (86)
Website+HCP: 37/49 (76)
Three or more website visits, n/N (%):
Website only: 16/44 (36)
Website+HCP: 29/49 (59)
Watched ≥ one video, n/N (%):
Website only: 16/44 (36)
Website+HCP: 17/49 (35)
Took part in 2-week challenge SMS text alerts, n/N (%):
Website only: 18/44 (41)
Website+HCP: 18/49 (37)
Notes: not the ITT populations. Results also reported for website groups combined, but not data extracted
Authors report that there were no differences between web and web+HCP group in any aspect of intervention use
(does not appear to have been statistically tested)
Uptake of HCP appointment (in web+HCP group), n/N (%): 23/50 (46). Reasons for non-uptake, n: 12 declined
appointment; 9 could not be contacted; 6 did not attend
Qualitative data
HCP
Feedback from interviews: feedback included being pleased to provide a self-care support role, but apprehensions because
they did not view themselves as eczema specialists. There were some concerns that they had received only minimal training
for the role. On the whole, reported that the consultations were useful and worked well. Perceived that some carers found
the intervention more useful than others and that some did not need the support of the HCP
Carers
Feedback on website: most feedback that the website was useful and easy to use. Only five of the 26 participants
interviewed reported that they did not find it useful (reasons: had previously more need for such support than now, and
child’s eczema was mild)
Feedback on HCP support: variation in the perceived value of this. Reasons for perceiving it as not useful: did not feel they
needed help in looking after their child’s eczema and confidence in ability to source information from the internet. Reasons
for finding it useful: helped them engage more with the website, increased confidence for consulting with HCPs in the
future, used it as an opportunity to discuss other health problems, had opportunity to obtain emollient samples (not part of
the intervention) and felt more comfortable consulting with HCP than using website
Comments:
General comments
Generalisability: good generalisability to patients managed in primary care the UK, as participants were recruited from
31 general and authors ensured that participants were recruited from a range of socioeconomic areas
Other: authors do not provide details about any inter-centre variability in the HCP support component of the intervention
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Quality criteria (Cochrane ‘risk of bias’ tool) randomised
controlled trials
Criteria
Judgement of
risk of biasa Support for judgement
Random sequence generation
(selection bias)
Low risk Computer randomisation carried out via LifeGuide software,
allocating 1 : 1 : 1
Allocation concealment
(selection bias)
Low risk Central (web-based) allocation used
Blinding of participants and
personnel (performance bias)
Unclear risk No details provided
Blinding of outcome assessment
(detection bias)
Unclear risk No details provided
Incomplete outcome data
(attrition bias)
Unclear risk States ITT analysis used, but Ns reported for outcomes are not the
ITT population. Attrition rates are small and similar across groups,
but reasons for attrition are unclear. Additionally, one participant
was randomised, but due to technical difficulties did not provide
useable baseline data and thus was not included in the analysis, and
it is unclear which group they were randomised to and whether they
took part in the intervention
Selective reporting
(reporting bias)
High risk Results for IDQoL and CDLQI measures of HRQoL not reported.
Results are also not reported for a number of other measures used
(specifically: self-report measure of emollient use; PETS, attitudes
measure, Patient Enablement Instrument)
Other bias Unclear risk Baseline imbalances in disease severity across groups, with both
website groups having slightly more severe disease at baseline.
Unclear if this is accounted for in the results. Also reports statistical
analyses inconsistently (e.g. combined website groups versus usual
care, not individual website groups versus usual care for mean
change in the POEM score, which has therefore not been data
extracted)
a High risk, unclear risk, low risk.
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Reference and
design Intervention Participants Outcome measures
First author and Year:
Staab et al., 200687
Study ID: 575
Country/location:
Germany
Setting: not reported
Trial design: RCT
Includes process
evaluation: no
Number of study
centres: seven
hospitals
Funding: German
Federal Ministry of
Health and Social
Services (grant
Number 01GL0010)
Conflicts of interest:
none
Trial/study number:
not reported
Study dates: not
reported
Was the educational
intervention an
adjunct to standard
medical care? Unclear –
treatment with topical
therapy or special
diets was not included
in the intervention
and remained the
responsibility of
the patients’ doctor
Treatment intervention
Overview: group-based
educational programme,
with different educational
sessions for a) parents of
children aged 3 months to
7 years, b) children aged
8–12 years and their parents
and c) adolescents with
atopic dermatitis aged
13–18 years (parents
optional for selected
sessions)
Intervention aim(s): not
reported in primary
publication, but the
intervention for children
aged 3 months to 7 years
was based on one reported
in Staab et al.93 and
Wenninger et al.,78 the aim
of which was improve
parents’ ability to manage
their child’s disease and thus
improve disease course and
the family’s HRQoL
Where delivered: not
reported
Self-help, individual- and/or
group-based? (State group
size): group-based
(5–8 participants)
Mode: face-to-face group
sessions
Materials: handouts for
participants with summary
points and timetable for the
sessions
Provider: multiprofessional
team of dermatologists or
paediatricians, psychologists
or dieticians
Duration and intensity:
six weekly 2-hour sessions
Scripting (level of detail
guiding interaction between
interventionist and
participants): a manual
specified content
Sensitivity to participant
characteristics: Different
groups for parents and
children of different age
groups
Skin condition: atopic dermatitis
Diagnostic criteria: diagnosis of
atopic dermatitis was made by
dermatologists or paediatricians
Specify if patients, parents
and/or carers:
Patients and parents
Patient general age group
(specify if children, young adults
and/or adults):
Children and adolescents
Stated target group: parents of
children aged 3 months to
7 years or 8–12 years, children
aged 8–12 years and adolescents
aged 13–18 years (parents of
adolescents optional for selected
sessions) with moderate to
severe atopic dermatitis
How recruited: recruited
consecutively from three
children’s hospitals, three
specialist dermatology hospitals
and one department of
psychosomatic medicine
Eligibility criteria:
Inclusion criteria: atopic
dermatitis diagnosis based on
criteria of Hanifin and Rajka;
eczema for ≥ 3 months; eczema
severity of ≥ 20 points on the
atopic dermatitis scale. Exclusion
criteria: presence of any other
physical or psychiatric conditions
that require treatment
Numbers involved
(randomised/allocated):
Total: 992
Intervention: 496
Control: 496
Numbers (%) completing,
attrition and reasons:
Attrition: 169 (17%)
[intervention 50 (10%); control
119 (24%)]
Reasons (n):
Died: intervention 0; control 1
Primary outcomes: eczema
severity (SCORAD index)
Parents’ QoL – parents of
children aged ≤ 13 years
(German questionnaire:
‘Quality of life in parents
of children with atopic
dermatitis’)
Secondary outcomes:
subjective severity score
(‘skin detective’)
Itching behaviour (JUCKKI
for 8–12 year olds and
JUCKKU for 13- to
18-year-olds)
Adverse events: not reported
Process evaluation measures:
not applicable
Individual preferred learning
style addressed? No
How outcomes assessed?
The SCORAD was scored by
study investigators
Normal range(s) for
outcomes/clinically
meaningful improvement
defined: no
Validated? Yes – all
validated
Timing of outcomes same
for both groups: yes
Length of follow-up:
12 months
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Reference and
design Intervention Participants Outcome measures
Interventionist characteristics
and training: all professionals
had undergone a 40-hour
training programme to
qualify as trainers
Content and topics:
summary – intervention for
parents of 3-month to
7-year-olds was based on the
one reported in Staab et al.93
and Wenninger et al.78 Across
the three groups, the
educational sessions covered
the following issues: medical
(information about atopic
dermatitis, understanding
triggers, skin care, symptom
treatment, unconventional
therapies), nutritional
(general child nutrition,
food allergies, types of diet)
and psychological (relaxation
techniques, managing
scratching and itching, sleep,
coping, self-management
plan, difficulties encountered
in transferring skills to
participants’ lives).
Participants were encouraged
to share experiences and to
put new skills into practice
Tailoring: not reported
Ongoing support: not
reported
Theory: social cognitive
theory – see Staab 801 and
Wenniger 2863 data
extraction
Control intervention
Description: no education
control
Duration and intensity:
not reported
Lost interest: intervention 7;
control 45
No sufficient response:
intervention 34; control 51
Other reasons: intervention 9;
control 22
Discontinued intervention:
intervention 0; control 0
Completers (n): 823
(intervention 446; control 377)
Sample cross-overs: none
Baseline characteristics
Comorbidities: not reported
Comedications/interventions:
not reported
Duration of disease: not
reported
Disease severity: (see baseline
values in results)
Sex (M/F), %:
3 months to 7 years age group:
intervention 52/48; control
52/48
8–12 years age group:
intervention 40/60; control
48/52
13–18 years age group:
intervention 41/59; control
36/64
Mean age (SD), years:
3 months to 7 years age group:
intervention 2.4 (1.8); control
2.4 (1.9)
8–12 years age group:
intervention 9.5 (1.6); 9.5 (1.5)
13–18 years age group:
intervention 14.9 (1.7);
14.8 (1.7)
Ethnic groups: not reported
Socioeconomic characteristics:
not reported
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Methods
Statistical analysis, including how missing data dealt with: authors report how data were statistically analysed.
Covariance analysis used for patient reported outcomes, but not stated what the covariates were (i.e. whether adjusted for
some or all baseline variables)
Power calculation: yes – power calculation was based on the eczema severity outcome (atopic dermatitis total score)
(the primary outcome). Based on an anticipated effect size was d= 0.40 with an alpha level of 0.05 and assuming a 20%
loss to follow-up, it was estimated that 125 participants would be needed per group to provide a power of 80%
Study adequately powered? Adequately powered for the 3 months to 7 years age group; may not be adequately
powered for the 8–12 years and 13–18 years age groups (sample sizes smaller than the 125 participants needed per group)
ITT used? Number Only completers included in analysis
Groups comparable at baseline? Yes – no statistically significant differences in eczema severity or any other outcome
measures at baseline. Mean age and sex similar between groups
Subgroups analyses: none, but data were analysed separately for the 3 months to 7 years, 8–12 years and 13–18 years
age groups. So essentially all were subgroups
Process evaluation methods (if relevant): no process evaluation
Outcome evaluation results
HRQoL outcomes: 3 months to
7 years age group
Educational
programme
(n= 274)
No education
(n= 244)
Difference (95% CI; p-value)
in change between baseline
and 12 months between
groups
Parental QoL
Psychosomatic well-being
Baseline, mean (SD) 29.3 (7.6) 29.1 (7.7)
12 months, mean (SD) 33.7 (7.0) 32.1 (7.1)
Mean difference/change in score
(95% CI)
4.4 (3.6 to 5.2) 3.1 (2.2 to 3.9) 1.4 (0.2 to 2.5; 0.0040)
Effects on social life
Baseline, mean (SD) 24.9 (4.0) 24.5 (4.4)
12 months, mean (SD) 26.7 (3.4) 25.5 (4.1)
Mean difference/change in score
(95% CI)
1.8 (1.4 to 2.3) 1.0 (0.6 to 1.5) 0.8 (0.2 to 1.4; < 0.0001)
Confidence in medical treatment
Baseline, mean (SD) 16.0 (4.0) 15.8 (4.4)
12 months, mean (SD) 20.0 (3.5) 17.8 (4.2)
Mean difference/change in score
(95% CI)
4.0 (3.5 to 4.5) 1.9 (1.4 to 2.4) 2.1 (1.4 to 2.8; < 0.0001)
Emotional coping
Baseline, mean (SD) 13.7 (3.2) 14.2 (3.4)
12 months, mean (SD) 16.8 (2.9) 15.4 (3.2)
Mean difference/change in score
(95% CI)
3.1 (2.7 to 3.5) 1.1 (0.7 to 1.6) 1.9 (1.3 to 2.5; < 0.0001)
Acceptance of disease
Baseline, mean (SD) 7.1 (1.9) 7.0 (1.9)
12 months, mean (SD) 8.2 (1.7) 7.5 (1.8)
Mean difference/change in score
(95% CI)
1.1 (0.8 to 1.3) 0.5 (0.3 to 0.8) 0.6 (0.2 to 0.9; < 0.0001)
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HRQoL outcomes – 8 – 12 years
age group
Educational
programme
(n= 102)
No education
(n= 83)
Difference (95% CI, p-value)
in change between baseline
and 12 months between
groups
Parental QoL
Psychosomatic well-being
Baseline, mean (SD) 31.5 (7.9) 31.2 (6.1)
12 months, mean (SD) 34.7 (6.0) 33.8 (7.0)
Mean difference/change in score
(95% CI)
3.2 (1.9 to 4.5) 2.6 (1.4 to 3.8) 0.6 (–1.2 to 2.4; 0.360)
Effects on social life
Baseline, mean (SD) 25.8 (4.2) 26.3 (4.0)
12 months, mean (SD) 27.0 (3.8) 27.2 (3.5)
Mean difference/change in score
(95% CI)
1.1 (0.4 to 1.8) 0.9 (0.2 to 1.6) 0.2 (–0.8 to 1.2; 0.940)
Confidence in medical treatment
Baseline, mean (SD) 17.0 (4.0) 17.4 (3.9)
12 months, mean (SD) 20.1 (3.2) 17.5 (4.4)
Mean difference/change in score
(95% CI)
3.1 (2.2 to 3.9) 0.1 (–0.7 to 1.0) 2.9 (1.7 to 4.1; < 0.0001)
Emotional coping
Baseline, mean (SD) 13.7 (3.3) 14.7 (3.2)
12 months, mean (SD) 16.4 (2.8) 15.6 (3.4)
Mean difference/change in score
(95% CI)
2.7 (2.0 to 3.4) 0.9 (0.2 to 1.6) 1.8 (0.9 to 2.8; 0.002)
Acceptance of disease
Baseline, mean (SD) 7.3 (1.9) 7.4 (1.7)
12 months, mean (SD) 8.1 (1.5) 7.7 (1.8)
Mean difference/change in score
(95% CI)
0.8 (0.4 to 1.2) 0.2 (–0.2 to 0.6) 0.6 (0 to 1.2; 0.031)
Comments: outcome data also collected at 6 months, but not reported in the paper
26 item questionnaire with five subscales as demonstrated above. No details of scoring provided, reference provided for
validation is in German
Other relevant outcomes –
3 months to 7 years age group
Educational
programme
(n= 274)
No education
(n= 244)
Difference (95% CI; p-value)
in change between baseline
and 12 months between
groups
SCORAD: total severity score
Baseline, mean (SD) 41.1 (16.6) 40.6 (15.2)
12 months, mean (SD) 23.7 (16.7) 28.4 (16.5)
Mean difference/change in score
(95% CI)
–17.5 (–19.6 to –15.3) –12.2 (–14.3 to –10.1) –5.2 (–8.2 to –2.2; 0.0002)
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Other relevant outcomes –
3 months to 7 years age group
Educational
programme
(n= 274)
No education
(n= 244)
Difference (95% CI; p-value)
in change between baseline
and 12 months between
groups
SCORAD: objective severity score
Baseline, mean (SD) 32.5 (14.3) 31.4 (13.0)
12 months, mean (SD) 19.5 (13.9) 22.6 (13.4)
Mean difference/change in score
(95% CI)
–13.0 (–14.8 to –11.2) –8.7 (–10.5 to –7.0) –4.2 (–6.8 to –1.7; 0.0009)
Subjective severity
Baseline, mean (SD) 8.3 (3.8) 8.3 (3.8)
12 months, mean (SD) 4.8 (3.4) 6.1 (3.6)
Mean difference/change in score
(95% CI)
–3.3 (–3.9 to –2.8) –2.2 (–2.7 to –1.6) –1.1 (–1.9 to –0.3; < 0.001)
Other relevant outcomes:
8- to 12-years age group
Educational
programme
(n= 102)
No education
(n= 83)
Difference (95% CI, p-value)
in change between baseline
and 12 months between
groups
SCORAD: total severity score
Baseline, mean (SD) 41.8 (16.6) 40.4 (15.1)
12 months, mean (SD) 25.8 (17.7) 32.6 (16.5)
Mean difference/change in score
(95% CI)
–16.0 (–20.0 to –12.0) –7.8 (–11.4 to –4.3) –8.2 (–13.6 to –2.8; 0.003)
SCORAD: objective severity score
Baseline, mean (SD) 34.0 (14.1) 32.5 (13.1)
12 months, mean (SD) 21.7 (15.1) 26.9 (14.2)
Mean difference/change in score
(95% CI)
–12.3 (–15.6 to –8.9) –5.6 (–8.7 to –2.5) –6.7 (–11.2 to –2.1; 0.005)
Subjective severity
Baseline, mean (SD) 8.5 (3.9) 8.6 (3.5)
12 months, mean (SD) 4.9 (2.9) 7.0 (3.8)
Mean difference/change in score
(95% CI)
–3.7 (–4.6 to –2.7) –1.6 (–2.5 to –0.7) –2.1 (–3.4 to –0.8; < 0.001)
Itching behaviour: catastrophisisationa
Baseline, mean (SD) 13.6 (8.5) 13.6 (8.2)
12 months, mean (SD) 6.6 (6.5) 11.8 (8.6)
Mean difference/change in score
(95% CI)
–7.0 (–8.9 to –5.1) –1.8 (–3.5 to –0.2) –5.2 (–7.7 to –2.7; < 0.0001)
Itching behaviour: coping
Baseline, mean (SD) 7.7 (5.1) 7.6 (4.6)
12 months, mean (SD) 8.8 (5.4) 7.2 (5.0)
Mean difference/change in score
(95% CI)
1.0 (–0.3 to 2.3) –0.4 (–1.6 to 0.8) 1.5 (–0.3 to 3.2; 0.047)
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Other relevant outcomes:
13–18 years age group
Educational
programme (n= 70)
No education
(n= 50)
Difference (95% CI, p-value)
in change between baseline
and 12 months between
groups
SCORAD: total severity score
Baseline, mean (SD) 43.1 (14.7) 40.4 (13.9)
12 months, mean (SD) 23.4 (12.6) 35.2 (15.2)
Mean difference/change in score
(95% CI)
–19.7 (–23.7 to –15.7) –5.2 (–10.5 to 0.1) –14.5 (–21.2 to –7.9;< 0.0001)
SCORAD: objective severity score
Baseline, mean (SD) 34.4 (12.4) 33.4 (12.0)
12 months, mean (SD) 19.5 (11.1) 28.3 (12.0)
Mean difference/change in score
(95% CI)
–15.0 (–18.4 to –11.6) –5.1 (–9.5 to –0.6) –9.9 (–15.5 to –4.3; < 0.0001)
Subjective severity
Baseline, mean (SD) 8.9 (3.2) 8.8 (3.5)
12 months, mean (SD) 5.8 (3.4) 8.1 (4.0)
Mean difference/change in score
(95% CI)
–3.1 (–4.1 to –2.2) –1.0 (–2.1 to 0.1) –2.1 (–3.5 to –0.7; < 0.0002)
Itching behaviour: catastrophisisationa
Baseline, mean (SD) 16.6 (7.9) 16.9 (8.6)
12 months, mean (SD) 9.8 (8.1) 14.9 (9.0)
Mean difference/change in score
(95% CI)
–6.8 (–8.6 to –5.0) –2.0 (–3.9 to –0.2) –4.7 (–7.3 to –2.2; 0.0002)
Itching behaviour: coping
Baseline, mean (SD) 15.4 (7.8) 14.0 (7.0)
12 months, mean (SD) 15.2 (8.2) 14.5 (7.0)
Mean difference/change in score
(95% CI)
–0.2 (–1.9 to 1.5) 0.4 (–1.2 to 2.1) –0.6 (–3.0 to 1.7; 0.875)
Comments: outcome data also collected at 6 months, but not reported in the paper
Adverse events
Educational
programme No education p-value/CI
Not reported
Comments:
Subgroup analysis results:
Comments: no subgroups reported
Outcome
Educational
programme No education p-value/CI
None
Comments:
a Defined as ‘negative thoughts on pain that have got out of control’ (p. 4) No information provided to interpret
the measures.
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Process evaluation results
No process evaluation
Comments:
General comments
Generalisability: large-scale study across seven study centres in Germany, conducted with a wide range of children age
groups. Therefore the study is likely to have good generalisation to the German context. Atopic dermatitis was moderate to
severe
Other: differences between groups on parental HRQoL appear to be small – unclear whether the statistically significant
changes are clinically meaningful
Quality criteria (Cochrane ‘risk of bias’ tool) randomised
controlled trials
Criteria
Judgement of
risk of biasa Support for judgement
Random sequence generation
(selection bias)
Low risk Computer-generated random numbers were used
Allocation concealment
(selection bias)
Unclear risk ‘The randomisation code was concealed in closed envelopes from
those entering patients into the study.’
Randomisation was carried out by an independent study centre, but
unclear if the envelopes containing the randomisation code were
opaque or sequentially numbered to adequately conceal allocation
from those entering patients into the study
Blinding of participants and
personnel (performance bias)
High risk Participants and trainers were not blinded to treatment allocation
Blinding of outcome assessment
(detection bias)
High risk Participants were not blinded to treatment allocation. Unclear if the
investigators who rated eczema severity were blinded to treatment
allocation
Incomplete outcome data
(attrition bias)
High risk A higher proportion of patients in the no education group (24%)
than in the education intervention group (10%) were lost to
follow-up, mainly due to no response or lost interest, which may
have impacted outcomes. Missing data were not imputed and
ITT analysis was not conducted
Selective reporting (reporting
bias)
Unclear risk All outcomes were measured at 6 and 12 months, but only
12-month results are reported
Other bias Low risk
a High risk, unclear risk, low risk.
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Reference and
design Intervention Participants Outcome measures
Author and year: van
Os-Medendorp et al.,
200789
Study ID: 505 (some
data from a secondary
publication 466)
Country/location:
Netherlands
Setting: secondary
care
Trial design: RCT
Includes process
evaluation: no
Number of study
centres: not reported
(recruitment was from
four centres)
Funding: Dutch
College of Health
Insurance (CVZ)
Conflicts of interest:
stated none declared
Trial/study number:
not reported
Study dates: not
reported
Was the educational
intervention an
adjunct to standard
medical care? Yes
Treatment intervention
‘Coping with itch’
Overview: individual sessions
with dermatology nurse, in
addition to usual medical
treatment by dermatologist.
Includes educational and
cognitive behavioural
interventions such as
individual patient education,
awareness training and habit
reversal, relaxation exercises
and psychosocial support
given according to a nursing
care plan. Referral to other
members of outpatient
dermatology multidisciplinary
team (social workers,
psychologists and
dermatologists) if needed
Intervention aim(s): to reduce
itch and to help patients cope
with itch
Where delivered: specialised
itch clinic in dermatology
outpatient department
Self-help, individual- and/or
group-based? (State group
size): individual-based
Mode: face to face
Materials: not reported
Provider: dermatology nurse
Duration and intensity:
patients visited the itch clinic
a mean of 2.9 times
(median 3, range 1–6);
duration of sessions not
reported
Scripting (level of detail
guiding interaction between
interventionist and
participants): not reported
Sensitivity to participant
characteristics: not reported
Interventionist characteristics
and training: not reported
Skin condition: chronic pruritic
skin disease (regardless of
specific diagnosis)
Diagnostic criteria: not
reported
Specify if patients, parents
and/or carers: patients
Patient general age group
(specify if children, young
adults and/or adults): adults
(aged 18 years or older)
Stated target group: adults
with chronic pruritic skin
disease
How recruited: by
dermatologists from four
dermatology outpatient
departments (no further
details reported)
Eligibility criteria: not reported
Numbers involved (stated as
the numbers included –
unclear if this means the
number randomised):
Total:120
Intervention (intervention): 63
Control: 57
Numbers (%) completing,
attrition and reasons
(percentages calculated by
reviewer):a
Attrition: 9 months: 69 (58)
[intervention 40 (63);
control 29 (51)]
Reasons: did not return
baseline and/or 3-month
and/or 9-month follow-up
patient-reported outcome
measures; in control group 4
patients received the
intervention and were
excluded
Completers: (9 months): 51
(43) [intervention 23 (37);
control 28 (49)]
Primary outcomes: disease
severity (patient-reported
frequency and intensity of
itching and scratching);
itch-related coping (ICQ);
skin-related psychosocial
morbidity including QoL
(ACS); general psychosocial
morbidity (SCL-90)
Secondary outcomes
(assessed by monthly
telephone interviews):
Health resource use (number
of dermatologist visits);
medication and ointment use
Adverse events: not reported
Process evaluation measures:
no process evaluation
Individual preferred learning
style addressed? No
How outcomes assessed?:
By patient self-report:
l itch and scratch
frequencies
(weekly diaries)
l itch-related coping (ICQ –
Dutch version)
l skin-related psycho-social
morbidity (ACS –
Dutch version)
l general psychosocial
morbidity (SCL-90 –
Dutch version)
l demographic data
(general questionnaire)
By monthly telephone
interviews with patients:
l medication use
l dermatology visits
l GP contactc
l days off workc
l hospitalisationsc
l costsc
Normal range(s) for
outcomes/clinically
meaningful improvement
defined: no
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Reference and
design Intervention Participants Outcome measures
Content and topics: education
about: itch causes,
consequences and treatment;
patient advocacy groups;
avoiding triggers; diet;
interventions to relieve itching
and scratching and their
consequences. Cognitive
behavioural therapy including
diary-based awareness
training, habit reversal to
reduce scratching, and
relaxation. Based on an initial
itch medical history
assessment taken by the nurse
and structured according
to an individual-based
nursing care plan
Tailoring: nursing care plan for
intervention was structured
according to patient’s
individual needs
Ongoing support: individual
counselling and ‘support’ (not
defined) provided as required
(no details given)
Theory: not reported
Control intervention
Description: normal care,
which consists of outpatient
consultations with a
dermatologist involving
diagnosis and therapeutic
intervention such as the use of
emollients and topical steroids
Duration and intensity: not
reported
Sample cross-overs: four
patients in control group
received the intervention and
were excluded from the
analysis
Baseline characteristicsb
Comorbidities: not reported
Comedications/interventions:
Not reported for baseline
Duration of disease and itch,
years, mean (SD):d
Disease duration: intervention
14.6 (14.4); control 17.4
(18.3)
Itch duration:
intervention: 12.3 (13.8);
control 12.3 (16.6)
Disease severity: not reported,
other than patients with high
frequency or high intensity of
itching/scratching (see
outcomes section below)
Diagnosis of skin disease,
n (%)d,e
Eczema: intervention 10 (34);
control 10 (29)
AD: intervention 5 (17);
control 3 (9)
Pruritus: intervention 4 (14);
control 5 (15)
Prurigo: intervention 1 (3);
control 2 (6)
Psoriasis: intervention 4 (14);
control 3 (8)
Chronic urticaria: intervention:
2 (7); control 2 (6)
Other: intervention 2 (7);
control 6 (18)
Unknown: intervention 1 (3);
control 1 (3)
Non-skin disease: intervention
0 (0); control 2 (6)
Validated? Stated that the
ICQ, ACS and SCL-90 are
validated instruments.
Self-reported itching and
scratching also validated
(internal consistency reported)
Timing of outcomes same for
both groups: yes
Length of follow-up: longest
follow-up time point:
9 months after start of
programme (same as
programme duration)
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Reference and
design Intervention Participants Outcome measures
Sex M/F, n (%):d
intervention: 13 (45)/16 (55)
control: 10 (28)/26 (72)
Mean (SD) [range] age, years:d
intervention: 57.0 (17.3)
[25.5–86.8]
control: 55.7 (17.2)
[23.8–82.8]
Ethnic groups: not reported
Socioeconomic characteristics:
Education level:
low/medium/high, n (%)d,f
intervention (n= 28):
13 (46)/6 (21)/9 (32)
control (n= 35): 18 (51)/11
(31)/6 (17)
a Different values for attrition and numbers completing follow-up are reported in the two publications.89,107 The data
extracted here are from the primary clinical publication.89
b Baseline characteristics are reported for the patients analysed, not the starting number randomised.
c Reported in secondary publication.107
d Different values for the baseline variables are reported in the two publications,89,107 based on sample sizes of intervention
n= 29 and control n= 3689 or intervention n= 25 and control n= 31.107 The data extracted here are from the primary
clinical reference89 which reports the larger sample sizes.
e Note that in the control group there were 36 patients89 or 31 patients107 who provided baseline data but diagnoses of
skin conditions in the control group are given for 32 patients89 or 27 patients.107
f Education levels not defined.
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Methods
Statistical analysis, including how missing data dealt with: analysis methods are reported. Missing data were not
included in analyses. Note that to analyse the use of medications and the number of visits to the dermatologist, data for
months 1–3 of the study period were used in lieu of baseline data (no explanation reported) and data for months 7–9 were
provided as the follow-up data. Reported results are those with a ‘trend to significance’, defined as p-value < 0.10
Power calculation: not reported
Study adequately powered? Not reported [note high rates of attrition (> 50%) at 9 months]
ITT used? No. Attrition was not accounted for in analyses
Groups comparable at baseline? Yes (stated that no significant differences were found between the characteristics of
the intervention group and the control group)
Subgroups analyses: none reported
Process evaluation methods (if relevant): none reported
Outcome evaluation results
HRQoL outcomes, mean (SD) score (3-month
outcomes also reported but not extracted here)
‘Coping with
itch’ group
Baseline n= 29
9 months n= 23
Control group
Baseline n= 36
9 months n= 30
(unless stated) p-value
ACS subscale: impact on QoL
Baseline 12.08 (5.00) 12.56 (4.93) Stated NS
9 months 13.10 (5.25) 12.68 (4.58) Stated NS
Other outcomes, mean (SD) score (3-month outcomes also reported but not extracted here)
ICQ subscale: catastrophising and helpless coping
Baseline 22.47 (11.44) 23.06 (8.88) Stated NS
9 months 17.23 (10.42) 20.19 (10.18) [n= 28] Stated NS
ICQ subscale: problem-focused coping
Baseline 18.95 (8.79) 21.24 (6.68) Stated NS
9 months 19.39 (9.47) 20.79 (7.06) [n= 28] Stated NS
ACS skin-related psychosocial morbidity
Baseline 138.39 (38.00) 141.26 (37.60) Stated NS
9 months 134.79 (42.69) 134.01 (40.85) Stated NS
ACS subscale: social anxiety and avoidance
Baseline 34.62 (14.49) 36.09 (14.19) Stated NS
9 months 34.80 (15.99) 35.46 (13.97) Stated NS
ACS subscale: vicious circle of itching and scratching
Baseline 28.41 (7.61) 30.20 (7.07) Stated NS
9 months 26.07 (8.17) 26.70 (8.00) Stated NS
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Outcome evaluation results
HRQoL outcomes, mean (SD) score (3-month
outcomes also reported but not extracted here)
‘Coping with
itch’ group
Baseline n= 29
9 months n= 23
Control group
Baseline n= 36
9 months n= 30
(unless stated) p-value
ACS subscale: helplessness
Baseline 26.02 (8.29) 26.01 (7.19) Stated NS
9 months 26.61 (7.87) 24.70 (8.27) Stated NS
ACS subscale: anxious depressive mood
Baseline 24.18 (8.74) 24.58 (8.67) Stated NS
9 months 23.30 (8.79) 23.97 (8.89) Stated NS
ACS subscale: deficit in active coping
Baseline 13.07 (3.36) 11.82 (3.24) Stated NS
9 months 10.91 (3.01) 10.50 (3.27) Stated NS
SCL-90 general psychosocial morbidity
Baseline 146.30 (60.02) 151.18 (52.60 Stated NS
9 months 134.41 (47.68) 159.81 (57.69) Stated NS
Comments: lower ICQ scores reflect better itch-related coping (or less itch-related catastrophising); lower ACS scores reflect
lower skin-related psychosocial morbidity; lower SCL-90 scores reflect lower general psychosocial morbidity burden
Patients with high frequency or high intensity
of itching and scratching, n (%)
‘Coping with
itch’ group
Baseline n= 25
9 months n= 24
Control group
Baseline n= 32
9 months n= 29 p-value
High frequency
Baseline 18 (72) 21 (66) Stated NS
9 months 12 (50) 15 (52) Stated NSa
High intensity
Baseline 20 (80) 25 (78) Stated NS
9 months 12 (50) 16 (55) Stated NS
Comments: continuous scale for frequency and intensity of itching/scratching was validated (internal consistency reported)
but authors subsequently converted it to a dichotomous measure with arbitrary cut-off (high frequency defined as > 4 and
high intensity defined as > 3 based on average from an original continuous itching scale of 0 (none) to 10 (unbearable)
and a continuous scratching scale of 0 (none) to 10 (bloody skin)
Data for 3 months also reported but not extracted
NS, not statistically significant.
a Stated that difference between groups at 3 months showed a ‘trend to significance’ [12 (48) vs. 23 (72); p-value= 0.07].
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Medication use, n (%)
‘Coping with itch’ group
Months 1–3 n= 29
Months 7–9 n= 27
Control group
Months 1–3 n= 35
Months 7–9 n= 31 p-value
Topical corticosteroids: mild
Months 1–3 3 (10) 0 (0) p= 0.053
Months 7–9 2 (7) 2 (6) Stated NS
Topical corticosteroids: moderately potent
Months 1–3 5 (17) 12 (34) Stated NS
Months 7–9 6 (22) 7 (23) Stated NS
Topical corticosteroids: potent
Months 1–3 9 (31) 11 (31) Stated NS
Months 7–9 5 (18) 7 (23) Stated NS
Topical corticosteroids: very potent
Months 1–3 0 (0) 3 (9) Stated NS
Months 7–9 3 (11) 2 (6) Stated NS
Systemic medication (ciclosporin, acitretin, prednisone, etc.)
Months 1–3 4 (14) 3 (9) Stated NS
Months 7–9 4 (15) 3 (10) Stated NS
Itch-relieving medication (hydroxyzine, cetirizine, etc.)
Months 1–3 12 (41) 17 (49) Stated NS
Months 7–9 13 (48) 13 (42) Stated NS
Proportion of patients visiting the
dermatologist, n (%)
‘Coping with itch’ group
Months 1–3 n= 29
Months 7–9 n= 27
Control group
Months 1–3 n= 35
Months 7–9 n= 31 p-value
Months 1–3 17 (59) 30 (86) p= 0.015
Months 7–9 17 (63) 18 (58) Stated NS
Comments: cost-effectiveness paper107 also reports the following outcomes as numbers of visits or events (mean and SD
reported but not extracted here): phone and face-to-face visits to the dermatologist; dermatology repeat prescriptions;
ultraviolet therapy visits; visits to the dermatology nurse; visits to the dermatology social worker; visits to the GP; repeat
prescriptions from the GP; repeat prescriptions from other HCPs; visits to hospital (any department except dermatology); use
of paramedical services; visits to a psychosocial worker; home visits by a nurse; visits to an alternative medicine provider;
days off work; days of hospitalisation. At 9 months of follow-up the difference between ‘Coping with itch’ and control
groups was not significant (at α= 0.05) (95% CIs for the differences included zero). An exception is that there were
significantly more visits to the dermatology nurse in the intervention group than the control group: intervention mean
(SD)= 3.1 (2.0); control mean (SD)= 0.5 (0.7); difference= 2.7; 95% CI 1.8 to 3.6107
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Adverse events ‘Coping with itch’ group Control group p-value
Comments: no adverse events reported
Subgroup analysis results:
Comments: no subgroups reported
Process evaluation results
Comments: no process evaluations reported
General comments
Generalisability: adult population, but generalisability unclear as ethnicity, body weight/BMI and comorbidities not
reported; range of skin diseases covered in population so unclear whether results applicable to specific skin diseases
NS, not statistically significant.
Quality criteria (Cochrane ‘risk of bias’ tool) randomised
controlled trials
Criteria
Judgement of
risk of biasa Support for judgement
Random sequence generation
(selection bias)
Unclear risk No information provided
Allocation concealment (selection
bias)
Unclear risk No information provided
Blinding of participants and
personnel (performance bias)
Unclear risk No information provided
Blinding of outcome assessment
(detection bias)
Unclear risk No information provided
Incomplete outcome data
(attrition bias)
High risk High rate of attrition in both study groups, with attrition excluded
from analyses (non-ITT). Slightly higher attrition rate in control than
intervention, especially early in period (9% difference after
3 months). Partly accounted for by four patients in control group
who elected to receive ‘Coping with itch’ intervention and were
excluded from analyses. Primary reason for attrition was failure to
provide patient-reported outcome measures for baseline and
follow-up assessments. Sample sizes are difficult to follow and are
different for patient-reported outcomes and medication use; and
data on attrition were different in the publications89,107
Selective reporting (reporting bias) Unclear risk No protocol reported. All outcomes stated in the methods are
reported in the results. However, arbitrary thresholds were used for
defining high frequency and high intensity of itching and
scratching (i.e. continuous measure converted to dichotomous with
arbitrary cut-off). Outcome timing for medication use appears
arbitrary without explanation (months 1–3 were used in lieu of
baseline and months 7–9 in lieu of 9-month follow-up)
Other bias Low risk No additional risk identified
a High risk, Unclear risk, Low risk.
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Appendix 5 List of excluded studies
with rationale
Below is a list of the publications excluded at the full-text screening stage of the clinical effectivenessreview and reasons for exclusion.
TABLE 30 List of publications excluded at the full-text screening stage
Publication Exclusion reason
Armstrong AW, Kim RH, Idriss NZ, Larsen LN, Lio PA. Online video improves clinical
outcomes in adults with atopic dermatitis: a randomized controlled trial. J Am Acad
Dermatol 2011;64:502–7
Did not measure HRQoL,
using a validated measure
Basak PY, Ozturk M, Baysal V. Assessment of information and education about topical
corticosteroids in dermatology outpatient departments: experience from Turkey.
J Eur Acad Dermatol Venereol 2003;17:652–8
Did not measure HRQoL,
using a validated measure
Bauer A, Kelterer D, Bartsch R, Schlegel A, Pearson J, Stadeler M, et al. Prevention of
hand dermatitis in bakers’ apprentices: different efficacy of skin protection measures and
UVB hardening. Int Arch Occup Environ Health 2002;75:491–9
Did not measure HRQoL,
using a validated measure
Bauer A, Kelterer D, Bartsch R, Pearson J, Stadeler M, Kleesz P, et al. Skin protection in
bakers’ apprentices. Contact Dermatitis 2002;46:81–5
Did not measure HRQoL,
using a validated measure
Bostoen J, Geusens B, Lambert J, Bracke S, Dekeyser S. An educational program for
patients with psoriasis and atopic dermatitis: A prospective randomized, controlled trial.
J Am Acad Dermatol 2012;66(Suppl. 1):AB84
Abstract or conference
presentation with insufficient
information
Bostoen J, Geusens B, Bracke S, Dekeyser S, Lambert J. Follow-up on the effect of a
patient educational programme: Early results of a prospective randomized controlled trial
in psoriasis and atopic dermatitis. Br J Dermatol 2011;165:e34–5
Abstract or conference
presentation with insufficient
information
Broberg A, Kalimo K, Lindblad B, Swanbeck G. Parental education in the treatment of
childhood atopic eczema. Acta Dermato-Venereologica 1990;70:495–9
Did not measure HRQoL,
using a validated measure
Chinn DJ, Poyner T, Sibley G. Randomized controlled trial of a single dermatology nurse
consultation in primary care on the quality of life of children with atopic eczema. Br J
Dermatol 2002;146:432–9
Not an educational
intervention focused on
improving HRQoL
Ehlers A, Stangier U, Gieler U. Treatment of atopic dermatitis: a comparison of
psychological and dermatological approaches to relapse prevention. J Consult Clin Psychol
1995;63:624–35
Did not measure HRQoL,
using a validated measure
Evers AWM, Duller P, de Jong EMGJ, Otero ME, Verhaak CM, Van Der Valk PGM, et al.
Effectiveness of a multidisciplinary itch-coping training programme in adults with atopic
dermatitis. Acta Derm Venereol 2009;89:57–63
Educational and other aspects
inseparable
Feldman SR, Vanarthos J, Fleischer AB, Jr. The readability of patient education materials
designed for patients with psoriasis. J Am Acad Dermatol 1994;30:284–6
Did not measure HRQoL,
using a validated measure
Fisker MH, Agner T, Lindschou J, Bonde JP, Ibler KS, Gluud C, et al. Protocol for a
randomised trial on the effect of group education on skin-protective behaviour versus
treatment as usual among individuals with newly notified occupational hand eczema –
the Prevention of Hand Eczema (PREVEX) Trial. BMC Dermatol 2013;13:16
Not a RCT or CCT
Flanders PA, McNamara JR. Enhancing acne medication compliance: a comparison of
strategies. Behav Res Ther 1985;23:225–7
Did not measure HRQoL,
using a validated measure
Flyvholm MA, Mygind K, Sell L, Jensen A, Jepsen KF. A randomised controlled
intervention study on prevention of work related skin problems among gut cleaners in
swine slaughterhouses. Occup Environ Med 2005;62:642–9
Did not measure HRQoL,
using a validated measure
continued
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TABLE 30 List of publications excluded at the full-text screening stage (continued )
Publication Exclusion reason
Fortune DG, Richards HL, Kirby B, Bowcock S, Main CJ, Griffiths CE. A cognitive-
behavioural symptom management programme as an adjunct in psoriasis therapy.
Br J Dermatol 2002;146:458–65
Did not measure HRQoL,
using a validated measure
Fortune DG, Richards HL, Griffiths CE, Main CJ. Targeting cognitive-behaviour therapy to
patients’ implicit model of psoriasis: results from a patient preference controlled trial.
Br J Clin Psychol 2004;43:1–82
Did not measure HRQoL,
using a validated measure
Fukuie T, Nomura I, Narita M, Suzuki T, Tajima I, Natsume O, et al. A randomized,
open-label, parallel group study to evaluate the efficacy and safety of proactive
management in pediatric subjects with moderate to severe atopic dermatitis.
J Allergy Clin Immunol 2013;131:AB101
Did not measure HRQoL,
using a validated measure
Futamura M, Masuko I, Hayashi K, Ohya Y, Ito K. Effects of a short-term parental
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Insufficient reporting of
results in paper
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Did not measure HRQoL,
using a validated measure
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of mindfulness-based stress reduction and an active control in modulation of neurogenic
inflammation. Brain Behav Immun 2013;27:174–84
Did not measure HRQoL,
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Not a RCT or CCT
Schuttelaar ML, Vermeulen KM, Drukker N, Coenraads PJ. A randomized controlled trial
in children with eczema: nurse practitioner vs. dermatologist. Br J Dermatol
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continued
DOI: 10.3310/hta19860 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 86
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Pickett et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
147
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Appendix 7 Excluded cost-effectiveness studies
TABLE 32 Excluded cost-effectiveness studies
Excluded study Reason for exclusion
Beikert FC, Langenbruch AK, Radtke MA, Augustin M. Willingness to pay and quality
of life in patients with rosacea. J Eur Acad Dermatol Venereol 2013;27:734–8
Inappropriate study design
van der Meer EW, Boot CR, Jungbauer FH, van der Klink JJ, Rustemeyer T,
Coenraads PJ, et al. Hands4U: a multifaceted strategy to implement guideline-based
recommendations to prevent hand eczema in health care workers: design of a
randomised controlled trial and (cost) effectiveness evaluation. BMC Public Health
2011;11:669
Ongoing trial
Bathe A, Matterne U, Dewald M, Grande T, Weisshaar E. Educational multidisciplinary
training programme for patients with chronic pruritus. Acta Derm Venereol
2009;89:498–501
Inappropriate study design
Hartman M, Prins M, Swinkels OQ, Severens JL, De BT, Van Der Wilt GJ, et al.
Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol
compared with UVB phototherapy and inpatient dithranol treatment. Br J Dermatol
2002;147:538–44
Intervention was not educational
Staab D, von RU, Kehrt R, Erhart M, Wenninger K, Kamtsiuris P, et al. Evaluation of a
parental training program for the management of childhood atopic dermatitis.
Pediatr Allergy Immunol 2002;13:84–90
Inappropriate study design
van Gils RF, Bosmans JE, Boot CRL, Rustemeyer T, van MW, Van Der Valk PGM, et al.
Economic evaluation of an integrated care programme for patients with hand
dermatitis. Contact Dermatitis 2013;69:144–52
Not clear if the intervention was
educational
Parsi K, Chambers CJ, Armstrong AW. Cost-effectiveness analysis of a patient-centered
care model for management of psoriasis. J Am Acad Dermatol 2012;66:563–70
Intervention was not educational
Healthcare Insurance Board/College voor Zorgverzekeringen. Evaluation of the
Combination Day- and Home Treatment of Psoriasis – Primary Research. Healthcare
Insurance Board/College voor Zorgverzekeringen (CVZ); 2000
Not in the English language
The Netherlands Organisation for Health Research and Development. E-health in
Caring for Patients With Atopic Dermatitis. An Economic Evaluation Comparing Usual
Care with Internet-Guided Monitoring and Self-Management Training by a Nurse
Practitioner. The Netherlands Organisation for Health Research and Development
(ZonMw). 2000. URL: www.zonmw.nl (accessed 19 October 2015)
Not in the English language
Kernick D, Cox A, Powell R, Reinhold D, Sawkins J, Warin A. A cost consequence study
of the impact of a dermatology-trained practice nurse on the quality of life of primary
care patients with eczema and psoriasis. Br J Gen Prac 2000;50:555–8
Not clear if the intervention was
educational
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Appendix 8 Data extractions from systematic
review of cost-effectiveness
1 Study Mason, 2013108
2 Research question To examine the effectiveness of a multifaceted educational support
programme to increase emollient use and reduce atopic eczema symptoms
in children
3 Country/setting The UK
4 Funding source Reckitt Benkiser Healthcare
5 Analysis type Cost analysis
6 Study type Before-and-after study
7 Perspective NHS
8 Time horizon Trial duration: 3 months
9 Analysis method
If estimations are based on a
model, state the model
assumptions where relevant
Not reported
10 Discounting (rate) None
11 Costing year, currency 2011, £
12 Population
Definition of condition Atopic eczema
Characteristics of baseline
cohort/risk factors
Eligible children were male and female aged 3 months to 6 years, with mild
to moderate atopic eczema; and using E45 Cream as their primary emollient
13 Intervention(s), comparator(s) A multifaceted educational support programme was evaluated as a method
of increasing emollient use and reducing atopic eczema in children. Support
provided for parents and carers included an educational DVD, online daily
diary and telephone helpline with dermatology nurses
14 Outcome measure
(a) Primary outcome(s) used in
the analysis
(b) Source of evidence for the
primary outcome
(c) Summary measure of effect
l Emollient use (grams per week)
l Severity of eczema
l Health-care contacts by patients
l Parent measures of perceived control in managing the child’s eczema
l Use of concurrent medication
The outcomes were collected as part of the before-and-after study in which
a purpose-designed multifaceted educational support programme (ESP)
was provided
Emollient use was estimated through telephonic questionnaire; severity of
eczema was captured using the Patient-Oriented Eczema Measure (POEM)
and Patient Eczema Severity Time (PEST). Health-care contacts were
determined via recorded number of GP and dermatology specialist visits;
parent measures were captured by telephone questionnaire and concurrent
medication use was recorded through telephone surveys
Not reported
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1 Study Mason, 2013108
15 Health benefits
(a) If relevant, specify the valuation
approach (and source).
(b) If relevant, state the instrument
used to measure health benefits.
Not reported but appears to be based on improved emollient uptake,
reduced eczema severity, reduced sleep disturbance and improved parent
control
Severity of eczema was captured using POEM and PEST. No single
instrument was used to measure health benefits; different aspects of health
benefits were measured separately
16 Costs
Intervention cost The cost of providing the ESP programme was estimated to be £32 per child
based on a resource analysis of providing the service
Indirect Costs Not stated
17 Results
Health economic outcomes were expressed in terms of costs, presented in the table below
Costs (£, 2011)
Pre-programmea Programmeb Changec,d
Mean (SD) Mean (SD) Mean 95% CI n p
Programme 32 – 32 – – –
Emolliente 9.29 (9.30) 19.57 (12.03) 10.28 (7.93 to 12.64) 132 0.001
Emollientf 9.72 (9.69) 22.64 (12.21) 12.91 (10.72 to 15.10) 115 0.001
GP visits 68.53 (76.70) 30.40 (31.67) –38.13 (–52.58 to –23.68) 135 0.001
Overall coste 78.29 (79.34) 82.66 (34.16) 4.37 (–10.55 to 19.30) 132 0.62
Overall costsf 80.32 (82.48) 84.37 (31.29) 4.06 (–12.00 to 20.11) 115 0.56
a Estimated for the 12 weeks preceding intervention, using 2-week baseline data and 12-week recall (GP visits).
b 12 weeks while receiving the patient support programme.
c Difference in costs in the two periods (negative denotes a reduction).
d Estimated by bootstrapping with 1000 replications.
e Emollient use costed using the daily diary method.
f Emollient use costed using the estimated time taken to use a 500-g pot of emollient.
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1 Study Mason, 2013108
Clinical outcomes of relevance (as included within the sensitivity analysis) are extracted in the table below
Outcomes
Baselinea 9–12 weeks Mean changeb
Mean SD Mean SD Mean 95% CIc n p-value3
Emollient use (g/week)d
Daily diary – 167.8 109.5 87.6 81.9 to 119.5 132 0.001
Time to use 79.2 79.2 197.4 106.5 110.0 94.6 to 131.3 115 0.001
Severity scores
POEMe 11.34 6.27 4.85 5.04 –5.38 –6.41 to –4.36 135 0.001
PESTf 2.26 0.81 1.53 0.68 –0.61 –0.75 to –0.47 135 0.001
a Weeks –2 to 0, except GP visits which included the previous 12 weeks to week 0.
b The mean change is the average of the programme period scores minus the baseline period score in subjects with
complete data. It is to be noted that data for week 1–4 weeks and 5–8 weeks were not extracted.
c Estimated by bootstrapping with 1000 replications.
d Emollient use was estimated using 2 methods: time to use a reported weight of emollient (500 g) and a daily
diary record of counts of pumps of emollient used by weight; the latter method was not available for the baseline
period.
e POEM score from 0 to 28, including seven signs of eczema at four levels of frequency in the past week at the end
of each period.
f PEST score, the child’s unhappiness with eczema: score 1 (not at all) to 5 (very unhappy), daily diary score
averaged over each period.
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1 Study Mason, 2013108
18 Sensitivity analysis
Bootstrapping method was adopted with 1000 replications. Analyses were repeated in 117 children, excluding
18 children who had visited an eczema specialist in the 3 months prior to joining the programme. Results of the
analyses are presented in the table below
Sensitivity analysis: excluding children who had recently seen a specialist
Pre-programmea Programmeb Changec,d
Mean SD Mean SD Mean 95% CI n p-value
Emollient use (g/week)
Daily diary 69.7 49.5 170.3 99.0 100.6 81.9 to 119.5 114 0.001
Time to use 72.2 49.6 184.3 97.6 112.2 94.6 to 131.3 99 0.001
Severity scores
POEM 11.03 6.49 5.83 4.67 –5.20 –6.39 to –4.34 117 0.001
PEST 2.26 0.82 1.66 0.62 –0.60 –0.74 to –0.47 117 0.001
Costs (£, 2011)
Programme 32 – 32 – – –
Emolliente 8.18 5.80 19.98 11.61 11.81 9.81 to 14.01 114 0.001
Emollientf 8.47 5.82 21.63 11.46 13.16 10.94 to 15.39 99 0.001
GP visits 63.23 63.80 30.46 30.86 –32.77 –45.77 to –19.77 117 0.001
Overall coste 71.81 66.37 83.25 33.75 11.44 –1.99 to 24.86 114 0.123
Overall costsf 72.11 68.24 83.45 33.75 11.35 –3.14 to 25.83 99 0.239
a Estimated for the 12 weeks preceding intervention, using 2 week baseline data and 12 week recall (GP visits).
b 12 weeks while receiving the patient support programme.
c Difference in costs in the two periods (negative denotes a reduction).
d Estimated by bootstrapping with 1000 replications.
e Emollient use costed using the daily diary method.
f Emollient use costed using the estimated time taken to use a 500-g pot of emollient.
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1 Study Mason, 2013108
19 Author’s conclusions Based on their findings, the authors concluded that, although a community-
based multi-faceted education support programme did not increase cost,
it helped increase the use of emollient. This further helped in reducing
symptoms associated with atopic eczema as well as contacts with the GPs.
It was also observed that such a programme could benefit the families and
carers of children with the condition as the children experienced improved
sleep patterns which gave the parents and carers greater feeling of control.
The authors, however, recommended further evaluation to assess the
effectiveness of PEST in helping parents and children to monitor and manage
eczema
20 Reviewer’s comments This study is relevant for the purpose of this review as it was based in the
UK. However, from an economic perspective, there were a few limitations.
First, a cost-effectiveness analysis was not conducted. Also, the sources of
the cost inputs and detailed composition of costs parameters used in the
analysis were not reported. Second, the analysis was not conducted over a
long period of time but for 3 months as the duration of the trial. Although
sensitivity analyses were conducted to check the robustness of the base case
results, probabilistic distributions were not assigned to the parameters, rather
bootstrapping method was adopted to avoid parametric assumptions
Systematic review quality-assessment checklist for economic
evaluations and notes for completion
Critical appraisal checklist for economic evaluations (based on Drummond et al., 2005110)
Item Y/N/?
1. Is the decision problem (including interventions compared and patient group) relevant to the UK? Yes
2. Is the setting comparable to the UK? Yes
3. Is the analytical and modelling methodology appropriate? ?
4. Are all the relevant costs and consequences for each alternative identified? ?
5. Are the data inputs for the model described and justified? ?
6. Are health outcomes measured in QALYs? No
7. Is the time horizon considered appropriate? No
8. Are costs and outcomes discounted? Noa
9. Is an incremental analysis performed? Yes
10. Is uncertainty assessed? ?
a Discounting was not applicable as the time horizon was < 1 year.
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1 Study Schuttelaar, 2011109
2 Research question To determine costs and cost-effectiveness of care provided by NPs vs.
dermatologists and to compare the results with those in studies from
other countries
3 Country/setting The Netherlands
4 Funding source Health Care Efficiency Research Programme of the University Medical
Centre Groningen, Groningen, the Netherlands
5 Analysis type CEA
6 Study type Economic evaluation based on the results of a RCT
7 Perspective Societal
8 Time horizon Trial duration: 1 year
9 Analysis method
(a) If estimations are based on a
model, state the model
assumptions where relevant
Not reported
10 Discounting (rate) None
11 Costing year, currency 2008, €
12 Population
(a) Definition of condition
(b) Characteristics of baseline cohort/
risk factors
Childhood eczema (mild, moderate and severe)
Patients aged ≤ 16 years with a diagnosis of eczema (‘atopic dermatitis’)
13 Intervention(s), comparator(s) Intervention: care by a NP
Comparator: conventional care by a dermatologist
14 Outcome measure
(a) Primary outcome(s) used in
the analysis
(b) Source of evidence for the
primary outcome
(c) Summary measure of effect
Between-group differences in the QoL of the child between baseline and
follow-up at 12 months
The outcome measure were collected as primary end point of the RCT
Mean difference
15 Health benefits
(a) If relevant, specify the valuation
approach (and source).
(b) If relevant, state the instrument
used to measure health benefits.
Scores assigned to individual health dimensions as well as patient
satisfaction within the instruments were added to obtain an overall score
For children aged < 4 years, IDQoL was completed by their parents.
Those aged 4–16 years completed CDLQI. For the cost-effectiveness
analysis, the severity of eczema was measured by the mean objective
SCORAD
Patient satisfaction at 12 months was measured by CSQ-8 which were
completed by the parents
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16 Costs
Intervention cost
Types of cost Unit price (£)
Health-care costs hospital
Visits dermatologista 1.66 per minute
Visit NPb 0.52 per minute
Phone consultations dermatologistc 8.30 per minute
Phone consultations NPd 5.20 per minute
Prescriptions Diverse
Laboratory tests Diverse
Admission day 512 per day
Group education session by the NP Diverse
Health-care costs community
Visits GP 21.70 per visit
Prescriptions Variable
Costs in other sectors
Home help visits 32.97 per visit
a First visit 20 minutes, follow-up visits 10 minutes.
b First visit NP 30 minutes, follow-up visits 20 minutes.
c Phone consultations 5 minutes.
d Phone consultations NP 10 minutes.
Estimates of unit costs were based on the Dutch guideline prices. Costs of medications were based on the listed
prices, including value added tax, obtained from the website of the Dutch Health Insurance Board
(www.fk.cvz.nl)
Indirect costs
Indirect costs were not reported explicitly in the study but based on the types of costs included; the reviewer
regarded family costs as indirect costs
Types of costs Unit prices (£)
Family Costs
Absence from work 37.23 per hour
Travelling expensesa 6.72/4.04 per visit
Out-of-pocket Variable
a Travelling expenses determined as standard price for private car/public transport based on mean distance to
hospital.
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1 Study Schuttelaar, 2011109
17 Results
Overall results
l At the baseline, the severity of the eczema (measured by the mean objective SCORAD (SD)) did not differ
significantly between the treatment groups as shown below:
Children aged < 4 years Children aged 4–16 years
Dermatologist group 33.4 (19.3) 35.4 (17.3)
NP group 33.4 (15.6) 29.9 (16.0)
l The difference between the dermatologist and NP groups in the 4–16 years age group was not considered
clinically relevant as the objective SCORAD ranged from 0 to 83
Clinical effectiveness
Measure Baseline (SD) [95% CI] 12 months (SD) [95% CI] Mean change (SD) [95% CI]
IDQOL Dermatologist
group
11.6 (SD 8.1) [9.0 to 14.2] 5.6 (SD 3.9) [4.3 to 7.0] –6.5 (SD 6.6) [–14.2 to –8.9]
NP group 10.7 (SD 4.9) [9.1 to 12.3] 5.7 (SD 5.4) [ 4.0 to 7.5] –4.9 (SD 5.5) [ –6.8 to –3.0]
CDLQI Dermatologist
group
12.1 (SD 6.3) [9.9 to 14.2] 5.6 (SD 4.2) [4.2 to 7.1] –5.9 (SD 6.0) [–8.0 to –3.9]
NP group 10.0 (SD 4.4) [8.5 to 11.4] 4.9 (SD 3.5) [3.7 to 6.1] –5.2 (SD 4.0) [6.6 to –3.8]
CSQ-8 Dermatologist
group
– 24.8 (SD 4.3) [23.6 to 26.0] –
NP group – 26.9 (SD 4.9) [25.5 to 28.2] –
Costs
l The mean (SD) total costs (expressed in €) and cost difference per child in the dermatologist and NP groups are
outlined below:
NP (n= 76) Dermatologist (n= 71) Difference (95% CI)a
Health-care costs hospital 632 (1198) 771 (1590) –139 (–520 to 291)
Health-care costs community 26 (39) 30 (59) –4 (–17 to 12)
Family costs 302 (511) 608 (1018) –306 (–475 to –16)
Costs other sectors 21 (182) 0.93 (7.83) 20 (–3 to 59)
Total costs 981 (1339) 1409 (2289) –428 (–910 to 197)
a Negative cost differences represent lower cost in the NP arm.
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1 Study Schuttelaar, 2011109
l The mean costs (SD), expressed in €, and cost difference per child per resource item is presented below:
NP (n= 76) Dermatologist (n= 71) Difference (95% CI)a
Health-care costs hospital
Outpatient visits 272 (143) 422 (238) –150 (–194 to –75)
Phone consultations 7.22 (9.23) 3.63 (7.72) 3.59 (0.91 to 5.93)
Oral medication 14 (36) 19 (30) –5 (–14 to 6)
Ointment active ingredients 69 (80) 87 (113) –18 (–42 to 15)
Emollients 17 (19) 17 (22) 0 (–6.48 to 5.92)
Bandages, dressings 47 (69) 26 (60) 21 (2 to 40)
Laboratory tests 9 (33) 17 (40) –8 (–17 to 4)
Hospital admission days 179 (1133) 163 (1376) 16 (–334 to 380)
Group education, NP 4.63 (7.91) – 4.63 (2.65 to 5.89)
Health-care cost community
General practitioner 10 (28) 18 (36) –8 (–15 to 3)
Oral medicationb 3.06 (13.42) 2.81 (10.30) 0.25 (–2.97 to 4.05)
Ointment with active ingredientsc 6.54 (21.09) 7.14 (40.20) –0.86 (–10.43 to 7.62)
Emollients 3.20 (5.79) 1.45 (3.93) 1.75 (0.28 to 3.08)
Protective dressingsd 2.64 (11.07) 0 (0) 2.64 (0.48 to 4.88)
Total health-care costs 658 (1213) 801 (1607) –143 (–544 to 299)
Family costs
Time costse 178 (357) 415 (735) –237 (–360 to –37)
Travelling expenses 20 (18) 30 (26) –10 (–13 to –1)
Bath oil 21 (20) 23 (26) –2 (–8 to 6)
Out-of-pocketf 83 (370) 134 (684) –51 (–221 to 97)
Costs other sectors
Home-help visits 21 (182) 0.93 (7.83) 20 (–3 to 59)
a Negative cost differences represent lower costs in the NP arm.
b Antibiotics, antihistamines.
c Steroids, calcineurin inhibitors, tar.
d Bandages, garments and gloves.
e Time missed in paid work and days missed in non-working activities of the parents.
f Self-medication, alternative practitioner, carpet changes, nutrition.
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l The costs [expressed in €, mean (SD)] of dermatological care and NP care estimated for different eczema
severity levels are shown below:
NP Dermatologist
Mild
eczema
(n= 12)
Moderate
eczema
(n= 44)
Severe
eczema
(n= 20)
Mild
eczema
(n= 13)
Moderate
eczema
(n= 31)
Severe
eczema
(n= 29)
Health-care costs hospital
Outpatient visits 178 (85) 270 (147) 340 (143) 257 (152) 404 (206) 521 (260)
Phone consultations 1.21 (1.99) 6.55 (8.13) 13 (12) 3.93 (9.49) 2.04 (6.33) 5.17 (8.05)
Oral medication 0 (0) 15 (44) 20 (26) 16 (33) 12 (21) 28 (35)
Ointment active
ingredients
35 (50) 71 (88) 85 (72) 26 (24) 83 (122) 118 (118)
Emollients 18 (18) 18 (21) 13 (17) 18 (12) 16 (17) 19 (30)
Bandages, dressings 15 (29) 45 (73) 73 (70) 16 (57) 17 (49) 40 (71)
Laboratory tests 11 (34) 12 (39) 0.45 (2.0) 7.62 (20.74) 19 (33) 19 (53)
Hospital admission
days
0 (0) 0(0) 6.80 (2.71) 0 (0) 0 (0) 429 (2239)
Group education, NP 4.4 (9.52) 5.84 (8.48) 2.10 (4.61) – – –
Total 287 (141) 450 (280) 1237 (2222) 386 (149) 567 (284) 1192 (2528)
Health-care cost community
General practitioner 11 (25) 13 (33) 3.3 (10.6) 13 (24) 11 (22) 25 (47)
Oral medicationa 0 (0) 4.9 (17) 0.9 (3.9) 8.90 (17.40) 1.69 (8.93) 1.27 (6.00)
Ointment with active
ingredientsb
1.23 (3.4) 3.16 (10.6) 17 (36) 8.30 (21.80) 2.20 (6.68) 12 (62)
Emollients 3.97 (6.5) 3.50 (6.3) 2.1 (3.89) 2.75 (6.25) 1.17 (2.76) 1.18 (3.72)
Protective dressingsc 3.24 (8.60) 1.15 (7.74) 5.47 (16.90) 0 (0) 0 (0) 0 (0)
Total 19 (27) 26 (40) 30 (43) 35 (57) 17 (25) 42 (82)
Total health-care costs 307 (146) 476 (275) 1267 (2254) 420 (144) 584 (295) 1234 (2553)
Family costs
Time costsd 31 (72) 153 (291) 320 (520) 315 (428) 256 (396) 645 (1048)
Travelling expenses 13 (16) 20 (17) 26 (20) 17 (13) 25 (20) 42 (32)
Bath oil 17 (63) 301 (560) 440 (516) 25 (50) 22 (17) 23 (22)
Out-of-pockete 15 (28) 110 (432) 64 (113) 33 (37) 233 (1023) 69 (201)
Total 77 (63) 301 (560) 440 (516) 366 (440) 522 (1068) 761 (1141)
Costs other sectors
Home-help visits 0(0) 36 (239) 0 (0) 0(0) 0 (0) 2.13
Total costs all
categories
384 (128) 814 (707) 1707 (2256) 811 (518) 1128 (1100) 2022 (3452)
a Antibiotics, antihistamines.
b Steroids, calcineurin inhibitors, tar.
c Bandages, garments and gloves.
d Time missed in paid work and days missed in non-working activities of the parents.
e Self-medication alternative practitioner, carpet changes, nutrition.
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1 Study Schuttelaar, 2011109
Note: the individual costs within each sub-group do not add to the total costs reported
l Mean annual health-care costs were higher in the dermatologist group than the NP group. These were driven
by higher costs for outpatient visits, laboratory tests and medication. The NP group had slightly higher costs for
phone consultations and protective dressings
l The dermatologist group had twice the cost for mean annual family costs compared with the NP group
l The NP group also had higher mean annual costs for home-help visits than the dermatologist group
Cost-effectiveness
The point estimate for ICER was €925 implying that one point less improvement in IDQOL in the NP group
compared to the dermatologist group at 1 year would save €925
Bootstrapping results showed a 95% CI of –€5748 to €6667 for the ICER
l For the IDQoL, the cost-effectiveness plane showed that the NP group incurred lower costs and less effect with
51% of the cost-effect pairs plotted in the south-west quadrant
l For the CDLQI, the cost-effectiveness plane showed similar results to the IDQoL, whereby the NP group
incurred lower costs and less effect than the dermatologist group, with 59% of the cost-effect pairs in the
south-west quadrant
l For the CSQ-8, NP dominated the dermatologist group as it was more effective and less expensive, with 92%
of the cost-effect pairs in the south-east quadrant
18 Sensitivity analysis
l Scenario analysis was conducted when 60% of the children in the NP group participated in a 1-hour group
education session with 5 children per group. The authors assumed an average decrease of 0.5 visits per child in
the NP group
l In the NP group, the mean annual societal costs per patient were €944 and the ICER for the CSQ-8 was €270
19 Author’s conclusions The authors concluded that care by NPs was cost-saving as well as
cost-effective compared with care by dermatologists
20 Reviewer’s comments The analysis was well-conducted; detailed descriptions of the model
parameters were presented. Uncertainty was accounted for; but
probabilistic sensitivity analysis was not conducted. However, the findings
of the analyses did not match exactly with the study conclusion. This is
considered to be a limitation of the study. Secondly, the different
sub-group of costs reported across the different levels of disease severity
did not match the sum total of the individual costs components within
the sub group
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Systematic review quality-assessment checklist for economic
evaluations and notes for completion
Critical appraisal checklist for economic evaluations (based on Drummond et al., 2005110)
Item Y/N?
1. Is the decision problem (including interventions compared and patient group) relevant to the UK? Yes
2. Is the setting comparable to the UK? No
3. Is the analytical and modelling methodology appropriate? ?
4. Are all the relevant costs and consequences for each alternative identified? Yes
5. Are the data inputs for the model described and justified? Yes
6. Are health outcomes measured in QALYs? No
7. Is the time horizon considered appropriate? Noa
8. Are costs and outcomes discounted? N/Ab
9. Is an incremental analysis performed? Yes
10. Is uncertainty assessed? Yes
N/A, not applicable.
a 1 year is considered to be too short for a chronic disease.
b As the analysis was conducted for a time horizon of 1 year, discounting is not appropriate.
1 Study van Os-Medendorp, 2008107
2 Research question To assess medical consumption, health-care costs and costs due to
loss of work in patients with chronic pruritic skin diseases enrolled in
the nursing programme ‘Coping with itch’ compared with a control
group of patients receiving the usual dermatological care
3 Country/setting The Netherlands
4 Funding source Dutch College of Health Insurance (CVZ)
5 Analysis type CEA
6 Study type Economic evaluation based on the results of a RCT
7 Perspective Not reported
8 Time horizon Trial duration: 9 months
9 Analysis method
(a) If estimations are based on a model, state
the model assumptions where relevant
Not reported
10 Discounting (rate) None
11 Costing year, currency Not stated, €
12 Population
(a) Definition of condition
(b) Characteristics of baseline cohort/
risk factors
Patients with chronic pruritic skin diseases
Patients with chronic pruritic skin diseases aged 18 years or older,
regardless of the underlying diagnosis who visited dermatology
outpatient department of the UMC of Utrecht, Leiden or Rotterdam
or the dermatology outpatient department of the Meander Medical
Centre in Amersfoort, the Netherlands
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1 Study van Os-Medendorp, 2008107
13 Intervention(s), comparator(s) Intervention: usual medical care from a dermatologist as well as
nursing care according to the programme ‘Coping with itch’.
The programme was carried out in a specialised itch clinic run by
dermatology nurses who provided individual sessions at the
dermatology outpatient department, while medical treatment by
the dermatologists continued as usual. The programme consisted of
educational and cognitive behavioural interventions, such as
individual patient education, awareness training and habit reversal,
and relaxation exercises
Comparator: usual dermatologist care, comprising diagnostic tests
and subsequent therapeutic intervention, such as the use of
emollients and topical steroids
14 Outcome measure
(a) Primary outcome(s) used in the analysis
(b) Source of evidence for the primary
outcome
(c) Summary measure of effect
Frequency of itching and scratching
Data for the primary outcome was recorded in diaries by patients in
the RCT that assessed the clinical effectiveness of the nursing
programme ‘Coping with itch’
Mean difference collected from the RCT
15 Health benefits
(a) If relevant, specify the valuation approach
(and source)
(b) If relevant, state the instrument used to
measure health benefits
Factor analysis was applied to the data on the number of times
patients felt itchy or scratched to reduce to one factor: the factor of
itching/scratching which was converted to a dichotomous measure:
high (> 4) and low (≤ 4) frequency of itching/scratching
Health benefits were expressed in terms of days with a low
frequency of itching and scratching
None used
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16 Costs
Intervention cost
All the costs are expressed in €
Months 1–3 Months 1–9
Intervention
(n= 22)
Comparator
(n= 26)
Difference
(95% CI)
Intervention
(n= 25)
Comparator
(n= 31)
Difference
(95% CI)
Costs at the dermatology outpatient department, mean (± SD)
l Costs of visit to
the dermatologist
212.7
(± 220.8)
303.7
(± 548.9)
–91.0 (–325.3
to 143.3)
742.0
(± 507.0)
770.7
(± 980.1)
–28.7 (–495.0
to 437.6)
l Costs of visit to the
dermatology nurse
133.3
(± 64.2)
26.3
(± 40.8)
107.1 (77.2
to 137.0)
232.3
(± 145.1)
34.2
(± 52.3)
198.2 (131.1
to 265.2)
l Costs of ultraviolet
therapy
47.2
(± 103.3)
22.4
(± 72.4)
24.8 (–24.5
to 74.1)
52.6
(± 106.6)
56.2
(± 122.7)
–3.7 (–71.1
to 63.7)
l Costs of visits to a
medical social worker
9.2
(± 45.8)
2.5
(± 13.7)
6.7 (–10.6
to 24.0)
10.4
(± 48.8)
2.9
(± 14.6)
7.5 (–12.8
to 27.7)
l Total costs at the
dermatology
outpatient department
402.3
(± 263.3)
354.8
(± 554.6)
47.5 (–194.5
to 289.6)
1037.3
(± 614.9)
864.0
(± 1019.3)
173.2 (–327.4
to 673.9)
Costs of visits to the GP 40.0
(± 37.1)
42.1
(± 39.1)
–2.0 (–22.6
to 18.6)
72.1
(± 56.0)
119.9
(± 93.2)
–39.8 (–83.9
to 4.3)
Costs of visits to other
HCPs
238.2
(± 252.9)
217.6
(± 296.5)
20.6 (–129.2
to 170.4)
668.1
(± 813.2)
521.0
(± 496.8)
147.1 (–237.9
to 532.1)
Costs of medication 243.5
(± 459.8)
129.4
(± 167.4)
114.1 (–64.3
to 292.5)
559.5
(± 630.3)
426.6
(± 486.9)
132.9 (–191.9
to 457.6)
Costs of days off work 1320.8
(± 3601.4)
343.0
(± 1271.6)
977.8 (–568.0
to 2523.6)
1946.2
(± 4852.0)
1302.3
(± 4285.1)
643.8
(–2010.8 to
3298.5)
Costs of hospitalisations 357.7
(± 1271.0)
721.2
(± 2585.3)
–363.5
(–1498.0 to
771.0)
757.6
(± 1866.2)
1250.8
(± 3617.5)
–493.2
(–2213.3 to
1226.9)
Total costs 2602.6
(± 3841.7)
1808.0
(± 2949.2)
794.5
(–1024.4 to
2603.5)
5040.6
(± 5442.4)
4476.7
(± 5822.9)
564.0
(–2731.9 to
3859.9)
Costs of visits to health-care workers, costs of days off work and hospitalisations were based on the guidelines for cost
studies of the Dutch College of Health Insurance (CVZ), whereas medication costs were obtained from the Dutch
website: www.medicijnkosten.nl
Indirect costs
To estimate the costs of days off work, an overall mean hourly productivity cost of €34.98 was applied for both men
and women
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17 Results
Costs
Benefits (days with a low frequency of
itching and scratching)
Cost-effectiveness
ratioIntervention Control
Difference after
bootstrap analyses
(95% CI) Intervention Control
Difference after
bootstrap analyses
(95% CI)
Months 1–3a
€2602.6 €1808.0 €793.8 (–970.3 to
2692.7)
34.3 28.4 6.1 (–15.7 to 27.8) €129.9
Months 1–9b
€5040.6 €4476.7 €582.0 (–2730.0 to
3877.0)
123.0 87.6 35.0 (–33.0 to 96.0) €16.6
a Intervention group n= 25, control group n= 31.
b Intervention group n= 22, control group n= 27.
18 Sensitivity analysis
The authors assessed the implications of variation in cut-off score of the frequency of itching and scratching on the
cost-effectiveness results. Using a cut-off score of 3 or 5, 61% of patients experienced benefits from the intervention,
and 12% had lower costs after 3 months. After 9 months, 63% and 78% of patients experienced benefits using a
cut-off score of 3 or 5, respectively and 22% and 28% of patients, respectively, had lower costs
19 Author’s conclusions It was observed that, although the first 3 months of the programme
‘Coping with itch’ incurred most of the expenses, the benefits (in
terms of days with little itch) accrued from the programme persisted
and increased beyond this period. Based on this observation, the
authors concluded that the ‘Coping with itch’ programme led to a
more favourable ICER
20 Reviewer’s comments Overall, the analysis was well conducted. The results of the analysis
were in line with study conclusions. Sources of model parameters
were well-defined. Price year was not reported. Although the study
accounted for uncertainty through bootstrapping, probabilistic
sensitivity analysis was not conducted. Only two sets of one-way
sensitivity analyses were conducted. The analysis accounted for a
time horizon of 9 months; however a longer time horizon would
have been appropriate. Discounting of costs and benefits were not
performed which was considered appropriate given the time horizon
of the model was < 1 year
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Systematic review quality-assessment checklist for economic
evaluations and notes for completion
Critical appraisal checklist for economic evaluations (based on Drummond et al., 2005110)
Item Y/N?
1. Is the decision problem (including interventions compared and patient group) relevant to the UK? Yes
2. Is the setting comparable to the UK? No
3. Is the analytical and modelling methodology appropriate? ?
4. Are all the relevant costs and consequences for each alternative identified? Yes
5. Are the data inputs for the model described and justified? Yes
6. Are health outcomes measured in QALYs? No
7. Is the time horizon considered appropriate? No
8. Are costs and outcomes discounted? Noa
9. Is an incremental analysis performed? Yes
10. Is uncertainty assessed? Yesb
a Discounting was not applicable as the time horizon was < 1 year.
b Uncertainty was assessed through bootstrapping; not via probabilistic sensitivity analysis. Also, a very limited sets of
one-way sensitivity analyses was performed.
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